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PREFACE 
 
 
The current thesis presents data obtained during my PhD research project, developed at 
Instituto de Medicina Molecular in the period of February 2012 to November 2015, under 
the supervision of Professor Doutor João Pedro Simas (Faculdade de Medicina, 
Universidade de Lisboa). 
 
This thesis is organized in 8 chapters, which are preceded by a summary written in 
Portuguese and an abstract. Before the description of the results, an introductory review 
of the subject is provided in chapter 1, followed by the aims of the work. In chapters 2, 3, 
4, and 5 the original data obtained during this research project are presented. Final 
considerations, which integrate the results presented in previous chapters as well as 
future directions are presented in chapter 6. Finally, chapter 7 concerns the description of 
the materials and methodologies employed to carry out the presented work. The 
publications that resulted from the research carried out throughout the duration of this 
project are included in appendixes 1 to 3. 
 
Data presented in this dissertation were purely the result of work carried out by me 
and it is clearly acknowledged in the text whenever data or reagents produced by 
other were utilized. This work has not been submitted for any degree at this or any 
university. 
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RESUMO 
 
A principal característica dos herpesvírus é a sua capacidade de estabelecer infeções 
persistentes, que permanecem por toda a vida do hospedeiro. Particularmente, os gama-
herpesvírus humanos infetam o tecido linfoide e estão consequentemente associados a 
doenças linfoproliferativas. Para atingir a persistência, os gama-herpesvírus estabelecem 
latência na população de células B de memória, que são de longa duração. O acesso a 
este compartimento depende da proliferação e diferenciação de células B latentemente 
infetadas em reações de centro germinativo, um processo que é dependente da ajuda 
das células T helper (TH) CD4+. Atualmente é desconhecido se o vírus tem a capacidade 
de manipular a interação entre células B e células TH. A proteína M2 associada à fase de 
latência do gama-herpesvírus de murídeo do tipo 4 (MuHV-4) coordena a formação de 
complexos multiproteicos com proteínas celulares envolvidas na sinalização da célula B. 
Logo, M2 interfere com as vias de sinalização que se desenrolam a jusante do recetor da 
célula B (BCR). Esta habilidade depende de dois resíduos de tirosina que formam um 
motivo de ativação do imunoreceptor baseado em tirosina (ITAM) não convencional. O 
presente estudo teve como principal objetivo investigar se a proteína M2 do MuHV-4 
desempenha um papel na modulação da interação entre células B e células TH. Para tal, 
a interação celular foi investigada com recurso a um sistema restrito para MHC do tipo 
classe II e específico para o péptido de OVA. A expressão de M2 levou ao aumento de 
moléculas de superfície em células B transduzidas, nomeadamente moléculas co-
estimulatórias e de adesão celular. Consistente com estas descobertas, M2 foi capaz de 
promover a formação de conjugados B-TH. Num sistema de competição in vitro, esta 
habilidade traduziu-se numa vantagem competitiva, tal como pôde ser observado pela 
preferência das células TH para conjugar com células B que expressavam M2. Contudo, a 
expressão de M2 em células B não foi suficiente para levar à ativação das células TH, 
uma vez que apenas ocorreu na presença de péptido específico. Para avaliar a 
importância biológica desta capacidade de M2 de promover a formação de conjugados B-
TH, desenhou-se um sistema de competição in vivo que assenta na purificação de células 
B primárias que expressam M2 a partir de ratinhos quimera. A capacidade de M2 de 
coordenar a formação de complexos multiproteicos com proteínas de sinalização revelou-
se deletéria para o desenvolvimento e/ou proliferação de células B nos ratinhos quimera. 
Como tal, não foi possível obter qualquer conclusão quanto ao papel de M2 na 
modulação da interação B-TH in vivo. In vivo, a mutação dos resíduos de tirosina que 
compõem o ITAM não convencional de M2 (vírus recombinante M2Y) resulta num atraso 
no estabelecimento de latência do vírus. Com o intuito de identificar a origem deste 
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atraso, a infeção com vírus do tipo selvagem (WT) e do tipo mutante (M2Y) foi seguida in 
vivo por métodos quantitativos e qualitativos. Os resultados foram inconclusivos, mas não 
excluíram a possibilidade de um fenótipo em células B. Coletivamente, estes resultados 
suportam um modelo em que a proteína M2 promove a formação de conjugados entre 
células B e TH. Num contexto fisiológico, esta habilidade pode conferir uma vantagem 
competitiva à célula B infetada na aquisição de ajuda por parte da célula TH, deste modo 
contribuindo para a iniciação de reações de centro germinativo e, consequentemente, 
para a colonização do hospedeiro. 
 
Palavras-chave: gama-herpesvírus; interação célula B-célula T; célula B; proteína M2. 
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ABSTRACT 
 
The main feature of herpesviruses is their ability to establish persistent infections. Human 
gammaherpesviruses, in particular, infect the lymphoid tissue and are associated with 
lymphoproliferative disorders. To attain persistence, gammaherpesviruses establish 
latency in the long-lived memory B cell population. Access to this B cell compartment 
depends on the initiation of germinal center reactions and the subsequent proliferation 
and differentiation of latently infected germinal center B cells, for which T cell help is 
essential. Whether the virus is capable of modulating B-T helper cell interaction for its own 
benefit is still unknown. Latency associated M2 protein, of the experimental mouse model 
of infection murid herpesvirus-4 (MuHV-4), assembles multiprotein complexes with B cell 
signaling proteins, therefore interfering with cell signaling pathways downstream of the B 
cell receptor (BCR). This ability depends on two phosphosites that constitute an 
unconventional immunoreceptor tyrosine-based activation motif (ITAM). The aim of this 
thesis was to investigate if the M2 protein played a role in the modulation of B-T helper 
cell interaction. To that end, cell interaction was addressed in an MHC-II restricted OVA 
peptide-specific system. M2 led to the upregulation of adhesion and co-stimulatory 
molecules in transduced B cell lines. Consistent with these findings, M2 promoted the 
formation of B-T helper cell conjugates. In an in vitro competition assay, this translated 
into a competitive advantage, as T cells preferentially conjugated with M2-expressing B 
cells. However, expression of M2 alone in B cells was not sufficient to lead to T cell 
activation, as it only occurred in the presence of specific peptide. To address the role of 
M2 in B-T helper cell interaction in vivo, a competition system was designed, that relied on 
the purification of M2-expressing primary B cells from chimeric mice. The ability of M2 to 
assemble multiprotein complexes with cell signaling proteins had a negative effect in the 
development and/or proliferation of this population in the mouse chimeras. Therefore, 
conclusions could not be drawn. Mutation of the unconventional ITAM in vivo results in a 
delay in latency establishment. To further understand the origin of this delay, YFP-
expressing mutant and wild type viruses were tracked in vivo by quantitative and 
qualitative methods. Data was inconclusive but did not exclude a B cell phenotype. Taken 
together, these findings support that M2 promotes the formation of B-T helper cell 
conjugates. In an in vivo context this may confer a competitive advantage to the infected B 
cell in acquisition of T cell help and initiation of a germinal center reaction, hence host 
colonization. 
 
Keywords: Gammaherpesvirus; B-T cell interaction; B cell; M2 protein. 
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1 INTRODUCTION 
 
Gammaherpesviruses, such as Epstein-Barr virus and Kaposi’s sarcoma-associated 
herpesvirus, are widely disseminated in nature. Co-evolution with their hosts has led to a 
fine balance that allows gammaherpesviruses to persist for the lifetime of the host without 
causing disease. Disruption of this balance results in lymphoproliferative disorders, 
especially in immunocompromised patients. The study of gammaherpesvirus infection is 
therefore of major clinical importance. 
 
Persistent infection depends on the ability of the virus to establish latency in the long-lived 
memory B cell population. To accomplish that, gammaherpesviruses have developed 
several strategies that allow them to exploit different aspects of the host B cell, such as 
the modulation of host cell signaling pathways. Specifically, both the Epstein-Barr virus 
and the mouse model Murid Herpesvirus-4 take advantage of the germinal center 
reaction, the process whereby B cells undergo affinity maturation and differentiation into 
plasma cells or memory B cells. In T cell dependent responses, GC initiation depends on 
the help provided by specific CD4+ T helper cells. B-T helper cell interaction is therefore a 
crucial step in GC responses, which makes it a rational target of gammaherpesviruses. 
Understanding whether B-T helper cell interaction is modulated by the virus for its own 
benefit will provide useful insight on viral pathogenesis. 
 
1.1 Introduction to Gammaherpesviruses 
 
Herpesviruses are widely disseminated in nature and are thought to originate at the very 
early stages of the evolution of parasitism. In fact, herpesviruses are thought to have a 
long co-evolutionary history with their hosts. Supposedly, this is on the basis of their good 
adaptation to the host. As a result, fatal infections in immunocompetent hosts are 
extremely rare. Historically, herpesviruses have been placed under the same category 
due to their common virion architecture. Typically, a virion is composed of a core 
containing a linear double-stranded DNA, surrounded by an icosahedral capsid composed 
of 162 capsomeres and a lipid envelope that contains viral glycoproteins at its surface. In 
some cases, a proteinaceous matrix named tegument can be found surrounding the 
capsid (Roizman and Pellett 2007). The acquisition of exogenous DNA sequences, DNA 
rearrangements and nucleotide substitutions are on the basis of herpesvirus diversity. As 
a result, herpesviruses present both conserved and divergent genome regions (Lacoste, 
Lavergne et al. 2010). Usually, the conserved part of the genome consists of structural 
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genes and/or genes involved in lytic replication. Between these conserved regions, 
specific genes that confer the particular characteristics of a given herpesvirus can be 
found. The gene products of herpesviruses frequently have multiple disparate functions 
(Roizman and Pellett 2007). 
 
So far eight human herpesviruses have been isolated and associated to disease. 
However, herpesviruses are highly divergent and their host range highly variable. Based 
on the host range, the Herpesvirales order is divided into three families: Herpesviridae 
(mammal, bird and reptile herpesviruses), Alloherpesviridae (fish and amphibian 
herpesviruses) and Malacoherpesviridae (bivalve herpesviruses) (Davison, Eberle et al. 
2009). Members of the Herpesviridae family have one defining characteristic in common: 
the ability to establish latency in their natural hosts. Besides latency establishment, host 
colonization includes two other stages: primary or lytic infection and reactivation from 
latency. Upon entry into a naïve host, the virus establishes an acute lytic infection that 
results in the production of infectious progeny, leading to the destruction of the infected 
cell. This allows virus spread, both to other hosts and within the host. This stage is then 
followed by the establishment of latency in a specific set of cells. During latency, the viral 
genomes are maintained as circular molecules and gene expression is very restricted. 
Although there is production of infectious progeny, viruses can reactivate from latency and 
begin a new stage of lytic infection. Such infection kinetics have allowed herpesvirus to 
establish persistent infections, that last for the lifetime of the host. Besides the ability to 
latently infect the host, members of the Herpesviridae family also share other 
characteristics. They code for enzymes involved in nucleic acid metabolism, DNA 
synthesis and processing of proteins. The localization of component steps in virion 
production is the same, namely viral DNA synthesis and capsid assembly take place in 
the nucleus, while the final processing of the virion takes place in the cytoplasm. On the 
other hand, the members of the Herpesviridae family differ in biological properties which 
led to their further division into three sub-families: Alphaherpesvirinae, Betaherpesvirinae 
and Gammaherpesvirinae. Of the nine gammaherpesviruses that infect humans, herpes 
simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2) and varicella-zoster virus (VZV) 
belong to the Alphaherpesvirinae sub-family; human cytomegalovirus (HCMV), human 
herpesvirus 6A (HHV-6A), human herpesvirus 6B (HHV-6B) and human herpesvirus 7 
(HHV-7) belong to the Betaherpesvirinae sub-family; and Epstein-Barr virus (EBV) and 
Kaposi’s sarcoma-associated herpesvirus (KSHV) belong to the Gammaherpesvirinae 
sub-family (Roizman and Pellett 2007). For the purpose of this thesis, only 
gammaherpesviruses will be described in more detail.  
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Gammaherpesviruses are usually specific for B or T lymphocytes. Concomitantly, latent 
virus is frequently detected in the lymphoid tissue. Moreover, some of these viruses are 
known to cause lytic infections in some types of epithelioid and fibroblastic cells (Roizman 
and Pellett 2007). On the basis of genome organization and DNA sequence homology this 
sub-family is further divided into four genera: Lymphocryptovirus (also known as gamma1-
herpesviruses), Rhadinovirus (gamma2-herpesviruses), Macavirus and Percavirus. The 
Lymphocrytovirus genus has only been found in primates and includes the human 
gammaherpesvirus EBV. The Rhadinovirus genus has been found in both primate and 
non-primate species, namely rodents, leporids and bovines. This genus includes the 
human gammaherpesvirus KSHV as well as the rodent virus, widely used as a laboratory 
model of gammaherpesvirus pathogenesis, Murid Herpesvirus-4 (MuHV-4). The 
Macavirus genus includes bovine, caprine, ovine and swine herpesviruses. The 
Percavirus genus includes equine, carnivore and non-mammalian herpesviruses 
(Davison, Eberle et al. 2009).  
 
1.1.1 Gammaherpesvirus and disease 
 
EBV and KSHV, the human viruses that belong to the Gammaherpesvirinae sub-family, 
usually coexist with their host without causing disease (Cesarman 2011). However, they 
have the ability to induce neoplasia in their natural hosts (Damania 2004). In fact, EBV 
was the first human virus to be related to oncogenesis. All members of this sub-family are 
capable of driving the proliferation of infected lymphocytes during the establishment and 
maintenance of latency. This lymphoproliferation is the cause of the majority of the 
diseases associated to gammaherpesvirus in immunocompromised hosts (Simas and 
Efstathiou 1998).   
 
More than 90% of the human adult population is infected with EBV. Primary infection 
usually occurs early in childhood and is most often asymptomatic. In the developed world, 
another classical presentation of primary infection with EBV is infectious mononucleosis, 
also known as glandular fever, in adolescents. Clinically, this is characterized by a sore 
throat, cervical lymphadenopathy, fever, splenomegaly, malaise, headache, sweating and 
gastro-intestinal discomfort (Ogilvie 2007). However, infectious mononucleosis in patients 
with X-linked lymphoproliferative syndrome (XLP), which are deficient for an important 
lymphocyte signaling protein, SAP, can be fatal (Rickinson and Kieff 2007). EBV is also 
associated with malignant disorders. In immunocompromised hosts, the inability of the 
immune system to control the EBV-driven B cell proliferation, results in post-transplant 
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lymphoproliferative diseases and immunoblastic lymphomas. The first occurs in patients 
that undergo transplantation and are, therefore, iatrogenically immunosuppressed. The 
latter occurs in patients with acquired immunodeficiency syndrome (AIDS) that are, 
therefore, immunocompromised due to human immunodeficiency virus (HIV) infection. In 
immunocompetent hosts, EBV is not considered the causative agent but, instead, it is a 
component in a complex process of malignant transformation. Other cofactors may be 
host somatic mutations or infection with other pathogens. EBV has different latency 
programs, characterized by different latent gene expression, as will be described in more 
detail in section 1.2.2. These patterns are associated with specific lymphoma subtypes 
(Mesri, Feitelson et al. 2014). Expression of lytic cycle genes has also been implied in 
oncogenicity (Thompson and Kurzrock 2004). Furthermore, EBV-encoded miRNAs target 
host genes that regulate cell growth and apoptosis pathways and are associated with 
some malignancies (Vereide, Seto et al. 2014). Examples of such malignancies are 
Burkitt’s lymphoma (BL), Hodgkin’s lymphoma (HL), nasopharyngeal carcinoma (NPC) 
and also a small subset of natural killer (NK) and T cell lymphomas, gastric carcinomas, 
follicular dendritic tumours and other epithelial carcinomas (Mesri, Feitelson et al. 2014). It 
was in cultured lymphoblasts from BL that EBV was first identified (Epstein, Achong et al. 
1964). BL is a germinal center (GC)-derived aggressive B cell lymphoma, that is divided 
into three different clinical variants on the basis of geographical and HIV status 
information. Endemic BL, for instance, is the most common cancer of childhood in 
equatorial Africa, where it overlaps with the geographical distribution of malaria infection. 
HL is seen worldwide and it has a first peak of incidence in persons aged 15-35 years, 
and a second one in elderly patients (Ok, Li et al. 2015). 
 
There is no unified therapeutic strategy for EBV-associated lymphoproliferative disorders. 
Antiviral agents used in the clinic, such as acyclovir, ganciclovir, and valaciclovir are 
broad-spectrum antivirals and, therefore, their efficiency against EBV is variable. 
Furthermore, they are only effective during the lytic phase of infection and, in most EBV-
associated lymphoproliferative disorders, EBV infection is latent. Recently, induction of 
EBV lytic phase followed by administration of antiviral drugs has been suggested as a way 
to overcome this problem (Geng and Wang 2015). In the case of transplant recipient 
patients, reducing immunosuppression is sometimes an option (Ogilvie 2007). Adoptive 
immunotherapy with EBV-specific donor-derived or HLA-matched cytotoxic T cells (CTLs), 
recovered from donors, expanded in vitro and infused into the patient is also an option. 
These CTLs are able to recognize and eliminate EBV-infected tumor cells that express 
more latent proteins. However, this strategy has several disadvantages, namely it is time-
consuming, costly, labor-intensive and carries many potential risks for the patient 
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(Rooney, Smith et al. 1998, Geng and Wang 2015). Once a tumor is developed, another 
therapeutic strategy is the use of specific monoclonal antibodies. Rituximab, a monoclonal 
antibody against CD20, may reduce the size of CD20-expressing B cell lymphomas 
(Choquet, Leblond et al. 2006). An antibody-drug conjugate, Brentuximab Vedotin, is 
under clinical trials (Ogura, Tobinai et al. 2014). Another approach is the targeting of 
oncogenic pathways, since aberrant oncogenic signaling is a characteristic of EBV-
associated lymphoproliferative disorders. The proteasome inhibitor Bortezomib, inhibits 
the NF-κB pathway and induces apoptosis of EBV lymphoblastoid cell lines (Zou, Kawada 
et al. 2007). 
 
KSHV is not as prevalent in the human population as EBV. Its incidence varies with 
geographic and demographic factors. Since its discovery, KSHV has been associated with 
three human malignancies: Kaposi’s sarcoma (KS), primary effusion lymphoma (PEL) and 
multicentric Castleman’s disease (MCD). Furthermore, KSHV is associated with several 
acute inflammatory syndromes (Giffin and Damania 2014). It was in KS lesions that KSHV 
was first identified (Chang, Cesarman et al. 1994). These lesions usually occur 
cutaneously or in mucosal surfaces, but can also be found on lymph nodes and visceral 
organs, such as lung and spleen. KS is divided into four subtypes: classic KS, found in 
elderly men of Mediterranean and eastern European descent; endemic KS, which occurs 
in eastern and central African countries; epidemic or AIDS-associated KS, the most 
common and aggressive form of the disease and the most frequent cancer in many Sub-
Saharan countries; and post-transplant or iatrogenic KS, associated with the use of 
immune suppressive therapy (Giffin and Damania 2014). Tumor cells in KS are of 
endothelial origin and most of them are latently infected. However, unlike classical tumors, 
KS lesions are composed of many cell types (Ganem 2007). PEL is an aggressive 
lymphoma characterized by the lack of a solid tumor mass. Instead, it is composed of a 
monoclonal population of malignant KSHV-infected B cells that expand within the 
pericardial, pleural, and peritoneal body cavities (Nador, Cesarman et al. 1996, Giffin and 
Damania 2014). Nonetheless, cases of solid PEL have been reported (Carbone, Gloghini 
et al. 2005). It occurs primarily, but not exclusively, in HIV-positive patients. Tumor cells 
are of B cell origin, most likely post-GC origin, given the expression of plasma cell 
markers and the evidence of immunoglobulin gene rearrangements and somatic 
hypermutation of the immunoglobulin genes (Cesarman 2011, Cesarman 2014). The vast 
majority of the KSHV-infected tumor cells are also infected with EBV (Nador, Cesarman et 
al. 1996, Cesarman and Knowles 1999). Upon diagnosis, the average survival time is 
about 6 months (Boulanger, Gerard et al. 2005). PEL-derived cell lines have a consistent 
growth in culture and have, therefore, been essential for in vitro studies regarding the 
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molecular pathogenesis of KSHV (Renne, Zhong et al. 1996). MCD is an uncommon 
lymphoproliferative disorder, characterized by an abnormal proliferation of plasmablasts 
within the mantle zone of B cell follicles. It usually affects several lymph nodes 
(multicentric) but it can also be localized (Cesarman 2011, Cesarman 2014). Gene 
expression observed in MCD suggests that, unlike KS and PEL, KSHV infection is mainly 
lytic (Chadburn, Hyjek et al. 2008, Polizzotto, Uldrick et al. 2012). It is thought that disease 
symptoms are a consequence of the production of excess cytokines, such as IL-6 
(Cannon, Nicholas et al. 1999). In HIV-positive patients MCD is most likely associated to 
KSHV infection, but that may not be the case in HIV-negative patients. MCF is also 
frequently observed in transplantation recipients (Kaplan 2013).  
 
Introduction of combination antiretroviral therapy (cART) has decreased the incidence of 
AIDS-associated KS, and is used to treat systemic disease. Localized KS lesions can be 
treated locally with liquid nitrogen. In the case of larger lesions, localized radiotherapy is 
an option. In patients where disease is more advanced, systemic chemotherapy is used. 
In clinical trials, KS responded to two drugs: imatinib and lenalidomide. There is no 
standard care for PEL (Kaplan 2013). The most commonly used treatment is 
chemotherapy, with a poor prognosis (Coen, Duraffour et al. 2014). Response to 
antiretroviral therapy or rituximab has only been reported in individual cases (Lim, Rubin 
et al. 2005). In MCD, given that infection is mainly lytic, antiviral therapy has been 
reported successful (Casper, Nichols et al. 2004). Considering the excess production of 
IL-6 in MCD, the use of an anti-human IL-6 receptor antibody as well as a novel chimeric 
monoclonal antibody against IL-6 are promising treatments (Coen, Duraffour et al. 2014).  
 
Summarizing, there is no unified, highly effective, treatment for gammaherpesviruses. 
Their ability to establish latency and to interfere with host signaling pathways are two of 
the major problems to overcome. This denotes the importance of understanding 
gammaherpesvirus pathogenesis and, in particular, latency establishment in order to 
develop a targeted therapy. Given the specificity of host infection, EBV and KSHV are 
unable to infect experimentally useful small animal hosts. To fill that gap, MuHV-4, a 
gammaherpesvirus of the Rhadinovirus genus that infects laboratory mice, has been 
widely used as an animal model of gammaherpesvirus pathogenesis.  
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1.2 Gammaherpesvirus infection 
 
Gammaherpesviruses establish life-long persistent infections and are highly prevalent in 
the human population. Furthermore, as described in section 1.1.1, they may be 
associated with lymphoproliferative disorders, which makes their treatment a major clinical 
goal. Understanding the different stages of infection, as well as the mechanisms and 
proteins/RNAs behind it, is essential for the development of a targeted therapy.  
 
Latent infection of circulating memory B cells is crucial to persistence and hence disease 
ontogeny. To access the memory B cell compartment gammaherpesviruses, such as EBV 
and murid herpesvirus-4 (MuHV-4), take advantage of germinal center (GC) reactions 
(Simas and Efstathiou 1998, Flano, Kim et al. 2002, Kim, Flano et al. 2003, Willer and 
Speck 2003, Roughan and Thorley-Lawson 2009, Barton, Mandal et al. 2011, Thorley-
Lawson, Hawkins et al. 2013). Infection with EBV, KSHV, and their mouse virus 
counterpart MuHV-4 will now be described in detail. 
 
1.2.1 Germinal Center reaction 
 
B cells are an important component of adaptive immunity, that is specialized in the 
recognition of antigens. Mature naïve B cells are short-lived cells that circulate through the 
bloodstream and migrate to secondary lymphoid organs, such as the spleen and lymph 
nodes, where they can encounter a specific antigen (Yuseff, Pierobon et al. 2013). 
Binding of antigen to the B cell receptor (BCR) provides survival signals to the B cell and 
promotes its initial activation. The BCR-antigen complexes are then internalized and the 
antigen is broken down to several peptides. These, in turn, bind to major histocompatibility 
complex class II (MHC-II) molecules that will present the antigen at the B cell surface. In T 
cell-dependent humoral immune responses, the specific interaction of these cells with 
CD4+ T helper (TH) cells is an essential step that will allow further B cell activation and 
initiation of a GC reaction (Pierce 2002). For that purpose, antigen-engaged B cells, 
present in the follicles of secondary lymphoid organs, migrate towards the T cell-rich 
periarteriolar lymphoid sheaths (PALS) in response to a ligand gradient (Okada, Miller et 
al. 2005). TH cells have also been exposed to antigen that is presented to them by 
dendritic cells (DCs) and macrophages and can, therefore, recognize the same specific 
antigen being presented by the B cell. Therefore, in the border area between follicles and 
T cell zones, TH cells scan for the highest affinity for an appropriate antigen by quickly 
interacting with antigen-presenting B cells, forming conjugates. Upon cognate interaction, 
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an immunological synapse is formed, as will be described in more detail in section 1.3.1. 
Through this interaction the B cells receive cytokine signals from the TH cells, that promote 
survival, proliferation and differentiation (Mills and Cambier 2003, De Silva and Klein 
2015).  
 
Interaction of antigen-engaged B cells with TH cells may have three different outcomes. B 
cells may move to the medullary chords where they differentiate into short-lived 
plasmablasts that secrete low affinity antibodies. B cells may also differentiate into 
unswitched memory B cells (Taylor, Pape et al. 2012). Finally, B cells may enter the GC 
pathway (Figure 1.1) (De Silva and Klein 2015). In this pathway, activated GC precursor B 
cells move to the center of the follicle to form an early GC. A rapid B cell proliferation 
takes place and at seven to ten days after antigen exposure a GC is formed. This 
transient structure supports affinity maturation, a process that generates and selects B 
cells expressing high affinity BCR. In the classical model the GC is divided into two 
microenvironments known as the dark zone and the light zone, which harbor different B 
cell types (Allen, Okada et al. 2007). The dark zone is densely populated by proliferating B 
cells, named centroblasts, and reticular cells that are morphologically similar to follicular 
dendritic cells (FDCs) (Bannard, Horton et al. 2013). In this region, B cells not only 
proliferate but also undergo somatic hypermutation (SHM) of the immunoglobulin variable 
region genes. The outcome is a diversity of affinities for the immunizing antigen. 
Centroblasts then move to the light zone for selection. This is more sparsely populated by 
B cells, named centrocytes, and also contains follicular helper T cells (TFH) and FDCs. 
Centrocytes with an unfavorable membrane immunoglobulin undergo apoptosis. 
Immunoglobulins with improved affinity for the immunizing antigen are positively selected. 
Positive selection depends on interaction with both FDCs and TFH cells. Access to the 
antigen deposited at the surface of FDCs is limited and only B cell clones that express a 
high affinity BCR are able to acquire antigen. Recently, it has been proposed that 
antibodies produced by GC-derived plasma cells help to limit access to antigen in a 
competitive manner (Zhang, Meyer-Hermann et al. 2013). Next, only the B cells that 
acquired antigen are able to present it to TFH cells, a crucial step in affinity maturation. 
Higher BCR affinity leads to greater antigen capture and, consequently, to higher density 
of peptide presented to the TFH cells. In turn, this results in largest longest contacts with 
the TFH cells and subsequent selection (Nutt and Tarlinton 2011, De Silva and Klein 2015). 
At this stage, centrocytes may undergo immunoglobulin class-switch recombination (CSR) 
which allows daughter B cells to produce antibodies with different isotypes but with the 
same specificity for the immunizing antigen (Guzman-Rojas, Sims-Mourtada et al. 2002, 
Klein and Dalla-Favera 2008). A subset of selected cells recirculates to the dark zone, for 
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further SHM of the immunoglobulin genes, whereas other cells directly differentiate into 
plasma cells or memory B cells. Cells that could not acquire survival signals from FDCs or 
selection signals from TFH cells undergo apoptosis (Victora and Mesin 2014, De Silva and 
Klein 2015). Plasma cells will produce and secrete high affinity antibodies, while memory 
B cells will survive for a long period of time and, upon secondary exposure to the same 
antigen, will differentiate into plasma cells (Calame 2001).  
 
 
Figure 1.1. Classical model of germinal center reaction. Upon interaction with CD4+ T helper 
(TH) cells, antigen-engaged B cells may enter the germinal center (GC) pathway. This transient 
structure supports a process that generates and selects B cells expressing high affinity BCR, 
named affinity maturation. In the dark zone of the GC, B cells, now named centroblasts, undergo 
proliferation and somatic hypermutation (SHM) of the immunoglobulin variable region genes. This 
process creates a diversity of B cell receptors (BCR) with different affinity for the immunizing 
antigen. These B cells then move to the light zone of the GC, where they are named centrocytes, 
to be selected. B cells with high affinity for the antigen interact with follicular dendritic cells (FDC) 
and TH cells and are positively selected. Selected centrocytes may recirculate to the dark zone for 
further SHM or they may undergo class switch recombination (CSR) and differentiation, leaving the 
GC as either plasma cells or memory B cells. Cells that are not positively selected undergo 
apoptosis. 
 
1.2.2 Model of EBV infection 
 
The human gammaherpesvirus EBV persists as a life-long infection in the circulating, 
resting, memory B cell population of healthy hosts. This is true for over 90% of the human 
population and may be associated with disease. As previously mentioned, EBV has four 
latency programs, that differ in latent gene expression, each of them associated with 
specific lymphoma subtypes (Table 1.1). Two main models of infection have been thus far 
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proposed to explain persistence: the GC model (Thorley-Lawson 2001, Thorley-Lawson 
2005, Thorley-Lawson, Duca et al. 2008, Thorley-Lawson, Hawkins et al. 2013) and the 
direct infection model (Kurth, Spieker et al. 2000, Kurth, Hansmann et al. 2003). The 
latter, which assumes direct infection of memory B cells, was proposed over 10 years ago 
but, to date, no strong experimental evidence has been able to support it and explain the 
mechanism behind it. Furthermore, predictions made according to this model are 
incorrect. An alternative perspective speculates that latently infected memory B cells 
derive directly from infected naïve B cells, without the need for a GC reaction (Heath, 
Begue-Pastor et al. 2012). Similarly, this model does not fit some of the in vivo evidences 
known so far. The GC model of infection, therefore, remains as the only model that can 
explain persistence in the memory B cell population, as well as account for the different 
latency programs and their characteristic association with different lymphoma subtypes 
(Table 1.1). For example, BL is believed to result from latently infected GC B cells that 
failed to differentiate into resting memory B cells (Thorley-Lawson and Gross 2004). This 
model considers that EBV exploits the normal biology of the host B cell, driving it to 
participate in the GC reaction, therefore acquiring access to the long-lived memory 
compartment, where the virus persists quiescently (Figure 1.2).  
 
Table 1.1. Patterns of EBV latent gene expression in different B cell subsets of healthy 
individuals and in malignancies. The corresponding expression profiles in malignant lymphomas 
have been designated latencies I, II and III (adapted from Thorley-Lawson, 2005). 
Transcription 
program 
Genes expresseda 
Infected normal 
B cell type 
Function Lymphoma type 
Growth 
(Latency III) 
EBNA1, 2, 3A, 3B, 
3C, LP, LMP1, 
LMP2A and LMP2B 
Naïve B cell activation Immunoblastic 
lymphoma, PTLD 
Default 
(Latency II) 
EBNA1, LMP1 and 
LMP2A 
GC Differentiation of activated 
B cell into memory 
Hodgkin’s disease, 
NK-T cell 
lymphoma 
EBNA1 
(Latency I) 
EBNA1 Dividing memory Cellular division of latently 
infected memory B cells 
BL, PEL 
Latency 
(Latency 0) 
None Resting memory Allow lifetime persistence  
Lytic All lytic genes Plasma cell Viral replication in plasma 
cell 
 
a Does not include the non-coding EBER and BART RNAs.  
PTDL – post-transplant lymphoproliferative disease 
 
Although virus entry is open to other interpretations (Gillet, Frederico et al. 2015), EBV is 
believed to reach a new host by oral transmission. A productive lytic infection is then 
established in the oropharynx, which contributes to the high levels of virus shed in saliva 
(Niederman, Miller et al. 1976). At this stage, viral replication takes place in both 
squamous epithelial cells and locally infiltrating B cells. This change in cellular tropism is 
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achieved by changing the composition of the glycoproteins present at the surface of the 
virion (Shannon-Lowe and Rowe 2014). Latently infected B cells then pass through a 
series of stages that lead to their activation and proliferation. These are associated with 
four distinct latency programs, which have been observed both in vitro and in vivo: growth 
program or latency III, default program or latency II, EBNA1 program or latency I, and 
latency program or latency 0 (Table 1.1) (Kempkes and Robertson 2015). The growth 
program starts upon infection of naïve B cells and is characterized by the expression of all 
nine known latent proteins, consisting of six EBV nuclear antigens (EBNAs) and three 
latent membrane proteins (LMPs). As a result, the infected B cells become activated, 
without the need for any external signals. B cells then migrate to secondary lymphoid 
organs where they participate in a GC reaction (Figure 1.2) (Babcock, Hochberg et al. 
2000, Roughan and Thorley-Lawson 2009). After a few cycles of proliferation, EBV 
switches to the more restricted default program, where only EBNA1, LMP1 and LMP2A 
are expressed (Table 1.1). EBNA1 is required to replicate the viral DNA. LMP1 and 
LMP2A provide the signals that are usually obtained through the BCR and through T cell 
help, as will be explained in more detail in section 1.4.2. This program, therefore, drives 
the differentiation of the latently infected B cells, that eventually leave the GC reaction as 
memory B cells and enter the peripheral circulation (Yates, Warren et al. 1985, Babcock, 
Hochberg et al. 2000, He, Raab-Traub et al. 2003, Casola, Otipoby et al. 2004). At this 
stage, EBV expresses only the viral genome tethering protein EBNA1 (EBNA1 program) 
or, alternatively, it does not express any viral proteins (latency program) (Babcock, 
Hochberg et al. 2000). The EBNA1 program takes place in dividing memory B cells and 
ensures the tethering to host chromosomes and segregation of EBV DNA and therefore, 
maintains the episomal DNA (Thorley-Lawson 2005). The latency or latency 0 program is 
considered the true latency. By shutting down protein expression the virus is quiescent 
and invisible to the immune response, allowing long-term persistence (Hawkins, Delgado-
Eckert et al. 2013). 
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Figure 1.2. Parallel between normal B cell response and EBV-driven response. In the normal 
B cell response, B cells that have encountered antigen migrate to the border between the B cell 
zone and the T cell zone, where they can present a specific peptide to CD4+ T helper (TH) cells. 
Upon cognate interaction, B cells receive activation signals from TH cells and establish a germinal 
center (GC) reaction. In the dark zone B cells undergo several rounds of proliferation, associated 
with somatic hypermutation. Selection of high affinity clones then takes place in the light zone 
through interaction with dendritic cells (DC) and TH cells. Selected cells may then undergo class 
switch recombination and differentiate into plasma cells or memory B cells, that leave the GC. 
Memory B cells can occasionally divide to maintain its pool. In the EBV-driven response, EBV 
infects a naïve B cell where it expresses the growth transcription program. EBV-infected B cells 
become activated and it is believed that they then establish a GC reaction, without the need for any 
external signals. Viral transcription then changes to the default program. This replaces the signals 
provided by TH cells and DCs and drives the differentiation of the infected B cells into memory B 
cells, where the latency program is expressed. Upon infected memory B cell division, there is a 
switch from the latency program to the EBNA1 program. Expression of EBNA1 then ensures 
episome maintenance during cell division, therefore maintaining the pool of latently infected 
memory B cells. Adapted from ThorleyLawson, 2001, Thorley-Lawson, 2005 and Klein & Dall-
Favera, 2008.  
 
In response to normal physiological signals, latently infected memory B cells may 
differentiate into plasma cells, resulting in virus reactivation from latency. This lytic 
reactivation is divided into three phases: immediate early, early and late. During the 
immediate early phase, there is expression of transcription factors that initiate viral 
replication. Next, in the early phase, there is production of proteins that are involved in 
viral DNA replication. Finally, both viral DNA and structural proteins are assembled into 
virions that are released and can either infect new cells or be shed in saliva (Kieff and 
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Rickinson 2007, Hawkins, Delgado-Eckert et al. 2013). Infection of new cells, as well as 
division of resting memory B cells, may be important to ensure the maintenance of a latent 
pool of virus. Furthermore, infection of epithelial cells may amplify the levels of infectious 
virus before shedding (Hadinoto, Shapiro et al. 2009). Shedding in saliva then completes 
the EBV cycle by allowing the infection of new hosts, therefore ensuring the high 
prevalence of this gammaherpesvirus. 
 
The EBNA proteins localize to the nucleus of the infected cell and are important for gene 
transcription and viral replication. EBNA1 is expressed in three of the four latency 
programs, namely growth, default and EBNA1 programs. It binds both to the viral episome 
and to the host chromosomes ensuring episome maintenance during cell replication. 
Furthermore, EBNA1 promotes LMP1 transcription and inhibits MHC-I-mediated peptide 
presentation. The remaining EBNA proteins are only expressed during the growth 
program. EBNA2 works as a transcriptional activator of the remaining EBNA and LMP 
proteins, as well as some cellular genes required for latency establishment. EBNA-LP 
works as a co-activator of EBNA2, enhancing transcriptional activation (Young and Murray 
2003, Speck and Ganem 2010). The EBNA3 family is important for the modulation of B 
cell lymphomagenesis. EBNA3A and EBNA3C target tumor suppressor pathways to 
promote B cell proliferation and are, therefore, considered oncoproteins. Interestingly, 
EBNA3B seems to restrain the oncogenic capacity of EBV and is, therefore, considered a 
tumor suppressor (Allday, Bazot et al. 2015). 
 
The mechanism and function of LMP1 and LMP2A will be described in more detail in 
section 1.4.2. As mentioned above, these proteins are produced during the growth and 
default latency programs but their role during the GC reaction is still unclear. On the one 
hand, in vitro studies demonstrate that LMPs have the ability to drive GC B cell survival 
and differentiation, independently of external signals (Gires, Zimber-Strobl et al. 1997, 
Caldwell, Wilson et al. 1998, Casola, Otipoby et al. 2004). On the other hand, latently 
infected B cells bear somatic mutations in their immunoglobulin genes and are isotype 
switched, suggesting a transition through the normal process of antigen selection and a 
passive role for the LMPs (Souza, Stollar et al. 2005, Souza, Stollar et al. 2007, Tracy, 
Kakalacheva et al. 2012). Therefore, the role of these proteins may be only to promote the 
survival of the infected cells. It is also possible that the LMPs ensure the differentiation of 
latently infected GC B cells into memory B cells, instead of plasma cells (Thorley-Lawson, 
Hawkins et al. 2013). Recent studies in mice that conditionally express LMP2A in GC B 
cells showed that expression of LMP2A reduces the stringency of GC B cell selection, as 
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observed by the preferential selection of low-afinity antibody-producing B cells 
(Minamitani, Yasui et al. 2015).  
 
In addition to the above mentioned latent proteins, EBV expresses EBV-encoded RNA 
(EBER) 1 and 2, which are small non-coding RNAs (Swaminathan 2008). EBV also 
encodes two clusters of miRNAs. Just like with latent gene expression, different patterns 
of miRNA expression have been detected and associated with the four latency programs. 
Furthermore, these miRNAs are expressed in tumor cells, which lack the growth program, 
where they are associated with viral driven lymphoproliferation (Qiu, Cosmopoulos et al. 
2011). Collectively, they confer an increased resistance to apoptosis (Seto, Moosmann et 
al. 2010). Therefore, they are an important component of EBV infection that contributes to 
survival and growth of both infected tumor cell and normal infected cell.  
 
Concluding, by exploiting the normal biology of the B cell, EBV is able to persist in a 
quiescent state, invisible to the immune response, for the lifetime of the host. To do so, 
the virus alternates amongst four different latency programs, characterized by distinct 
patterns of latent gene expression. During the growth and default latency programs, virus-
specific neutralizing antibodies and cytotoxic T lymphocytes counterweight the B cell 
proliferation promoted by the virus (Hislop, Taylor et al. 2007). Hence, an equilibrium is 
established between host and virus that, when disturbed, results in disease. By alternating 
between latent and lytic infection the virus is also able to increase its numbers and be 
transmitted to a new host. Although, to date, the GC model of infection is widely accepted 
as the only model that is able to explain EBV biology and the pathogenesis of EBV-
associated lymphomas, the development of a mathematical model of persistence has 
brought new insights into this field (Delgado-Eckert and Shapiro 2011). According to it, the 
basis of persistence is the cycle of infection itself, rather than the specific stage of 
quiescence in the memory compartment. Distinguishing these two possibilities is now 
crucial, as it will impact on the targets chosen in the future for anti-viral treatments. 
 
1.2.3 Model of KSHV infection 
 
KSHV prevalence in the human population is not as high as it is for EBV. Nonetheless, it 
is the most frequent cause of malignancy among AIDS patients. Because this is the most 
recently identified human herpesvirus, the mechanisms behind establishment and 
maintenance of latency are not as well studied as for EBV. Similar to EBV, the main target 
for latent infection in immunocompetent hosts is the B cell population (Ambroziak, 
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Blackbourn et al. 1995). However, KSHV has also been detected in epithelial cells, 
monocytes and endothelial cells. The latter seems to be limited to KS lesions (Dittmer and 
Damania 2013).  
 
Primary infection with KSHV may occur during childhood and adulthood and transmission 
may be through a sexual or non-sexual route (Minhas and Wood 2014). In KSHV-endemic 
regions, where seroprevalence is high, transmission is most commonly mediated by saliva 
and occurs among children. In non-endemic regions, where KSHV seroprevalence is low, 
sexual transmission may be the predominant route (Bagni and Whitby 2009). Although 
rare, transmission through blood transfusion or among intravenous drug users has been 
reported (Hladik, Dollard et al. 2006). The fact that KSHV can be found in cervico-vaginal 
secretions and the fact that KS develops in children under one year of age suggests 
vertical transmission, from mother to child (Minhas and Wood 2014). Similar to EBV, 
KSHV alternates between latent and lytic infection, relying on the first to persist in an 
immunological silent mode and on the latter to be shed and transmitted to new hosts 
(Coscoy 2007).  
 
During latency, as with EBV, few viral genes and miRNAs are expressed. These ensure 
genome maintenance, interfere with signaling pathways and manipulate the immune 
system in a strategy believed to be similar to the one developed by EBV. Studies 
performed in PEL cell lines allowed the characterization of a major latency locus that 
includes four major open reading frames (ORFs) which, in turn, encode the latency-
associated nuclear antigen (kLANA), the viral cyclin D homolog (v-Cyc), the Fas-
associated death domain-like interleukin-1β-converting enzyme-inhibitory protein (vFLIP) 
and the kaposin family of proteins (Kaposin A, B and C) (Kedes, Lagunoff et al. 1997, 
Sadler, Wu et al. 1999). Similar to EBNA1, kLANA ensures the maintenance and 
segregation of the viral genome during host cell division, by binding to the terminal repeat 
sequences of the viral episome and, simultaneously, to the host chromosome. Although 
central to KSHV latency, episome maintenance is not the only task carried out by this viral 
protein. kLANA also interacts with several cellular proteins, namely tumor suppressors, 
transcription factors, chromatin-binding proteins and signal transducers. Furthermore, it 
has been proposed to bind to viral promoters, repressing lytic gene transcription and 
promoting latency (Uppal, Banerjee et al. 2014). v-Cyc, like its cellular homologue cyclin 
D, is involved in modulation of cell cycle and sustains cell proliferation (Van Dross, Yao et 
al. 2005). vFLIP activates the NF-κB pathway, thereby promoting cell survival and 
proliferation. This protein has also been linked to suppression of lytic reactivation, hence 
contributing to latency maintenance and persistence (Ye, Zhou et al. 2008, Uppal, 
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Banerjee et al. 2014). The kaposin family of proteins is still poorly understood. Kaposin A 
is considered an oncogenic protein, while kaposin B acts as an adaptor protein and 
activates the p38/MAPK signaling pathway (Uppal, Banerjee et al. 2014). The kaposin 
locus also encodes twelve pre-miRNAs that produce eighteen mature, highly conserved, 
miRNAs. A function that appears to be common to most viral miRNAs is regulation of 
latent gene expression (Feldman, Kara et al. 2014). miR-K12-1 and miR-K12-3 repress 
lytic reactivation by modulating NF-κB, while miR-K12-5 maintains latency by reducing 
RTA expression. Few miRNAs have also been implicated in induction of viral reactivation. 
Summarizing, KSHV miRNAs are linked to modulation of host immune response, 
inhibition of apoptosis, and control of maintenance of latency and lytic reactivation. 
Besides the major latency locus described above, there are other genes whose 
expression has been detected during latency. Viral interferon regulatory factor 3 (vIRF-3) 
interacts with certain cellular IRFs and inhibits the expression of type I interferon. 
Furthermore, it inhibits NF-κB activation and decreases MHC-II expression. Viral 
interleukin 6 (vIL-6) promotes B cell proliferation and is an important contributor to the 
pathogenesis of PEL and MCD (Uppal, Banerjee et al. 2014, Schulz and Cesarman 
2015). The terminal membrane proteins K1 and K15, also expressed during latency, are 
involved in modulation of B cell signaling and will be described in more detail in section 
1.4.3. All of the above mentioned proteins are the core of KSHV latency and their 
expression was confirmed in vivo in cells derived from KSHV malignancies (Table 1.2). 
 
Table 1.2. KSHV latent gene expression in different malignancies (adapted from Damania, B., 
2004 and Wen, K.W. & Damania, B., 2010). 
Malignancy Proteins expressed in most tumor biopsies Proteins expressed in few tumor biopsies 
KS LANA, v-Cyc, vFLIP, kaposin vIL-6, K1 
PEL LANA, v-Cyc, vFLIP, kaposin, vIRF-3, vIL-6 K1 
MCD LANA, v-Cyc, vFLIP, vIRF-3, vIL-6 K1 
 
Certain environmental and physiological factors may lead to virus reactivation from 
latency, namely: viral co-infection, hypoxia, oxidative stress, inflammatory cytokines and 
histone deacetylase inhibitors. As with EBV, lytic reactivation of KSHV is divided into three 
phases: immediate early, early and late. Immediate early genes are responsible for the 
latent-to-lytic switch. Although several genes are associated with this phase, there is one 
central protein that is sufficient to disrupt latency and promote a complete lytic cascade, 
RTA or ORF50. Early genes encode proteins that are required for viral DNA replication 
and gene expression. Finally, late genes encode viral structural proteins that are required 
for virion assembly. New infectious progeny is then produced, ultimately resulting in host 
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cell death. This phase of KSHV infection is crucial for viral propagation and KSHV-induced 
tumorigenesis (Uppal, Banerjee et al. 2014, Purushothaman, Uppal et al. 2015).  
 
As in EBV infection, it is possible that the germinal center reaction plays a role in KSHV 
infection. PEL, for instance, is a B cell lymphoma of post germinal center origin. MCD 
cells, however, do not show signs of previous participation in the germinal center reaction 
(Dittmer and Damania 2013). Further studies are required to address this issue. 
Nonetheless, like EBV, KSHV seems to exploit the normal B cell biology and its pathways 
in order to promote cell proliferation and establish latency. Persistence is the result of an 
equilibrium between host and viral factors that, when perturbed, may result in disease. 
 
1.2.4 Model of MuHV-4 infection 
 
Understanding gammaherpesvirus pathogenesis is critical for the development of targeted 
therapies. Although much has been learned from in vitro studies with EBV and KSHV 
infected cells, in vivo studies remain the better way to understand host-pathogen 
interactions. Due to their narrow species tropism, the study of EBV and KSHV infection in 
vivo has been a difficult task. Although EBV is known to infect some primate species, this 
system does not properly reproduce a natural infection. Even infection of humanized mice 
does not reproduce a realistic infection. Isolation of a murine gammaherpesvirus from two 
species of free living small rodents, Apodemus flavicollis (yellow-necked mouse) and 
Clethrionomys glareolus (bank vole), in Slovakia in 1980 was the solution to this problem 
(Blaskovic, Stancekova et al. 1980). This virus, MuHV-4, was later on isolated in the 
United Kingdom from what is believed to be its natural host species, the Apodemus 
sylvaticus (wood mice) (Blasdell, McCracken et al. 2003). 
 
MuHV-4 lytically infects a variety of epithelial and fibroblast cells, and latently infects 
murine B cell lines such as NS0 (Svobodova, Blaskovic et al. 1982, Sunil-Chandra, 
Efstathiou et al. 1993). A B cell line has also been established from tumors of mice 
persistently infected with MuHV-4 (Usherwood, Stewart et al. 1996). Together, these cells 
allow the in vitro study of murid gammaherpesvirus infection. More importantly, MuHV-4 is 
able to infect laboratory mice, initiate a primary lytic infection and establish and maintain 
latency in B cells, as described for human gammaherpesviruses. It is classified as a 
rhadinovirus and is more closely related to KSHV than to EBV. In fact, 80% of MuHV-4 
genes are homologous to KSHV genes (Virgin, Latreille et al. 1997). Nonetheless, MuHV-
4 also genetically resembles EBV and shares its epithelial and B cell tropism, virus-driven 
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B cell proliferation, and an acute infectious mononucleosis syndrome (Simas and 
Efstathiou 1998, Doherty, Christensen et al. 2001, Nash, Dutia et al. 2001, Blackman and 
Flano 2002, Stevenson and Efstathiou 2005). Therefore, infection of laboratory mice with 
MuHV-4 provides a small tractable animal model for the study of gammaherpesvirus 
pathogenesis. The existence of a variety of transgenic mice, susceptible to MuHV-4 
infection, that are deficient for specific host proteins has also helped in understanding 
host-pathogen interaction. Furthermore, the development of a system of easy production 
of recombinant viruses allows the study of the function of specific viral proteins in an in 
vivo context (Adler, Messerle et al. 2000). Potentially, this is also a system where the 
effectiveness of therapeutic strategies against gammaherpesvirus infection may be 
assessed (Stevenson and Efstathiou 2005). In the immunology field, because it drives GC 
reactions, MuHV-4 can be used as a stimulus of immune response.  
 
MuHV-4 genome corresponds to 118kb of DNA flanked by terminal repeats, which 
contains approximately 80 ORFs. Although 80% of these genes are homologous to KSHV 
genes, MuHV-4 also encodes unique genes. ORFs M1-4, located at the left end of the 
genome, share no sequence relationship with any known viral or cellular genes. They 
may, however, have conserved functions. The M2 protein, for instance, is a presumed 
functional homologue of LMP1 and LMP2A from EBV and K1 and K15 from KSHV 
(Damania 2004, Pires de Miranda, Lopes et al. 2013). Because it is the focus of this 
thesis, the M2 protein will be described in detail in section 1.5. M1 is reminiscent of a viral 
superantigen and induces activation and proliferation of CD8+ Vβ4+ T cells (Evans, Moser 
et al. 2008). In turn, these produce IFN-γ that is required for virus reactivation from latency 
in macrophages. The secreted M3 protein binds several chemokines, therefore blocking 
normal CD8+ T cell function (Parry, Simas et al. 2000, Bridgeman, Stevenson et al. 2001). 
M4 codes for another secreted glycoprotein and is thought to act as an 
immunomodulatory and/or immunostimulator. In vivo, absence of M4 expression 
attenuates latency establishment (Geere, Ligertwood et al. 2006). 
 
Both the route of virus administration and the infection dose administered have an impact 
in MuHV-4 infection, and should be taken into account when comparing literature results. 
In pathogenesis studies, MuHV-4 has been administered intranasaly, intraperitonealy, 
orally and even subcutaneously into the footpad (Milho, Smith et al. 2009, Frederico, 
Chao et al. 2015). In adult mice oral MuHV-4 is non-infectious, unless it reaches the 
respiratory tract. Intranasal (i.n.) inoculation is believed to reproduce the physiological 
route. Nonetheless, intraperitoneal (i.p.) inoculation is also commonly used. Although they 
differ in the patterns of lytic infection following inoculation, both i.n. and i.p. routes allow 
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the virus to reach the lymphoid tissue (Milho, Smith et al. 2009). Furthermore, the steps of 
spleen colonization followed by MuHV-4 after i.n. or i.p. inoculation are the same 
(Frederico, Chao et al. 2014). The use of anesthesia in intranasal inoculation also alters 
the pattern of MuHV-4 infection. In the anaesthetized mice, MuHV-4 infects lung epithelial 
cells before spreading, while in the absence of anesthesia, MuHV-4 infects only the nose 
before spreading to the lymphoid tissue (Milho, Smith et al. 2009). Another possible route 
of virus shed is sexual transmission from female to male laboratory mice. MuHV-4 was 
identified in a vaginal excretion but this was not linked to vertical transmission nor 
horizontal transmission to other female mice (Francois, Vidick et al. 2013).  
 
Following i.n. inoculation of laboratory mice, MuHV-4 targets the olfactory neuroepithelium 
(Milho, Frederico et al. 2012). Free viruses then infect CD11c+ myeloid cells, which 
provide a conduit to lymph nodes (LN) (Figure 1.3) (Gaspar, May et al. 2011, Frederico, 
Milho et al. 2012). Simultaneously, the virus establishes a productive lytic infection in 
epithelial cells of the lungs, that peaks at 5 to 7 days post infection (dpi). At this stage, 
lung cells can be collected and co-cultured with permissive cells to measure the lytic viral 
load. CD8+ T cells, also known as cytotoxic T lymphocytes (CTL), with specificity for lytic 
viral antigens play an important role in immune response, and lung infection is resolved 
within 10 to 12 days. CD4+ T cells are also important for an efficient long-term response of 
CTLs (Cardin, Brooks et al. 1996). Besides the lungs, low titers of infectious virus can also 
be detected in the heart, kidney, major lymphoid organs, adrenal glands and whole blood 
(Sunil-Chandra, Efstathiou et al. 1992, Cardin, Brooks et al. 1996). Lytic infection is not a 
pre-requisite for latency establishment, as it has been observed by the ability of 
recombinant viruses, that cannot undergo lytic replication, to establish latency. However, 
lytic replication is a pre-requisite for virus trafficking and spleen colonization (Flano, Jia et 
al. 2005, Moser, Farrell et al. 2006).  
 
Once in the LN, subcapsular sinus macrophages limit acute virus dissemination by 
absorbing virions from the afferent lymph in a non-productive manner (Frederico, Chao et 
al. 2015). It is believed that MuHV-4 then infects B cells that differentiate into plasma cells, 
releasing virus into the afferent lymph. By accessing the bloodstream, MuHV-4 reaches 
the spleen (Figure 1.3). There, the virus explores normal splenic communication routes to 
get access to GC reactions (Frederico, Chao et al. 2014). Latently infected B cells 
proliferate, increasing the pool of latent virus. Expansion attains maximum levels at 14dpi, 
which then decrease to a steady state characterized by low numbers of infected cells that 
persist throughout the life of the host without causing disease. The peak of latent infection 
is also accompanied by a large increase in CD4+ and CD8+ T cell numbers. Together, the 
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increased numbers of latently infected B cells, CD4+ T cells and CD8+ T cells result in a 
transient splenomegaly and lymphadenopathy (Sunil-Chandra, Efstathiou et al. 1992). It is 
also at this stage that the unique secreted viral protein M1 activates and promotes a 
selective expansion of CD8+ Vβ4+ T cells, in a manner reminiscent of a viral superantigen 
(CS Evans et al., 2008). In addition, there are high levels of non-virus-specific antibodies 
in the peripheral blood, therefore resembling the infectious mononucleosis caused by EBV 
(Tripp, Hamilton-Easton et al. 1997, Blackman, Flano et al. 2000, Hardy, Silins et al. 
2000). 
 
 
Figure 1.3. Schematic representation of MuHV-4 infection of a murine host. Upon intranasal 
infection with MuHV-4, mice develop a lytic infection in the olfactory neuroepithelium. Through 
myeloid cells the virus reaches the lymph nodes. Next, by entering the blood stream, MuHV-4 
spreads to the spleen. Once in the spleen, the virus starts by infecting marginal zone (MZ) and 
metalophilic macrophages (MΦ). Then, it spreads to MZ B cells, which relocate to the white pulp 
(WP). Dendritic cells (DCs) then make the bridge between these cells and follicular (Fo) B cells. 
These, in turn, are able to participate in germinal center (GC) reactions. RP, red pulp. Adapted 
from Frederico, Chao et al. 2014 and Gillet, Frederico et al. 2015. 
 
Although memory B cells are the long-term target population of MuHV-4, other B cell 
subsets and other cell types are also infected during latency establishment (Flano, Kim et 
al. 2002, Marques, Efstathiou et al. 2003, Willer and Speck 2003, Collins, Boss et al. 
2009). In fact, it was demonstrated that, following i.p. infection, MuHV-4 is able to latently 
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infect mice that are deficient for mature B cells (Weck, Barkon et al. 1996). Initial analysis 
showed the presence of latent viral genomes in macrophages and dendritic cells, besides 
the already known B cell population (Flano, Husain et al. 2000). More recent studies have 
revealed the splenic populations exploited by the virus, as well as the order in which they 
are infected (Figure 1.3). MuHV-4 begins spleen colonization by infecting marginal zone 
macrophages. At this stage, infection is considered to be lytic and can also be detected in 
other macrophage populations, such as marginal metalophilic macrophages. 
Macrophages provide access to marginal zone B cells which, in turn, relocate to the white 
pulp. Follicular dendritic cells then transfer the virus to follicular B cells in a way that is 
reminiscent of their presentation of immune complexes to GC B cells (Frederico, Chao et 
al. 2014). Infected follicular B cells may then participate in a GC reaction. This is a critical 
step for persistence, as participation in a GC reaction provides access to the long-lived 
memory B cell population. In fact, at the latency peak, 70-80% of the infected B cells have 
a germinal center phenotype. Decrease of infection levels to a steady state corresponds 
to regression of GCs (Flano, Kim et al. 2002, Willer and Speck 2003). Therefore, MuHV-4 
infection resembles EBV infection in that it exploits the GC reaction to increase the pool of 
latently infected B cells and promote their differentiation into memory B cells, a population 
that supports long-term infection.  
 
Like EBV, MuHV-4 gene expression during latency is restricted. Furthermore, it is 
dependent on the type of cell infected. Gene transcription during this stage was analyzed 
by different groups but, due to the differences in study design, results were not 
consensual (Simas, Swann et al. 1999, Virgin, Presti et al. 1999, Rochford, Lutzke et al. 
2001, Marques, Efstathiou et al. 2003, Martinez-Guzman, Rickabaugh et al. 2003). A 
study performed by our group has looked into gene expression in macrophages, dendritic 
cells and different B cell subsets at the peak of latent infection (Marques, Efstathiou et al. 
2003). The unique genes M1 to M4, described above, were detected in all subsets of 
latently infected B cells, namely newly formed, marginal zone, follicular and GC B cells. 
Other ORFs that were transcribed during latency establishment were M8, M9, M11, K3, 
ORF72, ORF73 (mLANA) and ORF74. M8 and M9 function is still not clearly determined. 
Given its homology with KSHV and EBV proteins, M8 is predicted to encode a post-
transcriptional regulator (Mackett, Stewart et al. 1997). Similarly, M9 is predicted to 
encode a capsid protein (Nash, Dutia et al. 2001). M11, only detected in newly formed 
and marginal zone B cells, encodes a viral homologue of bcl-2 and is a potent inhibitor of 
apoptosis (Wang, Garvey et al. 1999). Furthermore, it contributes to viral latency 
amplification in the lymphoid tissue (de Lima, May et al. 2005). K3 downregulates the 
surface expression of MHC-I, therefore contributing to immune evasion from CTLs 
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(Boname and Stevenson 2001). ORF72 encodes a viral cyclin D homologue. ORF73 or 
mLANA, like EBNA1 from EBV and kLANA from KSHV, ensures viral episome 
maintenance. Also like its human counterparts, mLANA acts as an immune evasion 
protein, limiting epitope presentation to CD8+ T cells (Bennett, May et al. 2005). 
Furthermore, mLANA inhibits NF-κB transcriptional activity by promoting its ubiquitination 
and subsequent proteasome degradation of the sub-unit p65/RelA. Mutation of the SOCS 
box responsible for this function results prevents the expansion of latently infected GC B 
cells, therefore impairing persistence (Rodrigues, Filipe et al. 2009). Through its E3 
ubiquitin ligase activity, mLANA also promotes a heterotypic poly-ubiquitination of c-myc 
increasing its stability, which results in an increased progression through the cell cycle 
(Rodrigues, Popov et al. 2013). Recent resolution of the crystal structure of the C-terminal 
domain of mLANA allowed the identification and targeted mutation of a DNA binding 
region and a set of lysine residues that are predicted to mediate interaction with host 
cellular proteins. Their mutation has an impact in virus-driven GC B cell proliferation 
(Correia, Cerqueira et al. 2013). Therefore, mLANA promotes the expansion of MuHV-4 in 
GC B cells. ORF74, only detected in newly formed and marginal zone B cells, encodes a 
G-protein coupled receptor that is required for increased viral replication in response to 
chemokines (Wakeling, Roy et al. 2001, Lee, Koszinowski et al. 2003).  
 
Like its human virus counterparts EBV and KSHV, MuHV-4 encodes several miRNAs at 
the left end of its genome. In vitro, these are expressed in both lytic and latent infection 
(Pfeffer, Sewer et al. 2005, Zhu, Strehle et al. 2010). In vivo, they are highly expressed in 
GC B cells and hence are used as a marker of latent infection (Bowden, Simas et al. 
1997, Simas, Swann et al. 1999). However, their function is still unknown.  
 
MuHV-4 reactivation from latency is still poorly studied but, like with EBV and KSHV, it 
has been linked to plasma cell differentiation. The unique latency-associated M2 protein 
can drive plasma cell differentiation in vitro and it is required for an efficient differentiation 
of infected B cells to plasma cells in vivo. Therefore, this protein has been linked to virus 
reactivation from B cells (Liang, Collins et al. 2009). Manipulation of ORF50 expression, a 
gene that is responsible for the switch from latency to lytic virus replication, has been used 
to address this issue. A single study has demonstrated that exposure of infected cells to 
hypoxia conditions results in the up-regulation of ORF50 (Polcicova, Hrabovska et al. 
2008). Another study has placed the ORF50 gene under a doxycycline-inducible promoter 
to create an in vitro system where the latent to lytic switch can be controlled (May, Bennett 
et al. 2010). 
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Recent work from our laboratory assessed the role of BCR specificity in B cell 
susceptibility to latent infection. By taking advantage of the switch hen egg lysozyme 
(SWHEL) mice, where approximately 10% of the B cell population is specific for hen egg 
lysozyme (HEL), it was possible to observe that latency was restricted to HEL- B cells. 
This demonstrates that latency establishment is not a stochastic event in what concerns 
BCR specificity (Decalf, Godinho-Silva et al. 2014). Another study from our group has 
determined critical MHC-I and CD8+ T cell engagement thresholds for in vivo CTL control 
of virus-driven B cell proliferation, a step that is fundamental for the development of 
immunotherapies and vaccines (Godinho-Silva, Marques et al. 2014).  
 
Concluding, MuHV-4 is a critical tool in the study of gammaherpesvirus pathogenesis, that 
provides an understanding of host-pathogen interactions and allows the dissection of viral 
protein function in an in vivo context. Like EBV, MuHV-4 exploits the normal biology of the 
B cell. In particular, it takes advantage of the GC reaction to amplify the pool of latent 
genomes and get access to the long-lived memory B cell population, attaining persistence 
without causing disease. 
 
1.3 Gammaherpesviruses and B-T helper cell interaction 
 
CD4+ T cells are an important component of the immune response. For 
gammaherpesviruses they may have a dual role. On the one hand, they are important for 
immune surveillance against the virus. On the other hand, in cases where the virus takes 
advantage of the GC reaction, they are putatively important for B cell activation and GC 
initiation.  
 
1.3.1 B-T helper cell interaction 
 
As described in section 1.2.1, T cell help is critical for the initiation of a GC reaction in T 
cell-dependent immune responses. Antigen-presenting cells (APCs), such as B cells, 
process pathogen-derived peptides and present them in MHC-II molecules at the cellular 
surface. In response to a ligand gradient, B cells migrate within the follicles and towards 
the T cell zone. In that border area, TH cells may then scan for the highest affinity with 
particular B cells. The initial contact is peptide-independent and mediated by adhesion 
molecules, resulting in the formation of B-TH cell conjugates. This interaction is transient, 
unless the TH cell TCR recognizes the peptide for which it is specific at the surface of the 
B cell. In that case, the transient interaction is replaced by a stronger cognate interaction, 
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where an organized signaling structure, the immunological synapse (IS), is formed 
(Grakoui, Bromley et al. 1999). The final outcome is the activation of the interacting B cell, 
its subsequent proliferation and establishment of a GC (Allen, Okada et al. 2007). B-TH 
cell interaction is also important at a later step of the GC pathway, when B cells submitted 
to SHM are selected through interaction with DCs and TFH cells. 
 
B-T cell interaction is a highly dynamic process, as T cells can interact with several APCs 
simultaneously, selectively polarizing towards the strongest stimulus (Depoil, Zaru et al. 
2005). Typically, an IS is composed of spatially separated supramolecular activation 
clusters (SMACs), arranged in a bull’s eye shape (Figure 1.4) (Monks, Freiberg et al. 
1998, Grakoui, Bromley et al. 1999, Huppa and Davis 2003). The center of the contact 
zone is named central SMAC (cSMAC), which bears cell activation molecules, as well as 
TCR-CD3/MHC-II partners. The latter control the specificity of the immune response. 
Similar to the B cell receptor, the TCR complex contains ITAMs that, when 
phosphorylated, can recruit the tyrosine kinase zeta-associated protein of 70 kDa (ZAP-
70) and initiate signal transduction (Irving and Weiss 1991). CD80 and CD86 co-
stimulatory molecules can bind CD28 present at the surface of the interacting TH cell. In 
turn, this molecule contains a cytoplasmic tail with motifs that recruit Lck and, indirectly, 
PKC-ϴ, which are involved in signaling (Kong, Yokosuka et al. 2011). T cell activation is 
followed by the upregulation of another co-stimulatory molecule, the inducible T-cell 
costimulator (ICOS). This binds ligand of ICOS (LICOS) on the B cell and is important in 
GC reactions (Dustin 2014). Cell adhesion molecules, such as CD48 and ICAM1, locate 
to the periphery of the cSMAC, forming the peripheral SMAC (pSMAC). By promoting B-
TH cell interaction, these molecules are essential for sensitive antigen recognition. 
Surrounding these two regions is the distal SMAC (dSMAC) where larger molecules can 
be found (Huppa and Davis 2003, Krummel and Cahalan 2010). Advances in IS study 
have led to a revision of the canonical view of this signaling structure. It is now known that 
TCR-MHC-II partners are concentrated in microclusters that are formed in the dSMAC 
and then migrate through the pSMAC towards the cSMAC (Varma, Campi et al. 2006). 
TCR microcluster formation depends on the actin cytoskeleton, while their migration relies 
on both the actin cytoskeleton and microtubules (Alarcon, Mestre et al. 2011). This 
reinforces the vision of the IS as a highly dynamic structure. CD28 also co-localizes with 
the TCR micro-clusters but is segregated upon convergence in the cSMAC (Yokosuka, 
Kobayashi et al. 2008). The latter is now sub-divided into the endo-cSMAC, where CD28-
enhanced signaling continues, and the exo-cSMAC, composed of TCR-enriched 
extracellular vesicles that are collected by the B cell and moved away from the contact 
zone (Figure 1.4) (Dustin 2014).  
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Figure 1.4. Organization of representative receptor classes in B-TH immunological synapse. 
Immunological synapse formed between a B cell and a TH cell, with representative receptor classes 
organized in supramolecular activation clusters (SMACs). The central SMAC (cSMAC) is divided 
into two regions: exo-cSMAC and endo-cSMAC. The first is the site for budding of TCR-enriched 
vesicles and, therefore, does not support signaling. The latter contains TCR-MHC-II partners and 
co-stimulatory molecules. Signaling proteins are recruited to this region to allow signal 
transduction. This is also the place to where the microtubule organizing center (MTOC) polarizes to 
allow the polarized secretion of cytokines. The cSMAC is surrounded by the peripheral SMAC 
(pSMAC), which contains adhesion molecules. In turn, the pSMAC is surrounded by the distal 
SMAC (dSMAC). Adapted from Huppa and Davis, 2003, Friedl, 2005 and Dustin, 2014. 
 
Besides the reorganization at the cellular surface level, T cells also undergo 
morphological and cytoskeletal changes. Filamentous actin (F-actin) forms a ring that 
surrounds the previously mentioned structures (Le Floc'h and Huse 2015). Furthermore, 
there is polarization to the contact zone of the microtubule organizing center (MTOC) 
(Figure 1.4) (Monks, Freiberg et al. 1998, Huppa and Davis 2003, Depoil, Zaru et al. 
2005), an event that aligns the secretory organelles with the IS and enables the polarized 
secretion of cytokines like IL-2, IL-4, IL-5 and IFN-γ to the extracellular opening that exists 
between the interacting cells, named synaptic cleft (Friedl, den Boer et al. 2005, Huse 
2012). Cellular organelles and signaling machinery also polarize to the contact zone 
(Allen, Okada et al. 2007, Dustin 2014). Such polarization is reciprocal, as B cells also 
have the ability to polarize their MTOC and endocytic/exocytic compartments to the 
interface, although the functional role of such polarization has not been determined 
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(Duchez, Rodrigues et al. 2011). The IS therefore constitutes a local platform for 
signaling. As a result, the interacting B and TH cells are mutually activated. 
 
1.3.2 Modulation of B-T helper cell interaction by gammaherpesviruses 
 
Immune evasion is crucial for pathogen survival in the host. Gammaherpesviruses have 
developed several strategies, many of them revolving around downregulation of surface 
MHC-I expression and consequent dodging of CTL recognition. K3 and K5 from KSHV 
encode two endoplasmic reticulum proteins that downregulate surface MHC-I molecules 
by promoting their endocytosis (Coscoy and Ganem 2000, Ishido, Wang et al. 2000, 
Stevenson, Efstathiou et al. 2000). Further studies have shown that K5, which is part of 
the lytic replicative cycle of KSHV, also has an impact in B-T cell interaction and 
immunological synapse formation (Coscoy and Ganem 2001). Expression of K5 in the 
BJAB B cell line reduces ICAM-1 and CD86 surface expression by promoting their 
endocytosis and degradation. As a result, K5-expressing B cells lose the ability to activate 
T cells in the presence of superantigen, as assayed by the measurement of T cell 
transcription factors known to be stimulated upon B-T cell interaction. This suggests that 
K5 renders the infected B cells less visible to TH cells, thereby reducing antiviral cytokine 
responses and impairing the upregulation of stimulatory signals for CTL generation.  
 
Another gammaherpesvirus encoded protein implicated in the modulation of B-T cell 
interaction is the tyrosine kinase-interacting protein (Tip) of Herpesvirus Saimiri (HVS). 
Like K5 from KSHV, Tip inhibits T cell activation as a mechanism to disarm host immune 
surveillance. Unlike KSHV, HVS is a T-lymphotropic virus and, therefore, the mechanism 
behind such inhibition is different. Tip interacts with cellular tyrosine kinase Lck and the 
endosomal protein p80. By sequestering Lck, Tip inhibits ZAP70 tyrosine kinase activation 
and, consequently, inhibits TCR-mediated intracellular signal transduction. Tip also 
inhibits the movement of TCR and Lck to the site of B-T cell interaction and suppresses 
the formation of the immunological synapse (Cho, Feng et al. 2004). Furthermore, 
interaction of Tip with Lck recruits TCR complex to lipid rafts and, subsequently, the 
interaction of Tip with p80 induces their internalization. The concerted action of the two 
interactions results in downregulation of TCR complexes (Park, Cho et al. 2003).  
 
Despite the importance of CD4+ T cells in MuHV-4 infection, there are no known 
mechanisms of modulation of B-T helper cell interaction. Like for its human counterparts, 
CD4+ T cells play an important role in immune surveillance against the virus because they 
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are required for maturation of the antibody response and for antiviral cytokine activity, in 
particular IFN-γ (Christensen, Cardin et al. 1999, Stevenson and Doherty 1999, Sangster, 
Topham et al. 2000). Therefore, inhibition of B-T helper cell interaction in this context 
could be beneficial for the virus. Notably, CD4+ T cells play another major role in MuHV-4 
infection which is their requirement for GC initiation. In fact, in CD4-depleted mice, it is not 
possible to observe the normal increased B cell activation and increased levels of total 
serum IgG that is associated to MuHV-4 infection (Stevenson and Doherty 1998, 
Stevenson and Doherty 1999). Furthermore, absence of TH cells results in impaired 
proliferation in GC reactions, reduced latency amplification and no splenomegaly 
(Ehtisham, Sunil-Chandra et al. 1993, Usherwood, Ross et al. 1996, Kim, Flano et al. 
2003). During the GC response, insufficient help from T follicular helper cells also results 
in an inefficient establishment of latency in B cells. Fewer cells have a GC phenotype and, 
the ones that have, fail to proliferate. This is in contrast with what is believed to happen 
during EBV infection, which presumably bypasses the T cell help requirement (Collins and 
Speck 2014). For example, EBV expresses a protein that mimics CD40 signaling and, 
therefore, replaces T cell help. Infection of CD40+CD40- chimeric mice with MuHV-4 
revealed that latency is progressively lost in CD40- B cells, which fail to proliferate and 
differentiate into memory B cells through the GC reaction. On the other hand, CD40+ cells, 
which are able to receive signals from TH cells, selectively enter GC reactions and 
differentiate into memory B cells (Kim, Flano et al. 2003). Therefore, unlike EBV, MuHV-4 
depends on normal CD4+ T cell help for B cell activation, proliferation and differentiation. 
In this specific context, promotion of B-T helper cell interaction may be important to drive 
the infected B cells through a GC reaction contributing to host colonization. Although this 
putative role may be irrelevant for EBV infection, which encodes proteins believed to 
replace T cell help, that may not be the case for KSHV.  
 
1.4 Gammaherpesvirus terminal membrane proteins involved in 
modulation of cell signaling 
 
For a successful colonization of the host, gammaherpesviruses code for proteins that 
directly or indirectly promote immune evasion, cell survival, cell proliferation, cell 
differentiation and, in some cases, cell transformation and tumorigenesis. A set of those 
proteins is responsible for the modulation of the host B cell signaling. In human 
herpesviruses, these proteins correspond to LMP1 and LMP2A from EBV, and K1 and 
K15 from KSHV. Although different in sequence, these proteins share a functional 
homology as well as a positional homology, as their sequence can be found at the ends of 
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the coding region of the viral genomes. Furthermore, some of these proteins have a 
transforming potential, which has been linked to their ability to activate specific signaling 
pathways (Brinkmann and Schulz 2006). 
 
1.4.1 B cell signaling 
 
B cells are a component of adaptive immunity, specialized in the recognition of antigens 
(Yuseff, Pierobon et al. 2013). To carry out their function, B cells express a B cell receptor 
(BCR) at the cell surface. This is composed of an antigen-recognition subunit, the 
membrane immunoglobulin (Ig), and an Igα/Igβ heterodimer. The latter contains an 
immunoreceptor tyrosine-based activation motif (ITAM) at the cytoplasmic tail of each Ig, 
which is responsible for signal transduction (Reth 1989, Dal Porto, Gauld et al. 2004). 
Binding of antigen to the BCR drives its aggregation in lipid rafts (Pierce 2002). These 
domains are rich in Src family kinases, which phosphorylate the tyrosine residues of the 
ITAMs creating docking sites that allow the recruitment and activation of the Syk kinase. 
In turn, this recruits several cellular signaling proteins such as: Vav, phosphoinositide 3-
kinase (PI3K) and phospholipase C-γ2 (PLCγ2). These proteins contain SH2 and/or SH3 
domains that allow them to interact with other proteins and with each other. The outcome 
is the formation of a signalosome that will impact several signaling pathways. The 
cytosolic tail of CD19, a member of the B cell co-receptor, also contains tyrosine residues 
that are phosphorylated and interact with cellular signaling proteins, further enhancing 
BCR signaling (Dal Porto, Gauld et al. 2004, Harwood and Batista 2008).  
 
The PI3K pathway leads to the production of PIP3 and recruitment and activation of the 
serine/threonine kinase Akt, which interacts with proteins and transcription factors that 
control apoptosis, promoting B cell survival (Andjelkovic, Alessi et al. 1997). Moreover, Akt 
interacts with nuclear transcription factor NF-κB, which upregulates genes involved in B 
cell development and proliferation (Okkenhaug and Vanhaesebroeck 2003). Activation of 
PLCγ2 results in the cleavage of phosphoinositide PIP2 into the second messengers IP3 
and DAG, which promote the mobilization of calcium and the activation of mitogen-
activated protein kinases (MAPK), respectively. These events promote the activation of 
the transcription factors NFAT and NF-κB, ultimately contributing to B cell proliferation and 
differentiation (Niiro and Clark 2002). Vav proteins promote GDP/GTP exchange on 
Rho/Rac proteins which, when activated, promote changes in intracellular pathways 
related to cytoskeletal change, mitogenesis and cell survival (Etienne-Manneville and Hall 
2002). Vav proteins also play in role in the activation of the before mentioned signaling 
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pathways, PLCγ2 and PI3K pathways, and it modulates the activity of the NFAT and NF-
κB transcription factors (Bustelo 2000, Turner and Billadeau 2002).  
 
1.4.2 EBV LMP1 and LMP2A proteins 
 
LMP1 is a transmembrane protein, encoded by the first ORF of the EBV genome, that 
localizes to lipid rafts. It has a short amino terminus, six transmembrane-spanning 
domains and a 199-amino acid long cytoplasmic tail (Damania 2004, Brinkmann and 
Schulz 2006). Functionally, this viral protein mimics the CD40 receptor, which promotes B 
cell survival and proliferation, GC and memory B cell differentiation, isotype switching and 
affinity maturation (Bishop and Hostager 2003). In contrast to CD40, which requires 
binding to the ligand CD154 present in TH cells to be activated, LMP1 is a constitutively 
active receptor molecule that does not require the presence of specific extracellular 
signals (Gires, Zimber-Strobl et al. 1997, Kilger, Kieser et al. 1998). This ability was 
shown to be dependent on the transmembrane domains of the protein (Yasui, Luftig et al. 
2004), which allow ligand-independent oligomerization, trafficking to membrane lipid rafts 
and constitutive C-terminal tail signaling. The cytoplasmic tail of LMP1 is divided into two 
C-terminal activation regions, CTAR1 and CTAR2, also termed transformation effector 
sites, TES1 and TES2. These regions are involved in the interaction with tumor-necrosis 
factor (TNF)-receptor-associated factors (TRAFs) and TNF-receptor-associated death 
domains (TRADDS), resulting in the activation of NF-κB. This, in turn, is responsible for 
the ability of LMP1 to induce immortalization of human primary B lymphocytes (Devergne, 
Hatzivassiliou et al. 1996). LMP1 was also described to activate the PI3K pathway 
(Dawson, Tramountanis et al. 2003), associated with suppression of apoptosis and cell 
survival, the mitogen-activated protein kinase (MAPK) pathway and the interferon-
regulatory factor 7 (IRF7) pathway. The latter is known to up-regulate LMP1 expression, 
constituting a positive feedback circuit (Ning, Hahn et al. 2003). Furthermore, LMP1 
activates the JNK pathway (Eliopoulos and Young 1998), which can lead to the 
expression of proteins involved in cell proliferation and transformation, linking the ability of 
the viral protein to modulate cell signaling with its ability to promote cell transformation. 
Concomitantly, LMP1 is expressed in latently-infected B cells in transplant lymphoma, 
nasopharyngeal carcinoma and Hodgkin’s disease and its expression in vivo is associated 
with an increased frequency of B cell lymphomas (Uchida, Yasui et al. 1999). 
Furthermore, LMP1 can transform rodent fibroblasts, which can generate multiple tumors 
upon injection into nude mice (Wang, Liebowitz et al. 1985), and its expression is 
essential for the immortalization of primary human B lymphocytes (Dawson, Rickinson et 
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al. 1990, Kaye, Izumi et al. 1993). Its expression has also been detected during the lytic 
cycle of infection, in epithelial and B cells (Boos, Berger et al. 1987, Contreras-Salazar, 
Ehlin-Henriksson et al. 1990). Collectively, the functions of LMP1 described above 
indirectly promote the activation, survival, proliferation and transformation of EBV-infected 
cells (Damania 2004, Brinkmann and Schulz 2006). Furthermore, the ability to mimic the 
CD40 receptor suggests that LMP1 renders the infected B cell independent of T cell help. 
 
The LMP2 gene of EBV, located at the 3’ end of the genome, is transcribed into two 
mRNAs that share exons 2-9 and give rise to the two isoforms LMP2A and LMP2B. 
LMP2A is a transmembrane protein that localizes to lipid rafts and consists of a short C-
terminal domain, 12 transmembrane-spanning domains and a 119 amino acid-long N-
terminal domain. The latter contains eight tyrosine residues, two of which form an ITAM, 
and multiple PXXP motifs, which are responsible for the molecular functions of the protein. 
The LMP2B isoform lacks the N-terminal domain found in LMP2A (Damania 2004, 
Brinkmann and Schulz 2006, Kempkes and Robertson 2015). Through the tyrosines 
present in the N-terminal domain, LMP2A is able to bind to the tyrosine kinase Lyn, a 
member of the Src family. This, in turn, phosphorylates the tyrosine residues within the 
ITAM resulting in the recruitment of another tyrosine kinase, Syk. By binding to these 
kinases and by preventing the BCR from entering lipid rafts, LMP2A inhibits BCR 
signaling (Thorley-Lawson 2001, Brinkmann and Schulz 2006, Rovedo and Longnecker 
2008). Moreover, through the PXXP motifs present in the N-terminal domain, LMP2A 
interacts with WW domains of several members of the Nedd4-like ubiquitin protein ligase 
family, resulting in the ubiquitination and degradation of LMP2A and LMP2A-associated 
proteins, contributing to BCR inhibition (Ikeda, Ikeda et al. 2000). Since binding of specific 
antigen to the BCR has been associated to virus reactivation from latency, LMP2A 
inhibition of BCR signaling is an important mechanism for the maintenance of the latency 
pool. Signal transduction following binding of specific antigen to the BCR results in the 
activation of growth-promoting signaling cascades. Blocking this mechanism would 
therefore negatively impact B cell survival. However, expression of LMP2A was found to 
be capable of replacing the survival signal usually provided by the BCR. This was 
observed in vivo when expression of LMP2A was able to rescue B cells from death, 
driving those cells out of the bone marrow to the periphery in BCR-deficient transgenic 
mice (Caldwell, Wilson et al. 1998). This function of LMP2A is most likely due to the 
activation of the PI3K pathway, which results in AKT activation (Fukuda and Longnecker 
2004). Among other outcomes, AKT results in inhibition of apoptosis, therefore promoting 
B cell survival. Collectively, results indicate that LMP2A may both mimic and inhibit active 
BCR signaling. 
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The C-terminal domain of LMP2A mediates the homodimerization and heterodimerization 
of LMP2 protein isoforms (Cen and Longnecker 2015). Binding of LMP2B to that region of 
LMP2A prevents its phosphorylation and restores normal BCR signaling (Rovedo and 
Longnecker 2007). As an outcome, EBV latently-infected cells are more prone to switch to 
lytic infection (Rechsteiner, Berger et al. 2008). Like LMP1, LMP2A expression is detected 
in latently-infected B cells in transplant lymphoma, nasopharyngeal carcinoma and 
Hodgkin’s disease. Although initially thought to not be an oncogenic protein (Kim and 
Yates 1993), more recent studies have shown that expression of LMP2A results in cell 
transformation (Scholle, Bendt et al. 2000, Fukuda and Longnecker 2007, Fukuda and 
Kawaguchi 2014). Summarizing, LMP2A ensures latency maintenance by inhibiting B cell 
activation through BCR signaling and, at the same time, promoting B cell survival. 
 
1.4.3 KSHV K1 and K15 proteins 
 
Similar to EBV LMP1, K1 is a transmembrane protein encoded by the first ORF of the 
KSHV genome. It contains an N-terminal extracellular domain, a single transmembrane 
region and a short C-terminal cytoplasmic tail (Lagunoff and Ganem 1997, Damania 2004, 
Brinkmann and Schulz 2006). The extracellular domain has a high degree of amino acid 
sequence variability and is implicated in K1 oligomerization (Lee, Veazey et al. 1998, 
Lagunoff, Majeti et al. 1999). Structurally, K1 resembles the Igα/Igβ heterodimer. In 
agreement, the cytoplasmic tail contains a functional ITAM that allows signal transduction 
in a constitutive manner (Lee, Guo et al. 1998, Lee, Veazey et al. 1998, Lagunoff, Majeti 
et al. 1999). Specifically, two phosphorylated tyrosines of the ITAM allow binding to SH2-
containing molecules and, consequently, the assembly of a signalosome that includes 
Lyn, Syk, p85α subunit of PI3K, PLCγ2, RasGAP120, Vav1/3 and the protein tyrosine 
phosphatases SHP1/2 (Lee, Lee et al. 2005). Signal transduction then induces calcium 
mobilization, tyrosine phosphorylation of cellular kinases and activation of the transcription 
factors NF-κB, NFAT and AP-1, all indicative of lymphocyte activation (Lee, Veazey et al. 
1998, Lagunoff, Majeti et al. 1999, Prakash, Tang et al. 2002). Binding of K1 to the p85α 
subunit of PI3K results in Akt activation. Furthermore, in B cells, K1 was found to 
inactivate the negative regulator of the PI3K/Akt pathway, PTEN. Accordingly, K1 protects 
the infected cell from FKHR- and FAS-mediated apoptosis (Lee, Guo et al. 1998). K1 
expression is also described to induce the expression of cytokines (Lee, Lee et al. 2005). 
Further studies have shown that K1 is internalized via clathrin-mediated endocytosis. 
Blocking this phenomenon prevents K1-mediated activation of the PI3K/Akt pathway 
demonstrating that, even though K1 is a transmembrane protein, internalization is 
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required for its signaling function (Tomlinson and Damania 2008, Sousa-Squiavinato, 
Silvestre et al. 2015). Similar to LMP2A, K1 downregulates BCR expression at the cell 
surface, inhibiting normal signaling from the BCR. However, the mechanisms used by the 
two proteins are different. The extracellular domain of K1 induces the retention of BCR 
subunits in the endoplasmic reticulum by interacting with the µ chains of the BCR complex 
(Lee, Alvarez et al. 2000). Summarizing, the known functions of K1 suggest that it 
promotes the proliferation and survival of the infected cells and, at the same time, inhibits 
normal BCR signaling, as described for LMP2A. 
 
K1 expression is detected in PELs, MCD and KS lesions (Damania 2004). Like LMP1, K1 
is an oncogenic protein able to induce transformation in vitro and cell proliferation in vivo. 
Transgenic K1 mice, for example, develop spindle-cell sarcomas and malignant 
plasmablastic lymphomas (Prakash, Tang et al. 2002, Prakash, Swamy et al. 2005). In 
contrast to the EBV latent membrane proteins LMP1 and LPM2A, K1 appears to be 
primarily expressed during lytic replication. Despite the functional characterization of K1 
described above, the in vivo role of the protein is not fully understood. Given the apparent 
restriction of K1 to lytic infection, its role in disease may be related to paracrine effects of 
the expression of cellular cytokines induced by the viral protein, upon virus reactivation 
from latency. However, a role for K1 in latent infection cannot be excluded since there are 
some reports that show K1 is expressed at low levels during latent infection (Cousins and 
Nicholas 2014). 
 
Similar to EBV LMP2A, K15 protein localizes to lipid rafts and is coded by a multiply 
spliced gene located at the 3’ end of the KSHV genome that originates different isoforms. 
These differ in the number of transmembrane domains, which ranges from four to twelve, 
and have in common a cytoplasmic tail at the C-terminal end. The latter contains several 
putative signaling motifs, namely: one SH3-binding motif, two SH2-binding sites and a 
TRAF binding site (Glenn, Rainbow et al. 1999, Choi, Lee et al. 2000, Brinkmann, Glenn 
et al. 2003). Although different in sequence, K15 is structurally and functionally similar to 
LMP1 and LMP2A. Like LPM1, K15 interacts with TRAF proteins, activating MAPKs and 
ultimately leading to activation of the transcription factors NF-κB and AP-1 (Glenn, 
Rainbow et al. 1999, Brinkmann, Glenn et al. 2003). Furthermore, through its cytoplasmic 
tail, K15 interacts with Hax-1, inhibiting Bax-induced apoptosis (Sharp, Wang et al. 2002). 
K15 is also able to recruit Src family kinases which, in turn, are responsible for a 
constitutive phosphorylation of the tyrosine residues present at its cytoplasm tail. Like 
LMP2A, by interacting with Src family kinases, K15 reduces their availability to the Igα/Igβ 
complex, resulting in BCR downregulation. Moreover, due to its localization, it is possible 
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that K15 is able to block BCR entry to lipid rafts, contributing to the inhibition of normal 
signaling downstream of the BCR (Choi, Lee et al. 2000, Brinkmann, Glenn et al. 2003). 
Like with LMP2A, this strategy may be related to latency maintenance, as KSHV 
reactivation from latency has also been associated to the activation of the infected cell. 
K15 expression is also related to cell motility, achieved through the induction of 
expression of microRNAs miR-21 and miR-31, a function that may contribute to KSHV-
mediated tumor metastasis (Tsai, Wu et al. 2009). In vivo, K15 function is not yet fully 
understood. In part, this is due to the difficulty in understanding when K15 is expressed, 
which has been associated with both lytic (Glenn, Rainbow et al. 1999, Choi, Lee et al. 
2000) and latent infection (Sharp, Wang et al. 2002). One of the studies that links K15 
expression to lytic infection also shows that the viral protein is capable of inducing the 
expression of multiple cytokines and chemokines (Brinkmann, Pietrek et al. 2007). 
Summarizing, K15 promotes the proliferation and survival of the infected cells by 
activating specific pathways and, at the same time, may inhibit normal BCR signaling and, 
therefore, virus reactivation from latency.   
 
1.5 MuHV-4 M2 protein 
 
M2 was initially classified as a latency-candidate protein due to the genomic position of its 
coding gene, homologous to the position of genes that code for latency proteins in other 
gammaherpesviruses (Virgin, Latreille et al. 1997, Virgin, Presti et al. 1999). This idea was 
reinforced when M2 transcripts were detected by reverse transcriptase PCR in the latently 
infected murine B cell lymphoma line S11 and in splenocytes obtained from mice, 
intranasaly infected with MuHV-4, during the establishment of latency (Husain, 
Usherwood et al. 1999). Moreover, no M2 transcripts were detected in lyticaly infected 
fibroblasts (Husain, Usherwood et al. 1999, Virgin, Presti et al. 1999). Initial long-term in 
vivo studies demonstrated that, following intranasal inoculation with MuHV-4, M2 is 
expressed in GC B cells and memory B cells (Flano, Kim et al. 2002). Further studies on 
the establishment of latency in the spleen confirmed that M2 gene is expressed in GC B 
cells and demonstrated that it is also expressed in DCs and other B cell subsets, namely: 
marginal zone B cells and follicular B cells (Flano, Kim et al. 2002, Marques, Efstathiou et 
al. 2003). In agreement with M2 being a latency-associated protein, expression of M2 is 
not detected in macrophages (Marques, Efstathiou et al. 2003), a population shown to be 
lyticaly infected (Frederico, Chao et al. 2014).  
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The M2 gene is composed of two exons that, upon splicing, produce a unique 192 amino 
acid-long protein, which bears no discernable homology to any other known cellular or 
pathogen protein (Husain, Usherwood et al. 1999). Although it has no obvious conserved 
domains or intracellular localization signals, examination of its primary structure revealed 
the presence of eight proline-rich regions and three tyrosine residues, two of which 
correspond to phosphorylation sites that are part of a motif recognized by Src family 
kinases (Rodrigues, Pires de Miranda et al. 2006) (Figure 1.5). M2 also contains an 
epitope that is recognized by CD8+ T cells from BALB/c (H2d) mice but not from 
C57BL76J (H2b mice), and is therefore an H2Kd-restricted epitope (Husain, Usherwood et 
al. 1999). 
 
Figure 1.5. Primary sequence of the M2 protein. The proline residues organized in PxxP motifs 
(P represents a proline residue and x any amino acid) are shown in blue, the H2Kd-restricted 
epitope is shown in green and underlined and two tyrosine residues with the potential to be 
phosphorylated by kinases are shown in red.  
 
To specifically address the role of M2 in MuHV-4 pathogenesis different groups 
constructed M2-deficient recombinant viruses, revealing that M2 plays an important role in 
both latency establishment and reactivation from latency (Jacoby, Virgin et al. 2002, 
Macrae, Usherwood et al. 2003, Herskowitz, Jacoby et al. 2005). Concomitant with M2 
being a latency-associated protein, all three studies demonstrated that the lack/deficiency 
of M2 has no impact in the lytic infection that develops in the lungs following intranasal 
inoculation. Jacoby el al observed a decrease in the establishment of latency in the spleen 
at 16 days post intranasal inoculation of C57BL/6J mice with MuHV-4. Moreover, the 
authors demonstrated that the mutant virus also has an inefficient reactivation from 
latency, when compared to the WT virus. Long-term infection was similar for both WT and 
M2 mutant viruses suggesting that M2 is more important in the initial stages of latency 
establishment. Strikingly, following intraperitoneal infection, no differences in latency 
establishment nor reactivation from latency were observed. However, a second study 
performed by the same group showed that, by decreasing the virus dose administered 
intraperitoneally, it is possible to reproduce the defects in latency establishment observed 
via the intranasal route (Herskowitz, Jacoby et al. 2005). This demonstrated that M2 plays 
a role in latency establishment, independently of the administration route. Macrae et al 
also observed the impairment in latency establishment following intranasal inoculation of 
MAPTPPQGKIPNPWPGGCSQNPVLWGDGTDGNYRPSEPWILGQVPCDQRFPHPSGNKNSSSTSGGRPQRP
PLPRTRFPKTIRRGFNKLRSTLKSPWKPRPSPVPSPEEVNPAGSPEENIYETANSEPVYIQPISTRSLM
MLDSGSTDSPENLGPPTRPLPKLPNQHPMNPEIRLPIIPPSKCHKGFVEWGEE 
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BALB/c mice, confirming the previous results. In contrast with the previous experiments, 
long-term infection with the M2 mutant virus led to higher frequencies of infection, when 
compared to WT levels. Furthermore, these authors showed that, in B cells, the M2 
protein is predominantly localized in the cytoplasm and plasma membrane (Macrae, 
Usherwood et al. 2003).  
 
The studies described above were performed in total splenocytes. A more detailed study 
from our group addressed the role of M2 in the establishment of latency in different B cell 
subsets (Simas, Marques et al. 2004). Infection of BALB/c mice with a M2 frame-shift 
mutant virus (M2FS) resulted in a reduced number of infected splenic follicles, as 
analyzed by in situ hybridization on spleen sections. However, the mean number of 
infected cells per infected follicle was equivalent between M2FS and WT viruses. 
Together, these observations indicate that M2 is required for an efficient colonization of 
splenic follicles but is dispensable for the expansion of latently infected cells within 
infected follicles. Analysis of the frequency of virus genome-positive cells in total, GC and 
memory B cells revealed lower frequencies of infection in all of the populations analyzed 
in M2FS-inoculated mice, when compared to WT. At late times post infection, 50 and 
70dpi, the absence of M2 resulted in an increased and sustained infection of GC B cells. 
Concomitantly, the percentage of infected follicles as well as the percentage of infected 
cells per infected follicle were increased in M2FS-infected mice. The fact that these 
increased latency levels did not result in an increased infection of memory B cells 
suggested that M2 is important for an efficient differentiation of infected GC B cells into 
memory B cells and/or termination of the GC reaction.  
 
As demonstrated by the studies described above, long term latency levels in M2-deficient 
virus infection are dependent on the host H2 haplotype. While inoculation of C57BL/6J 
mice (H2Kb) results in low levels of infection, equivalent to WT infection (Jacoby, Virgin et 
al. 2002), inoculation of BALB/c mice (H2Kd) is associated with increased long term latent 
loads (Macrae, Usherwood et al. 2003, Simas, Marques et al. 2004). This is the result of 
an immunological effect, rather than abrogation of the M2 functions. As mentioned before, 
M2 protein contains an H2Kd-restricted epitope that is recognized by CD8+ T cells of 
BALB/c mice. In infection of these mice with M2-deficient viruses, infected cells cannot be 
recognized by CD8+ T cells and their proliferation is not controlled. In agreement, a study 
performed by our lab, has shown that mutation of the epitope anchor residues, which 
allow binding of the epitope to MHC-I molecules and consequent presentation to CD8+ T 
cells, leads to increased viral loads (Marques, Alenquer et al. 2008). 
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The fact that M2 seemed to be important to drive the differentiation of GC B cells into 
memory B cells allied to the localization of M2 in the cytoplasm and plasma membrane of 
B cells, raised the possibility of M2 having a role in signaling. In order to characterize the 
molecular function of the M2 protein, several biochemical assays were conducted by 
different groups.  
 
The first in vitro study confirmed the previous observation that M2 localizes to the 
cytoplasm and plasma membrane of lymphocytes. Furthermore, it showed that M2 
localization is cell type dependent, as the protein localized to the nucleus in infected 
epithelial cells and fibroblasts (Liang, Shin et al. 2004). Liang et al also showed that M2 is 
able to interact with the cellular p32 acidic protein promoting its translocation to the 
nucleus, which contributed to the downregulation of STAT1 and STAT2 proteins, thereby 
inhibiting the IFN-α/β- and IFN-γ-mediated transcriptional activation. The same authors 
also found that M2 suppresses DNA damage induced apoptosis (Liang, Pickering et al. 
2006). Viral replication is sensed by the host cell as DNA damage stress, which promotes 
a DNA damage signal transduction that ultimately leads to cell apoptosis. By interacting 
with the DDB1/COP9/cullin DNA repair system and the ATM DNA damage signal 
transducer, M2 was able to inhibit that response. Collectively, these two studies suggest 
that M2 may be protecting the latently infected cells from elimination by affecting two 
defense mechanisms of host innate immunity, the IFN-mediated antiviral pathway and 
DNA damage induced apoptosis. However, the relevance of these functions has not been 
confirmed in vivo.  
 
Through yeast two-hybrid screen, the signaling molecule Vav1 was the first to be found to 
interact with M2 (Madureira, Matos et al. 2005). The same study also demonstrated that 
M2 similarly binds Vav2 but not Vav3. Further studies performed by our group allowed the 
identification of other binding partners of M2 (Rodrigues, Pires de Miranda et al. 2006, 
Pires de Miranda, Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013). At the core 
of these interactions are a C-terminal proline-rich SH3 binding region and two closely 
spaced tyrosine residues of M2 (Y120 and Y129) (Figure 1.5). The first is responsible for the 
interaction of M2 with Src family kinases, which in turn is crucial for the juxtamembranar 
localization of M2 in B cells and the consequent phosphorylation of the mentioned tyrosine 
residues. The latter constitute an unconventional ITAM, where each phosphomotif binds 
directly and selectively to several cellular SH2 containing signaling molecules, namely: 
Fyn, Lyn, Vav1, NCK1, PLCγ2, the p85α subunit of PI3K and the tyrosine phosphatase 
SHP2 (Rodrigues, Pires de Miranda et al. 2006, Pires de Miranda, Lopes et al. 2013). 
Surprisingly, functional analysis of some of the mentioned interactions revealed that they 
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do not point to the same outcome. On the one hand, M2 interaction with the Fyn/Vav 
pathway leads to the activation of Vav1. Furthermore, M2 drives tyrosine phosphorylation 
of PLCγ2. On the other hand, M2 expression leads to inhibition of AKT activation upon 
BCR stimulation, a kinase that is linked to proliferation, survival and differentiation in B 
cells. However, it is possible that this inhibitory effect is compensated by the activation of 
Vav1 and PLCγ2. Summarizing, M2 acts as a modulator protein, mediating the assembly 
of multiprotein complexes with cell signaling proteins. This ability is lost upon mutation of 
the tyrosine residues (M2Y mutant protein). In vivo work as demonstrated the 
physiological importance of the unconventional ITAM for the establishment of latency. 
Intranasal infection with a recombinant virus, designated M2Y, where the tyrosine 
residues were mutated to phenylalanines, resulted in a delay in latency establishment 
(Pires de Miranda, Alenquer et al. 2008). This was characterized by a deficit in latent 
infection levels and splenic follicle colonization at the latency peak (14dpi). Maximal levels 
of GC infection were only observed at 21dpi. Long term comparison between the levels of 
infection of WT and M2Y viruses showed no differences, indicating that the 
unconventional ITAM of the M2 protein is not important for the maintenance of long term 
latency. Biochemical dissection of the interactions carried out by each tyrosine residue 
has shown that they are differentially required. More recently, in vivo analysis of the 
phosphomotifs revealed that only Y129 is critical for reactivation from latency and plasma 
cell differentiation (Rangaswamy, O'Flaherty et al. 2014). 
 
M2 was also shown to drive IL-10 dependent B cell proliferation and survival, both in vitro 
and in vivo (Madureira, Matos et al. 2005, Siegel, Herskowitz et al. 2008). Further in vitro 
work provided insight on the possible mechanism behind the upregulation of IL-10 
(Rangaswamy and Speck 2014). Expression of M2 activated the NFAT pathway in a Src 
kinase-dependent manner leading to the induction of IRF4. This, in turn, is able to 
regulate the IL-10 promoter in B cells. Manipulation of IL-10 expression may be a common 
strategy among gammaherpesviruses, as EBV not only encodes an IL-10 homolog but it 
also encodes a protein, LMP2A, that upregulates IL-10 production in mitogen-stimulated 
primary B cells and B cell lymphomas, promoting the survival of these cells (Incrocci, 
McCormack et al. 2013).  
 
Analysis of cell surface markers in M2-transduced B cells suggested that M2 expression 
leads to B cell activation and differentiation similar to a functional activated, pre-plasma 
memory B cell phenotype (Siegel, Herskowitz et al. 2008, Liang, Collins et al. 2009). 
Plasma cells have been linked to virus reactivation from latently infected cells. In 
agreement to M2 promoting B cell differentiation into plasma cells, infection of mice with a 
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M2-null mutant virus results in the absence of virus infected plasma cells at the latency 
peak. Therefore, M2 may be responsible for virus reactivation from latency, by 
manipulating plasma cell differentiation (Siegel, Herskowitz et al. 2008, Liang, Collins et 
al. 2009).  
 
Collectively, studies of M2 have classified it as a B cell signaling modulator protein. M2 is, 
therefore, a putative functional homologue of the transmembrane proteins LMP1 and 
LMP2A encoded by EBV, and K1 and K15 encoded by KSHV, which either mimic or 
interfere with BCR signaling (Damania 2004). Contrarily to these proteins, M2 is a 
cytosolic protein that is not known to be tumorigenic.  
 
1.6 Aims 
 
Successful colonization of the host by gammaherpesviruses requires proliferation and 
access to the memory B cell compartment, attained through GC reactions. Interaction with 
TH cells provides the B cell with proliferation and survival signals and is required for GC 
initiation in T cell-dependent responses. TH cells are required for normal levels of MuHV-4 
latent infection. B-TH cell interaction is, therefore, a possible target of virus manipulation. 
The M2 protein is able to assemble multiprotein complexes with cell signaling proteins 
through an unconventional ITAM and is required for a normal establishment of latency. 
Therefore, the main aim of this thesis was to assess whether the molecular functions of 
M2 allowed it to beneficially modulate B-TH cell interaction. This possibility was analyzed 
in vitro, in the context of a peptide-specific system. Another aim of this thesis was to 
address this possibility in vivo, in the context of an immune response to T cell-dependent 
stimulus. 
 
Abrogation of the ability of M2 to assemble multiprotein complexes with cell signaling 
proteins (M2Y virus) results in a delay in latency establishment and spleen colonization. 
The stages of splenic infection with MuHV-4 are now well characterized. Using that 
knowledge, the final aim of this thesis was to identify the step of spleen colonization where 
M2Y virus is delayed.  
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2 M2 PROMOTES THE FORMATION OF B-T HELPER CELL 
CONJUGATES 
 
2.1 Introduction 
 
Gammaherpesvirus latent infection of circulating memory B cells is crucial to persistence 
and hence disease ontogeny. To access the memory B cell compartment 
gammaherpesviruses take advantage of germinal center (GC) reactions (Simas and 
Efstathiou 1998, Flano, Kim et al. 2002, Kim, Flano et al. 2003, Willer and Speck 2003, 
Roughan and Thorley-Lawson 2009, Barton, Mandal et al. 2011, Thorley-Lawson, 
Hawkins et al. 2013). In the case of MuHV-4, at the latency peak (14dpi), it has been 
estimated that 70% of the infected B cells have a GC phenotype (Collins, Boss et al. 
2009), which suggests some modulation of this route by the virus. 
 
T cell help is critical for the initiation of a GC reaction in T cell-dependent immune 
responses. Before engaging in a cognate interaction with a B cell that will lead to its 
activation, proliferation and establishment of a GC (Allen, Okada et al. 2007), T helper 
(TH) cells scan for the highest affinity with particular antigen-presenting cells (APC). Such 
transient interactions occur in the border area between follicles and T cell zones and are 
mediated by adhesion molecules, resulting in the formation of B-TH cell conjugates. Upon 
peptide recognition, the formation of an organized signaling structure, the immunological 
synapse (IS), takes place (Grakoui, Bromley et al. 1999). This process has been shown to 
be highly dynamic as T cells can interact with several APCs simultaneously, selectively 
polarizing towards the strongest stimulus (Depoil, Zaru et al. 2005). Typically, an IS is 
composed of spatially separated supramolecular activation clusters (SMACs), which 
contain TCR-CD3/MHC II partners, co-stimulatory molecules and cell adhesion molecules 
(Monks, Freiberg et al. 1998, Grakoui, Bromley et al. 1999, Huppa and Davis 2003). 
Besides this reorganization at the cellular surface level, T cells also undergo 
morphological and cytoskeletal changes. Filamentous actin (F-actin) forms a ring that 
surrounds the previously mentioned structures (Le Floc'h and Huse 2015).  
 
MuHV-4 is known to exploit normal splenic immune communication routes, eventually 
reaching follicular B cells (Frederico, Chao et al. 2014). At this pre-GC stage, the ability of 
the infected follicular B cells to attract T cell help would be a major advantage for these 
viruses. In fact, importance of T cell help is reflected in studies that show defects in in vivo 
B cell activation (Stevenson and Doherty 1999) or demonstrate lower latency levels in the 
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absence of CD4+ T cells (Ehtisham, Sunil-Chandra et al. 1993, Usherwood, Ross et al. 
1996) or T follicular helper cells (TFH) (Collins and Speck 2014).  
 
To investigate if MuHV-4 had the ability to modulate B-TH cell interactions, the latency-
associated M2 protein was chosen as a potential candidate. Although no sequence 
homology is known for this protein, M2 is a putative functional homologue of the 
transmembrane proteins LMP1 and LMP2A encoded by EBV, and K1 and K15 encoded 
by KSHV, which either mimic or interfere with BCR signaling (Madureira, Matos et al. 
2005, Rodrigues, Pires de Miranda et al. 2006, Pires de Miranda, Alenquer et al. 2008). 
Contrarily to these proteins, M2 is a soluble cytoplasmic protein expressed in B cells 
(Marques, Efstathiou et al. 2003), where it localizes to juxtamembranar areas of the cell 
(Macrae, Usherwood et al. 2003, Liang, Shin et al. 2004, Pires de Miranda, Lopes et al. 
2013). It contains two phosphosites (tyrosine residues Y120 and Y129), that are 
constitutively phosphorylated by Src family kinases (Rodrigues, Pires de Miranda et al. 
2006, Pires de Miranda, Alenquer et al. 2008), that form an unconventional ITAM. This 
ITAM is implicated in M2 ability to work as a modulator protein, coordinating the assembly 
of multiprotein complexes with cell signaling proteins, namely NCK1, Vav1, PLCγ2, the 
tyrosine phosphatase SHP2 and the p85α subunit of PI3K (Pires de Miranda, Lopes et al. 
2013). Therefore, just like its putative functional homologues, M2 mediates the assembly 
of specific signalosomes. Mutation of the phosphosites in vitro results in the loss of such 
ability. In vivo, M2 is important for latency establishment and efficient proliferation of 
infected GC B cells (Jacoby, Virgin et al. 2002, Macrae, Usherwood et al. 2003, Simas, 
Marques et al. 2004). Infection of mice with a virus encoding the M2Y mutant (designated 
vM2Y, with Y120 and Y129 residues mutated to phenylalanine) results in a delay in latency 
establishment (Pires de Miranda, Alenquer et al. 2008).  
 
Preliminary data, obtained by Dr. Filipa Lopes in the framework of this project, revealed 
that in the context of an MHC class II-restricted OVAp-specific system, where M2-
expressing B cells presenting OVAp are placed in contact with OVAp-specific CD4+ T 
cells, M2 polarizes to the B-TH cell contact zone and promotes an incomplete polarization 
of the B cell MTOC to that interface. Given all of the above, the ability of the latency-
associated M2 protein to modulate B-TH cell interaction was investigated. To control the 
requirement of the assembly of a signalosome in such modulation, the M2Y mutant 
protein was included as a control. M2 was first analyzed for its ability to upregulate cell 
surface molecules involved in B-TH cell interaction. Subsequently, expression of M2 was 
tested for the ability to promote the formation of B-TH cell conjugates, in the context of an 
MHC class II-restricted OVAp-specific system.  
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2.2 Results 
 
2.2.1 The A20 B cell-TCR Tg DO11.10 CD4+ T cell system 
 
TH cells interact with B cells while scanning for the highest affinity, forming conjugates. 
Upon cognate interaction, the formation of an organized signaling structure, the IS, takes 
place. To address B-TH cell interaction, a MHC class II-restricted OVAp-specific in vitro 
cellular system was chosen. This system comprises A20 B cells and primary transgenic 
CD4+ T cells, that have a TCR with specificity for the ovalbumin peptide (OVAp, 
ISQAVHAAHAEINEAGR, aa 323-339). These primary cells were purified by negative 
selection (MACS, Miltenyi Biotech) from the spleen of Balb/c DO11.10 mice, as described 
in detail in section 7.2.3.2. Flow cytometric analysis of the initial splenocyte suspension, in 
parallel with the purified population, confirmed the enrichment in CD4+ T cells (Figure 2.1). 
CD4+ T cell purity was consistently above 90%.  
 
 
Figure 2.1. Flow cytometric analysis of DO11.10 CD4+ T cell purity. Briefly, CD4+ T cells were 
purified from the spleen of DO11.10 mice, using a negative selection kit (MACS, Miltenyi Biotec), 
according to manufacturer’s instructions. A fraction of the splenocyte suspension (before) and a 
fraction of the purified population (after) were stained with anti-CD4 and anti-TCR DO11.10 
antibodies and analyzed on a LSR Fortessa flow cytometer (BD Biosciences). The percentage of 
cells in each quadrant is shown. CD4+ T cell purity was consistently above 90%. 
 
Following purification, CD4+ T cells were stimulated by incubation with Dynabeads® 
Mouse T-activator CD3/CD28 (Invitrogen) and 60U/mL of mrIL-2. To ensure that B-TH cell 
interaction observations resulted from the specific interaction with B cells and not from the 
activated state of the TH cells, Dynabeads® were removed from T cell culture for a resting 
period, prior to cell use in B-TH cell interaction analysis. To decide on the duration of this 
Before Af ter
CD4+ T cell purif ication
TCR DO11.10
C
D
4
6.8% 18.9% 19.6% 77.3%
71.0% 3.3% 2.5% 0.5%
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resting period, T cell death and TCR down-regulation were monitored by flow cytometry 
(Figure 2.2 and Table 2.1). As expected, T cell size and complexity, as assessed by FSC 
and SSC parameters, decreased with time resulting in a well-defined cellular population 
(Figure 2.2A). This was accompanied by a downregulation of the transgenic TCR, visible 
from day 5 onwards as a decrease in the percentage of double positive events  (Figure 
2.2B). Such downregulation was also observed as a decrease in TCR mean fluorescence 
intensity (MFI) (Figure 2.2C).  
 
The use of propidium iodide, a cell viability dye, showed an increase in cellular death with 
time (Figure 2.2A). To investigate if adding a higher amount of mrIL-2 to the culture, 
during the resting period, could improve T cell survival, the use of 90 and 120U/mL of 
mrIL-2 was tested in parallel with the initial 60U/mL, in cells purified from two spleens 
(Table 2.1). Results showed that an increased IL-2 concentration did not significantly 
impact cell survival. For that reason, primary CD4+ T cells were cultured with 60U/mL of 
mrIL-2 throughout this study. Furthermore, the use of T cell populations purified from the 
spleens of two independent mice showed that variability among individuals is to be 
expected.  
 
Collectively, results showed that the choice of the duration of the resting period was a 
balance between CD4+ T cell resting and T cell death. For flow cytometric analysis, cells 
were rested for seven to eight days, since dead or dying cells could be easily excluded 
from analysis. For confocal microscopy analysis, T cells were rested for five days. This 
timepoint was chosen because the cells had already decreased in size and complexity, 
there was a visible downregulation of the TCR, and it was still possible to recover 25-40% 
of live cells. Live resting CD4+ T cells were then sorted prior to their use (Figure 2.3). 
Purity of the sorted T cell population was assessed by flow cytometry and was 
consistently above 96% (Figure 2.3, post-sort). 
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Figure 2.2. Analysis of a CD4+ T cell population during the resting period. Please see figure 
legend on the next page. 
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Figure 2.2. Analysis of a CD4+ T cell population during the resting period. CD4+ T cells were 
purified from two spleens of DO11.10 mice (spleen 1 and 2), using a negative selection kit (MACS, 
Miltenyi Biotec). Cells were stimulated by incubation with Dynabeads® Mouse T-activator 
CD3/CD28 (Invitrogen), according to manufacturer’s instructions. After three days of stimulation, 
Dynabeads® were removed to initiate the resting period (day 0) and cells were cultured in 24-well 
plates (1x106 cells/well) in the presence of 60U/mL of mrIL-2. On each resting day, cells were 
collected from a different well for analysis. Representative FACS plots shown correspond to spleen 
1. (A) Cells were stained on each resting day with propridium iodide to allow the discrimination 
between live (blue) and dead (red) cells. (B) and (C) Cells were stained on each resting day with 
anti-CD4 and anti-TCR DO11.10 antibodies, to assess TCR downregulation. (B) The percentage of 
cells in each quadrant is shown. (C) TCR DO11.10 mean fluorescence intensity (MFI) for both 
spleens on each resting day.  This experiment was performed by me in collaboration with Dr. Sofia 
Marques. 
 
Table 2.1. Percentage of live CD4+ T cells during the resting period. Percentage of live cells 
identified in Figure 2.2A. was analyzed using FlowJo (Tree Star, Inc.). 
  Resting day 
Spleena IL-2 (U/mL)b 0 1 2 3 4 5 6 7 
1 
60 64.6 57.0 65.2 55.8 50.6 41.9 28.2 17.5 
90 64.6 54.7 67.7 57.9 53.1 45.6 29.9 17.3 
120 64.6 - - 58.0 - 43.5 30.8 18.3 
2 
60 66.0 50.3 67.2 39.7 30.5 27.8 17.7 9.3 
90 66.0 51.1 69.8 40.7 31.5 25.7 15.4 8.9 
120 66.0 - - - - 25.0 17.6 15.2 
a Two independent spleens were analyzed. 
b Three IL-2 concentrations were tested. 
- Analysis not performed. 
 
 
Figure 2.3. Sorting live resting CD4+ T cells. CD4+ T cells were purified from the spleen of 
DO11.10 mice, using a negative selection kit (MACS, Miltenyi Biotec). Cells were stimulated by 
incubation with Dynabeads® Mouse T-activator CD3/CD28 (Invitrogen). After three days of 
stimulation, Dynabeads® were removed to initiate the resting period. For confocal microscopy 
analysis, live resting CD4+ T cells were flow cytometrically sorted, based on their FSC-A SSC-A 
profile (pre-sort). Purity of the isolated T cell population was assessed (post-sort) and was 
consistently above 96%.  
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A20 B cell lines stably expressing M2 or M2Y proteins had been previously generated by 
Dr. Marta Alenquer, and will be referred to as A20 B cell lines. To exclude the possibility of 
the observations made throughout the study being a cell line effect, independent cell lines 
were generated by transduction of A20 B cells with the appropriate viral particles, as 
described in section 7.2.3.6. In these cell lines, M2 and M2Y proteins were N-terminally 
fused to EGFP. These will be referred to as independent A20 B cell lines. Since the M2Y 
mutant only controls the requirement of the assembly of a signalosome, an EGFP 
expressing cell line was generated as a second negative control. The most efficiently 
transduced cells were sorted by gating on the 10-20% brightest EGFP+ events, for EGFP-
M2 and EGFP-M2Y samples (Figure 2.4). The same gate was then applied to the EGFP 
sample, which was more efficiently transduced. Constitutive expression of M2, M2Y or 
EGFP/EGFP-tagged proteins was confirmed on both A20 B cell lines and independent B 
cell lines by Western Blot analysis (Figure 2.5). 
 
 
Figure 2.4. Sorting EGFP+ A20 B cells for the generation of EGFP/EGFP-M2/EGFP-M2Y-
expressing cell lines. For the generation of independent B cell lines, A20 B cells were transduced 
with retroviruses that allow the expression of EGFP-M2, EGFP-M2Y or EGFP. The most efficiently 
transduced cells were sorted by gating on the 10-20% brightest EGFP+ events, for M2 and M2Y 
samples (pre-sort). The same gate was applied to the EGFP sample. Purity of the isolated B cell 
populations was assessed (post-sort) and was consistently above 98%. 
 
EGFP
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EGFP-M2 EGFP-M2Y EGFP
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99.7% 98.2% 99.2%
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Figure 2.5. A20 B cell lines express M2/M2Y. (A) M2/M2Y expression on total cellular lysates of 
the A20 B cell lines. M2/M2Y proteins were detected on Western Blot with an anti-M2 antibody. An 
A20 B cell line expressing the viral protein K3 (lane 3) was used as a negative control. (B) M2/M2Y 
expression on total cellular lysates of the independent A20 B cell lines. EGFP or EGFP-M2/M2Y 
fusion proteins were detected on Western Blot with an anti-EGFP antibody. An A20 B cell line 
expressing non-tagged M2 (lane 4) was used as a negative control. (A) and (B) An anti-actin 
antibody was used to demonstrate that similar amounts of cellular lysates were used.  
 
A20 B cell lines and independent A20 B cell lines interact with the OVAp-specific TCR-
transgenic CD4+ T cells, forming B-TH cell conjugates. In the presence of high 
concentrations of OVAp (above 1μM), such interaction results in the formation of a highly 
organized signaling structure at the interface between both cells, the IS. Previous work 
from Dr. Filipa Lopes, carried out in the context of this project, has shown that the M2 
protein polarizes to the B-TH contact zone in this in vitro system. This polarization is 
dependent on the integrity of the unconventional ITAM, as the M2Y mutant protein 
remains localized in juxtamembrane areas of the cell. Dr. Filipa Lopes has also observed 
that M2 promotes B cell polarization, as its expression increases the B cell MTOC 
proximity to the contact zone. Collectivelly, these observations validate the use of this 
system and are concomitant with an involvement of M2 in the modulation of B-TH cell 
interaction, that is dependent on the protein ability to assemble specific signalosomes 
(Fontinha, Lopes et al. 2015). 
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2.2.2 Expression of the latency-associated M2 protein leads to the 
upregulation of adhesion and co-stimulatory molecules in B cells 
 
In order to investigate if M2 plays a role in B-TH cell interaction, the influence of the viral 
protein on the levels of selected B cell surface molecules, some of which are involved in 
IS, was evaluated. The M2Y mutant protein was used in parallel to assess the 
requirement of the unconventional ITAM motif. A20 B cell lines stably expressing M2 or 
M2Y were stained for the indicated markers and analyzed by flow cytometry (Figure 2.6). 
Untransduced A20 B cells were used as a negative control. Mean fluorescence intensity 
(MFI) fold change of M2 or M2Y relative to that of the control was then quantified (Figure 
2.6A). Levels of CD80, a co-stimulatory molecule found in the cSMAC of IS (Monks, 
Freiberg et al. 1998, Grakoui, Bromley et al. 1999, Huppa and Davis 2003), was 2-fold 
higher in M2-expressing B cells (open bars) than in the control (black bars). The cell 
adhesion molecules ICAM1 and CD48, found in the pSMAC of IS (Monks, Freiberg et al. 
1998, Grakoui, Bromley et al. 1999, Huppa and Davis 2003), were 1.5- and 1.2-fold 
upregulated, respectively. These differences can be observed as a shift in fluorescence 
intensity in the representative FACS histograms (Figure 2.6B). This upregulation was 
specific as M2 expression did not significantly alter the levels of CD86, CD40, MHCII, 
CD19, CD21, CD23, CD69, and CD95. M2Y-expressing B cells (grey bars) did not show 
increased levels of any of these molecules, denoting the requirement of the ITAM for such 
upregulation. Moreover, this observation corroborates the use of M2Y as a negative 
control.  
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Figure 2.6. M2 expression leads to the upregulation of adhesion and co-stimulatory 
molecules in B cells. (A) Fold increase of the mean fluorescence intensities (MFI) of several 
surface molecules, relative to untransduced A20 B cells. A20 B cells (black bars) and A20 B cells 
stably expressing M2 or M2Y were stained with fluorescently labeled antibodies and the surface 
expression of the indicated molecules was analyzed on a LSR Fortessa flow cytometer. Bars 
represent the mean of three independent experiments. Error bars represent standard error of the 
mean. Statistical significance was evaluated using a one-tailed Students t-test. (B) Representative 
FACS histogram plots for the indicated surface molecules. 
 
To exclude the possibility of a cell line effect, the influence of M2 on the levels of CD80, 
CD86 and ICAM-1 was evaluated on the independent A20 B cells lines (Figure 2.7). 
EGFP-expressing B cells were used as a negative control. CD80 and ICAM-1 were up-
regulated in EGFP-M2-expressing B cells, 2.5- and 2.3-fold, respectively (Figure 2.7A). 
This upregulation can be observed as a shift in fluorescence intensity in the representative 
FACS histograms (Figure 2.7B). CD86 up-regulation, which was slight and non-significant 
in the A20 B cell lines, was visible as a 1.4-fold significant increase. This difference 
observed between both B cell lines may be a consequence of choosing the 10-20% 
brightest EGFP+ events and, therefore, the cells with higher expression of M2 or M2Y, 
when generating the EGFP-M2- and EGFP-M2Y-expressing B cells.  
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The levels of the surface molecules analyzed in the EGFP-M2Y-expressing B cells were 
comparable to those of the EGFP-expressing B cells. This demonstrates that the 
upregulation observed upon expression of M2 is entirely dependent on the unconventional 
ITAM and further corroborates the use of M2Y as a negative control. 
 
These results show that expression of M2 leads to the upregulation of B cell co-
stimulatory and adhesion molecules that participate in the formation of an IS. This function 
is dependent on tyrosine phosphorylation at the ITAM, hence related to the ability of M2 to 
assemble multiprotein complexes with B cell signaling proteins. 
 
 
Figure 2.7. M2-expressing independent B cell line shows upregulation of adhesion and co-
stimulatory molecules. (A) Fold increase of the mean fluorescence intensities (MFI) of several 
surface molecules in the independent B cell lines, relative to the EGFP-expressing A20 B cell line. 
A20 B cells stably expressing EGFP, EGFP-M2 or EGFP-M2Y were stained with fluorescently 
labeled antibodies and the surface expression of the indicated molecules was analyzed on a LSR 
Fortessa flow cytometer. Bars represent the mean of eight independent experiments. Error bars 
represent standard error of the mean. Statistical significance was assessed with a one-tailed 
Students t-test. (B) Representative FACS histogram plots for the indicated surface molecules. 
 
2.2.3 M2 competitively promotes the formation of B-TH cell conjugates 
 
B and TH cells interact with each other forming conjugates, a process that is mediated by 
adhesion molecules. Given that M2-expressing B cells showed increased levels of such 
molecules, the impact of M2 in B-TH cell conjugate formation was investigated in the MHC 
class II-restricted OVAp-specific system described above.  
 
Mouse A20 B cells, stably expressing M2 or M2Y, were loaded with CMFDA live dye and 
pulsed with increasing concentrations of OVAp. CD4+ T cells were loaded with DDAO live 
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dye. M2- or M2Y-expressing B cells and T cells were then incubated in a 2:1 ratio, for 30 
minutes. Conjugate formation was next assessed by flow cytometry, based on the 
percentage of CMFDA+DDAO+ events in the total DDAO+ population (Figure 2.8A and B).  
 
The percentage of T cells conjugating with M2- (black circles) or M2Y-expressing B cells 
(grey squares), pulsed or not with increasing concentrations of OVAp, was then quantified 
(Figure 2.8C). Conjugate formation occurred in a peptide dose-dependent manner. In the 
absence of peptide, there was a basal level of conjugate formation, where less than 10% 
of the TH cells conjugated with M2Y-expressing B cells. Conjugate formation in the M2Y 
condition only exceeded basal levels when the B cells were loaded with 0.01µM of OVAp. 
In contrast, the integrity of the phosphosites resulted in a three-fold increase in conjugate 
formation with M2-expressing B cells, even in the absence of specific peptide. Expression 
of M2 was therefore able to promote conjugate formation up to 0.1µM of OVAp. Above 
0.1µM of OVAp, conjugate formation reached a plateau for both M2 and M2Y conditions. 
 
To exclude a cell line effect, the impact of M2 in B-TH cell conjugate formation was 
investigated with the independent A20 B cell lines. Conjugate formation was assessed by 
flow cytometry, based on the percentage of EGFP+DDAO+ events in the total DDAO+ 
population (Figure 2.8A). The percentage of T cells conjugating with EGFP-M2- (black 
circles), EGFP-M2Y- (grey squares) or EGFP-expressing B cells (grey triangles), loaded 
or not with increasing concentrations of OVAp, was then quantified (Figure 2.8D). Results 
reproduced the observations made with the A20 B cell lines. Conjugate formation in the 
EGFP-M2Y and EGFP conditions was the same, demonstrating that the increased 
conjugate formation promoted by the M2 protein was entirely dependent on the 
unconventional ITAM. 
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Figure 2.8. M2 promotes the formation of B-TH cell conjugates, as assessed by flow 
cytometric analysis. A20 B cells stably expressing the indicated proteins were pulsed overnight, 
or not, with different concentrations of OVA peptide (OVAp) and incubated with OVAp-specific 
CD4+ T cells at a 2:1 ratio for 30min. Prior to incubation B and T cell populations were incubated 
with the live dyes CMFDA and DDAO, respectively, to allow their discrimination. In the case of 
EGFP-expressing B cell lines, the use of CMFDA was not necessary. (A) Gating strategy used to 
assess B-TH cell conjugate formation. (B) Representative FACS plots for the percentage of 
conjugates upon variation of the OVAp concentration. Conjugate formation was evaluated as the 
percentage of CMFDA+DDAO+ events in the total DDAO+ population. (C) Quantification of the 
percentage of conjugates upon variation of the OVAp concentration, after 30min of incubation. 
Symbols represent the mean of four independent experiments. This experiment was performed by 
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Dr. Sofia Marques. (D) Quantification of the percentage of conjugates after 30min of incubation 
upon variation of the OVAp concentration, after 30min of incubation, for independent EGFP-
expressing A20 B cell lines.  Conjugate formation was evaluated as the percentage of 
EGFP+DDAO+ events in the total DDAO+ population. Symbols represent the mean of three 
independent experiments. (C) and (D) Error bars represent standard error of the mean. Statistical 
significance between groups was evaluated by a one-tailed unpaired Student’s t test.  
 
To further address conjugate formation, B-TH cell interaction was assessed by confocal 
microscopy, including a marker for phosphorylated tyrosines (pTyr). Using the MHC class 
II-restricted OVAp-specific system, M2- or M2Y-expressing B cells, pulsed or not with 
different concentrations of OVAp, were incubated with CD4+ T cells in a 2:1 ratio, for 30 
minutes. Prior to incubation, B cells were loaded with CMFDA live dye. Cells were also 
stained for F-actin, to allow the visualization of B-TH cell interaction. Conjugate count was 
blind and based on B-TH cell contact and pTyr (purple) accumulation at the contact zone 
(Figure 2.9A).  
 
The percentage of T cells conjugating with either M2- (black circles) or M2Y-expressing 
(grey circles) B cells was then quantified (Figure 2.9B). Corroborating the previous results, 
confocal microscopy revealed that M2 expression in B cells promoted conjugate formation 
with TH cells, as indicated by the increased percentage of conjugates relative to the 
control. Notably, in the absence of peptide, there was a basal level of conjugates with 
pTyr accumulation at the contact zone in the M2Y condition, which was significantly higher 
under M2 expression. This is indicative of signaling and peptide-independent formation of 
a functional immunological synapse. However, in this particular case, it can also be 
associated with the constitutive phosphorylation of the tyrosine residues of M2, and the 
consequent phosphorylation of Vav1 and PLCγ2 (Rodrigues, Pires de Miranda et al. 2006, 
Pires de Miranda, Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013). 
 
To exclude a cell line effect, the impact of M2 in B-TH cell conjugate formation was 
investigated by confocal microscopy with the independent A20 B cell lines, in a single 
experiment. Overall, the percentage of conjugates was higher than the one obtained with 
the A20 B cell lines. Nonetheless, expression of EGFP-M2 promoted the formation of 
conjugates with CD4+ T cells, when compared to the EGFP-M2Y and EGFP conditions.  
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Figure 2.9. M2 promotes the formation of B-TH cell conjugates, as assessed by confocal 
microscopy. A20 B cells stably expressing the indicated proteins were pulsed overnight, or not, 
with different concentrations of OVA peptide (OVAp) and incubated with OVAp-specific CD4+ T 
cells at a 2:1 ratio. Prior to incubation B cell populations were incubated with the live dye CMFDA, 
to allow their discrimination. (A) Representative images of pTyr polarization to the contact zone. 
After 30min of incubation, cells were fixed and stained for F-actin with TRITC-phalloidin (red), and 
for pTyr (purple). Images are from one representative experiment out of three. (B) Percentage of 
conjugates per field after 30min of incubation, as determined by confocal microscopy, upon 
variation of the OVAp concentration. A total of 45 images were taken per sample from three 
independent experiments. Only images with a minimum of three T cells were considered for 
analysis. (C) Percentage of conjugates per field after 30min of incubation, for the independent 
EGFP-expressing A20 B cell lines. 15 to 35 images were taken per sample in a single experiment. 
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(B) and (C) Conjugate count was blind and based on B-TH cell contact and pTyr polarization to the 
contact zone. Statistical significance of the difference between groups was evaluated by a Mann-
Whitney U test. 
 
To understand whether the increase in conjugate formation described above translated 
into a competitive advantage, M2- and M2Y-expressing B cells were placed in direct 
competition for conjugation with CD4+ T cells, in an in vitro competition assay. Briefly, 
CD4+ T cells were simultaneously incubated with equal numbers of M2- and M2Y-
expressing B cells, pulsed with the same concentration of OVAp, in a 1:1:1 ratio. Prior to 
incubation, M2-expressing B cells, M2Y-expressing B cells and CD4+ T cells were loaded 
with CMFDA, CMTMR and DDAO live dyes, respectively, to allow their discrimination 
(Figure 2.10A).  
 
Conjugate formation with M2-expressing B cells was evaluated as the percentage of 
CMFDA+CMTMR- events, while conjugate formation with M2Y-expressing B cells was 
evaluated as the percentage of CMFDA-CMTMR+ events in the total DDAO+ population 
(Figure 2.10A, B cell lines, and 2.10B). The fold difference of the percentage of T cells 
conjugating with M2-expressing B cells relative to the M2Y condition was then quantified 
(Figure 2.10C). Up to 0.01µM of OVAp, on average, there were 2.5-fold more M2 
conjugates. Above 0.1µM of OVAp this difference was smaller, although it was still visible. 
This shows that TH cells preferentially conjugated with B cells expressing the wild-type 
viral protein.  
 
To exclude the possibility of a cell line effect, the in vitro competition assay was performed 
with the independent A20 B cell lines. Prior to incubation, M2Y-expressing B cells and 
CD4+ T cells were loaded with CMTMR and DDAO live dyes, respectively, to allow their 
discrimination (Figure 2.10A). Identification of M2-expressing B cells relied solely on the 
expression of EGFP. Conjugate formation with M2-expressing B cells was evaluated as 
the percentage of EGFP+CMTMR- events, while conjugate formation with M2Y-expressing 
B cells was evaluated as the percentage of EGFP+CMTMR+ events in the total DDAO+ 
population (Figure 2.10A, Independent B cell lines, and 2.10D). The fold difference of the 
percentage of T cells conjugating with EGFP-M2-expressing B cells relative to the EGFP-
M2Y condition reproduced the preferentiality of TH cells to conjugate with M2-expressing B 
cells (Figure 2.10E). 
 
Taken together, these results show that expression of M2 favors the formation of 
conjugates with TH cells, in a competitive manner. Such ability is dependent on the 
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integrity of the unconventional ITAM and, therefore, dependent on the ability of M2 to 
assemble multiprotein complexes with B cell signaling proteins.  
 
 
Figure 2.10. M2 promotes the formation of B-TH cell conjugates in a competitive manner. A20 
B cells stably expressing the indicated proteins were pulsed overnight, or not, with different 
concentrations of OVA peptide (OVAp). M2-expressing B cells, M2Y-expressing B cells and T cells 
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were mixed on the same tube at a 1:1:1 ratio and incubated for 30min. Prior to incubation M2-
expressing B cells and M2Y-expressing B cells were incubated with the live dyes CMFDA and 
CMTMR, respectively, to allow their discrimination. In the case of the independent A20 B cell lines, 
only EGFP-M2Y-expressing B cells were incubated with the live dye CMTMR. T cells were 
incubated with the live dye DDAO. (A) Gating strategy used to assess B-TH cell conjugate 
formation. (B) Representative FACS plots for the percentage of conjugates upon variation of the 
OVAp concentration. Conjugate formation with M2-expressing B cells was evaluated as the 
percentage of CMFDA+CMTMR- events in the total DDAO+ population. Conjugate formation with 
M2Y-expressing B cells was evaluated as the percentage of CMFDA-CMTMR+ events in the total 
DDAO+ population. (C) Fold difference of the number of conjugates formed with M2-expressing B 
cells relative to the M2Ycondition. (D) Representative FACS plots for the percentage of conjugates 
upon variation of the OVAp concentration. Conjugate formation with EGFP-M2-expressing B cells 
was evaluated as the percentage of EGFP+CMTMR- events in the total DDAO+ population. 
Conjugate formation with EGFP-M2Y-expressing B cells was evaluated as the percentage of 
EGFP+CMTMR+ events in the total DDAO+ population. (E) Fold difference of the number of 
conjugates formed with EGFP-M2-expressing B cells relative to the EGFP-M2Y condition. (B) and 
(D) The percentage of T cells conjugating with M2- or M2Y-expressing B cells is indicated in the 
respective quadrant. (C) and (E) Bars represent the mean of three independent experiments. Error 
bars represent standard error of the mean. 
 
2.3 Discussion 
 
Although in vivo studies show that the M2 protein is required for the initial colonization of 
the lymphoid follicles, the mechanism behind this process is still unknown. The data 
described in this chapter supports a model where expression of MuHV-4 M2 protein 
competitively promotes interaction with TH cells in vitro, in the context of a MHC class II-
restricted OVAp-specific cellular system. This process was independent of presentation of 
specific antigen, as indicated by the increased number of M2-expressing B-TH cell 
conjugates observed in the absence of peptide, and may be the outcome of the 
upregulation of adhesion molecules observed in M2-expressing B cells. Preliminary work 
performed by Dr. Sofia Marques in our laboratory has shown that upregulation of the 
costimulatory molecules CD80 and CD86 also occurs in vivo in infected GC B cells, upon 
intranasal infection of C57BL/6J mice with 104 PFU of MuHV-4. This observation supports 
that there may be a physiological significance for the in vitro results obtained in this 
chapter. 
 
The previously observed B cell polarization (Fontinha, Lopes et al. 2015) and the 
upregulation of co-stimulatory molecules observed under expression of M2 suggest a role 
for the viral protein in IS modulation. Furthermore, measurement of B-TH cell conjugates 
by confocal microscopy revealed a pTyr accumulation in the contact zone in the absence 
of peptide, that may be indicative of signaling and peptide-independent formation of a 
functional IS, raising the possibility of M2 replacing the need for cognate T cell help. 
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Modulation of T-APC interaction, and more specifically IS, by a viral protein has been 
previously described. Protein Nef from Human Immunodeficiency Virus type 1 (HIV-1) has 
been shown to impair IS formation, as a means of optimizing the environment for HIV 
infection (Haller, Rauch et al. 2006, Thoulouze, Sol-Foulon et al. 2006, Haller, Rauch et 
al. 2007, Saxena, Shrivastava et al. 2012). In the Gammaherpesvirinae sub-family there 
are also two examples of impairment of B-TH cell interactions and IS formation, namely K5 
from Kaposi Sarcoma-associated Herpesvirus (KSHV) (Coscoy and Ganem 2001), and 
tyrosine kinase-interacting protein (Tip) from the T lymphotropic Herpesvirus Saimiri 
(HVS) (Cho, Feng et al. 2004). In contrast, the results obtained with the M2 protein 
support a model where a viral protein promotes B-TH cell interaction, instead of impairing 
it. This is concomitant with the high prevalence of infection in GC B cells. Such positive 
effect does not exclude the possibility that, at some point during infection, MuHV-4 impairs 
IS formation as a mechanism of immune evasion.  
 
Collectively, results support a model where the latency-associated M2 protein 
competitively promotes B-TH cell interaction, a process that is dependent on the 
modulation of B cell signaling. In vivo, this ability to attract T cell help in a competitive 
manner during the T cell scanning process, carried out in secondary lymphoid organs, 
may account for the selection of infected B cells for GC initiation, a crucial step in latency 
establishment, hence host colonization. 
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3 M2-EXPRESSING B CELLS DO NOT PROMOTE T CELL 
ACTIVATION INDEPENDENTLY OF SPECIFIC PEPTIDE 
 
3.1 Introduction 
 
Formation of an IS upon cognate B-TH cell interaction triggers signaling cascades that 
lead to T cell activation. One of the outcomes of such interaction is the increase of 
intracellular calcium concentration (Gray, Gnarra et al. 1988, Friedl, den Boer et al. 2005). 
This step is critical as it induces the nuclear localization of nuclear factor of activated T 
cells (NFAT), resulting in changes in gene expression (Feske, Giltnane et al. 2001). The 
IS is also a place for the polarized secretion of cytokines, namely: IL-2, IL-4, IL-5 and IFN-
γ (Kupfer, Mosmann et al. 1991, Kupfer, Monks et al. 1994, Trautmann and Valitutti 2003). 
Typically, an IS is composed of spatially separated supramolecular activation clusters 
(SMACs), arranged in a bull’s eye shape, forming a synaptic cleft between the interacting 
cells (Grakoui, Bromley et al. 1999, Huppa and Davis 2003, Krummel and Cahalan 2010). 
The pSMAC, where there is an accumulation of adhesion molecules, helps stabilize the 
cell-cell interaction. It is possible that this outer adhesive ring also prevents leakage of 
cytokines from the synaptic cleft and, therefore, promotes a focal delivery of the released 
factors (Friedl, den Boer et al. 2005).  
 
In the context of an adaptive immune response, this cognate interaction between a TH cell 
and a B cell presenting the appropriate antigen is required for germinal center (GC) 
initiation. There, B cells undergo affinity maturation and class-switch recombination, giving 
rise to plasma cells and to the long-term target population of gammaherpesviruses, 
memory B cells (Allen, Okada et al. 2007, De Silva and Klein 2015),. 
 
The results presented in chapter 2 revealed that expression of M2 in B cells promoted 
their interaction with TH cells. This was true even in the absence of specific peptide and 
was accompanied by pTyr accumulation at the interface between B and CD4+ T cells 
(section 2.2.3), suggesting peptide-independent signaling and IS formation. To address 
that possibility, T cell activation was assessed by measurement of intracellular calcium 
and analysis of IFN-γ polarization in CD4+ T cells, in the context of the MHC class II-
restricted OVAp-specific system. 
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3.2 Results 
 
3.2.1 M2 expression in B cells increases the number of CD4+ T cells 
mobilizing calcium, but not the magnitude of individual responses 
 
To investigate if conjugation with M2-expressing B cells resulted in T cell activation, 
intracellular calcium was measured on CD4+ T cells.  
 
To measure the intracellular calcium, TCR-transgenic CD4+ T cells were loaded with the 
calcium indicator Indo-1, which changes its emission spectrum by chelating free calcium 
ions. As a result, the intensity of the emission at 405nm increases and, simultaneously, 
the intensity of the emission at 530nm decreases. Therefore, the 405/530 ratio provides a 
measure of intracellular calcium increase. To assure that the events would be within the 
scale of the FACS plot after calcium increase, the 405nm laser was set at a low voltage, 
while the 530nm laser was set at a high voltage, as can be observed in the middle column 
plots of Figure 3.1. A baseline of 405/530 MFI through time was then established by 
acquiring unstimulated TH cells alone, for approximately two minutes (Figure 3.1, baseline 
condition, third plot), as has been described (Valitutti and Dessing 2000). To assess 
whether the primary CD4+ T cells were able to respond by mobilizing calcium, these were 
stimulated with ionomycin (Figure 3.1, ionomycin condition). This stimulation was followed 
by a strong response, as observed by the increase in the 405/530 ratio of nearly all 
analyzed T cells. To confirm that calcium mobilization would occur in the MHC class II-
restricted OVAp-specific system, Indo-1 loaded CD4+ T cells were incubated with M2-
expressing B cells pulsed with a saturating concentration of OVAp (10µM). Calcium 
mobilization, although lower than the one observed after the ionomycin stimulus, was 
clearly visible as an increase in the 405/530 ratio (Figure 3.1, M2 + 10μM OVAp 
condition).  
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Figure 3.1. Intracellular calcium quantification by flow cytometry. For all three conditions, live 
resting OVAp-specific CD4+ T cells were sorted as described in section 2.2.1 and loaded with the 
calcium indicator Indo-1. FACS plots depict the gating strategy used for calcium mobilization 
analysis. After gating on live cells, analysis was restricted to CD4+ T cells by gating in Indo-1+ 
events (405+530+). The 405nm laser was set at a low voltage, while the 530nm laser was set at a 
high voltage to account for the change in Indo-1 emission spectrum upon calcium increase. Next, 
the 405/530 ratio was measured against time. In the first condition a baseline was established by 
acquiring unstimulated T cells for two minutes. In the second condition, ionomycin was used to 
stimulate the T cells as a positive control. In the third condition, Indo-1 loaded CD4+ T cells were 
incubated with M2-expressing B cells, previously pulsed with 10μM of OVAp.  
 
Two minute baselines were established for every sample by acquisition of unstimulated 
CD4+ T cells. Next, the effect of incubation with M2- or M2Y-expressing B cells on TH cell 
intracellular calcium increase was assessed (indicated by an arrow in Figure 3.2A). The 
percentage of activated TH cells, determined as the percentage of 405/530 positive events 
above baseline (Figure 3.2A), was quantified (Figure 3.2B). The positive control, 
ionomycin, led to the activation of more than 97% of the T cell population. The percentage 
of activated TH cells increased with the OVAp concentration (Figure 3.2B). Between 
0.005µM and 0.1µM of OVAp, M2-expressing B cells (filled bars) led to an increase in the 
number of TH cells mobilizing calcium, compared to M2Y-expressing B cells (open bars). 
This correlated with the increased number of B-TH cell conjugates observed in section 
FSC-A
S
S
C
-A
FL8 (530)
F
L
7
 (
4
0
5
)
Time (seconds)
4
0
5
/5
3
0
Baseline
Ionomycin
M2 + 10μM 
OVAp
Live cells
Indo-1+
CHAPTER 3 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
68 
 
2.2.3. However, this difference was only statistically significant for the 0.01μM of OVAp 
condition. To assess if M2-expressing B cells were also able to promote stronger 
individual responses, the 405/530 ratio MFI of responding TH cells was quantified (Figure 
3.2C). M2 and M2Y conditions showed no statistically significant differences in MFI 
demonstrating that, even though there were more TH cells mobilizing calcium, there was 
no difference in the magnitude of individual responses. In the absence of peptide, M2-
expressing B cells did not promote intracellular calcium increase in TH cells. This indicates 
that expression of M2 in the context of B-TH cell interaction is not enough to drive T cell 
activation.  
 
To exclude the possibility of a cell line effect, TH cell calcium increase was measured after 
incubation with the independent A20 B cell lines, in a single experiment (Figure 3.2D). The 
increase in the number of CD4+ T cells mobilizing calcium after incubation with EGFP-M2-
expressing B cells (filled bars) pulsed with 0.005µM or 0.01µM of OVAp, corroborated the 
previous results. 405/530 MFI for the EGFP-M2 condition was the same or lower than that 
of the controls, which was in agreement with the inability of M2 to promote a stronger 
individual T cell response, observed with the A20 B cell lines. 
 
Measurement of intracellular calcium in TH cells showed that incubation with M2-
expressing B cells did not promote T cell activation in the absence of peptide. In the 
presence of specific peptide, M2 expression in B cells increased the number of activated 
TH cells, but not the magnitude of individual responses. 
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Figure 3.2. Calcium mobilization in M2-expressing B-TH cell conjugates requires specific 
peptide presentation. A20 B cells stably expressing the indicated proteins were pulsed overnight, 
or not, with different concentrations of OVAp and incubated with OVAp-specific CD4+ T cells for 5 
min. Live resting CD4+ T cells were sorted as described in section 2.2.1. Prior to conjugation T cells 
were loaded with the calcium indicator Indo-I. Ionomycin (Iono) was used as a positive control. (A) 
Representative FACS plots of calcium measurements. A baseline was established by acquiring 
unstimulated TH cells alone, for approximately two minutes. Calcium fluxes were then measured on 
a MoFlow cytometer for 18 minutes (when indicated by the arrow) and were based on the 405/530 
emission ratio over time. 405/530 mean fluorescence intensity (MFI) is shown. (B) Average of the 
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percentage of CD4+ T cells mobilizing calcium when conjugated with M2- (filled bars) or M2Y-
expressing (open bars) B cells. (C) 405/530 MFI average within responding T cells. (B) and (C) 
Bars represent the results from three to seven experiments. Error bars represent standard error of 
the mean. Statistical significance of the difference between groups was evaluated by a one-tailed 
unpaired Student’s T test. This experiment was performed in collaboration with Dr. Sofia Marques. 
(D) Average of the percentage of CD4+ T cells mobilizing calcium when conjugated with EGFP-M2- 
(filled bars), EGFP-M2Y- (open bars) or EGFP-expressing B cells (grey bars). (E) 405/530 MFI 
average within responding T cells conjugating with the independent A20 B cell lines. (D) and (E) 
Bars represent the results from a single experiment. 
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3.2.2 M2-expressing B cells do not promote IFN-γ polarization in CD4+ T 
cells in the absence of specific peptide 
 
To further investigate if conjugation with M2-expressing B cells resulted in T cell 
activation, IFN-γ polarization to the contact zone was assessed by confocal microscopy. 
 
Using the MHC class II-restricted OVAp-specific system, M2- or M2Y-expressing B cells, 
pulsed or not with different concentrations of OVAp, were incubated with CD4+ T cells in a 
2:1 ratio, for 2.5 hours. Prior to incubation, B and CD4+ T cells were loaded with CMFDA 
(green) and CMAC (blue) live dyes, respectively. Cells were then stained for IFN-γ and for 
the previously used pTyr marker. Conjugate count was blind and based on B-TH cell 
contact and IFN-γ (red) accumulation at the contact zone (Figure 3.3A). The percentage 
of T cells conjugating with either M2- (black circles) or M2Y-expressing (grey circles) B 
cells, that polarized IFN-γ to the contact zone, was then quantified (Figure 3.3B). IFN-γ 
polarization was at all times accompanied by pTyr accumulation at the contact zone. 
Presentation of a specific peptide was an absolute requirement, as demonstrated by the 
absence of IFN-γ polarization to the contact zone when B cells were not pulsed with 
OVAp. In the presence of specific peptide, conjugate formation with M2-expressing B cells 
resulted in more activated TH cells, compared to the M2Y condition, as was previously 
observed with intracellular calcium measurements (section 3.2.1). 
 
To exclude the possibility of a cell line effect, the detection of IFN-γ polarization to the 
contact zone by confocal microscopy was performed after incubation of CD4+ T cells with 
the independent A20 B cell lines, in a single experiment (Figure 3.3C). Once again, 
cognate interaction was an absolute requirement, as observed by the absence of 
conjugating T cells with IFN-γ polarization to the contact zone upon interaction with 
unpulsed B cells (0μM of OVAp). Presentation of specific peptide in the context of M2 
expression resulted in an increased number of T cells conjugating and polarizing IFN-γ to 
the contact zone, compared to the M2Y condition. This observation was in agreement with 
the results obtained with the A20 B cell lines (Figure 3.3B). 
 
IFN-γ analysis revealed that expression of M2 in B cells was not sufficient to promote T 
cell activation. Presentation of specific peptide by the B cell is, therefore, an absolute 
requirement for T cell activation upon B-TH cell interaction. In the presence of specific 
peptide, consistent with the increased number of conjugates, interaction with M2-
expressing B cells increased the number of activated TH cells.  
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Figure 3.3. IFN-γ production in M2-expressing B-TH cell conjugates requires specific peptide 
presentation. A20 B cells stably expressing the indicated proteins were pulsed overnight, or not, 
with different concentrations of OVA peptide (OVAp) and incubated with OVAp-specific CD4+ T 
cells. (A) Representative confocal images of IFN-γ polarization to the contact zone. Prior to 
incubation B and T cells were labelled with CMFDA (green) and CMAC (blue) live dyes, 
respectively. Cells were incubated for 2.5h, fixed and stained for IFN-γ (red), and for pTyr (yellow). 
Images are from one representative experiment out of three and were obtained using a Zeiss LSM 
510 META microscope. (B) Quantification of conjugates with IFN-γ polarization, upon variation of 
the OVAp concentration. 45 to 55 images were acquired per sample from three independent 
experiments. (C) Quantification of conjugates with IFN-γ polarization, for the independent EGFP-
expressing A20 B cell lines. 15 to 35 images were acquired per sample from a single experiment. 
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(B) and (C) Conjugate count was blind and based on B-TH cell contact and IFN-γ polarization to the 
contact zone. Only images with a minimum of three T cells were considered for analysis. Statistical 
significance of the difference between groups was evaluated by a Mann-Whitney U test.   
 
3.3 Discussion 
 
The previous chapter allowed to conclude that expression of M2 protein in B cells 
promotes their interaction with TH cells. However, it did not clearly discriminate between 
productive and non-productive B-TH cell contact, i.e. whether such interaction resulted in T 
cell activation. The fact that B-TH cell interaction was increased in the absence of peptide 
and the fact that pTyr accumulation at the B-TH contact zone was observed in those 
conditions raised the possibility of M2 promoting the formation of a functional IS and, 
therefore, T cell activation, independently of specific peptide.  
 
Measurement of intracellular calcium levels and IFN-γ polarization in TH cells revealed that 
conjugate formation with M2-expressing B cells in the absence of peptide does not lead to 
T cell activation. This dependence on the presence of specific peptide therefore 
suggested that the pTyr accumulation observed in the previous chapter (section 2.2.3) 
was not an indication of T cell signaling and activation, but was instead due to the 
constitutive phosphorylation of the tyrosine residues of M2, and the consequent 
phosphorylation of Vav1 and PLCγ2 on the B cell side (Rodrigues, Pires de Miranda et al. 
2006, Pires de Miranda, Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013). 
Nevertheless, concomitant with the increased number of conjugates, the number of 
activated TH cells was higher in the presence of M2-expressing B cells. 
 
Just like IFN-γ, the cytokines IL-2, IL-4 and IL-5 are also known to be secreted to the 
synaptic cleft following T cell activation (Friedl, den Boer et al. 2005). Measurement of the 
production of these cytokines by ELISA, performed by Dr. Filipa Lopes in our laboratory, 
revealed no differences between the conjugation of CD4+ T cells with M2- or M2Y-
expressing B cells. 
 
These findings support a model where expression of M2 in B cells promotes their 
interaction with TH cells but does not drive T cell activation. Instead, T cell activation upon 
conjugate formation is a product of cognate interaction. 
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4 M2 AND M2Y PROTEIN IN VIVO COMPETITION 
 
4.1 Introduction 
 
During T cell-dependent responses, naïve B cells present in the follicles of secondary 
lymphoid organs are activated by exogenous antigen (Batista and Harwood 2009), 
migrate towards the border area between follicles and T cell zones and interact with 
antigen-specific TH cells to become fully activated (Okada, Miller et al. 2005). 
Consequently, B cells follow one of three destinies: differentiation into short-lived 
plasmablasts, GC-independent differentiation into unswitched memory B cells (Taylor, 
Pape et al. 2012), and differentiation into plasmablast and memory B cells through the GC 
pathway (De Silva and Klein 2015). Access to the latter is a crucial step in 
gammaherpesvirus pathogenesis. T cell help is limited and selective, which requires that 
B cells compete with each other for this interaction (Schwickert, Victora et al. 2011).  
 
Hematopoietic stem cells (HSCs) are a self-renewing population capable of differentiating 
into all blood cell lineages. Furthermore, these cells can be efficiently transduced by 
retroviruses, allowing the expression of a protein of interest (Ide, Javazon et al. 2008). 
Due to these characteristics, HSCs are widely used in transplantation as they have the 
ability to repopulate adult mice and sustain hematopoiesis, the developmental process 
that ensures the formation of all blood cell types. HSCs can be recovered from the bone 
marrow of adult mice or from fetal liver, a major hematopoietic organ in the 12.5-15.5 
days-old mouse embryo (Morrison, Hemmati et al. 1995, Medvinsky, Rybtsov et al. 2011). 
Notably, the repopulation potential of fetal liver HSCs has been shown to surpass that of 
bone marrow HSCs, in that they present a greater proliferative activity (Rebel, Miller et al. 
1996). Purification of HSCs has been the focus of many studies and strategies. The 
tyrosine kinase receptor cKit (CD117), along with Sca-1, is a widely used marker for HSC 
enrichment. However, this marker is also expressed in many hematopoietic progenitor 
cells that, like HSCs, do not express lineage markers (Ogawa, Matsuzaki et al. 1991). 
Therefore, the use of cKit enriches a population for hematopoietic reconstituting activity 
but it does not convey a pure population of HSCs.  
 
The CD45 congenic marker system is widely used in mouse transplantation experiments. 
This takes advantage of the easy discrimination of the different CD45 alleles, for which 
there are commercially available monoclonal antibodies. Cells can be isolated from 
CD45.1 donor mice and adoptively transferred to CD45.2 recipient mice, or vice-versa, 
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where exogenous cells are easily distinguished from the endogenous population. 
Although CD45.1 and CD45.2 are considered to be functionally equivalent, differences in 
host reconstitution upon adoptive cell transfer have been described (Waterstrat, Liang et 
al. 2010, Basu, Ray et al. 2013).  
 
MuHV-4 exploits the GC reaction pathway to proliferate and get access to the long-lived 
memory B cell population. Results from Chapter 2 demonstrated the ability of the M2 viral 
protein to competitively promote B-TH cell interaction in vitro, when expressed in B cells. 
To assess whether this ability occurred in vivo and translated into a better access to GC 
reactions, a competition system was designed in collaboration with Dr. Henrique Veiga-
Fernandes. This consists of placing primary M2- or M2Y-expressing B cells in direct 
competition with mock B cells, in the context of a T cell-dependent stimulus. To obtain 
primary B cells expressing M2-IRES-GFP, M2Y-IRES-GFP and GFP, mouse chimeras 
were generated by transplantation of transduced, HSC-enriched, fetal liver populations 
using the CD45 congenic marker system to allow tracking of cells. 
 
4.2 Results 
 
4.2.1 The in vivo competition system 
 
B cell cognate interaction with TH cells, in the context of an immune response to T-cell 
dependent antigens, results in the initiation of a GC reaction, a critical step in the life cycle 
of MuHV-4. In vitro, expression of M2 in B cells competitively promoted conjugation with 
TH cells. To assess whether this advantage had a physiological significance, an in vivo 
competition system was designed (Figure 4.1), in collaboration with Dr. Henrique Veiga-
Fernandes.  
 
Briefly, the system consists of placing GFP- (also referred to as mock or empty) and M2-
IRES-GFP- (Figure 4.1A) or M2Y-IRES-GFP-expressing (Figure 4.1B) primary B cells in 
competition for acquisition of T cell help and, consequently, initiation of a GC reaction. 
These primary B cells are recovered from chimera mice (described in detail in section 
4.2.2) and co-transferred in direct competition (1:1 ratio) to sub-lethally irradiated B6 
recipient mice. To allow the tracking and discrimination of the adoptively transferred 
cellular populations the CD45 congenic marker system is used. Therefore, 
CD45.1/CD45.2 M2-IRES-GFP- and CD45.1 GFP-expressing B cells are co-transferred to 
CD45.2 B6 mice (Figure 4.1A), while CD45.2 M2Y-IRES-GFP- and CD45.1 GFP-
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expressing B cells are co-transferred to CD45.1/CD45.2 B6 mice (Figure 4.1B). Moreover, 
expression of M2 and M2Y in those populations can be confirmed by detection of GFP. In 
addition to B cells, CD4+ T cells are also transferred to the recipient mice to compensate 
for the decrease in the correspondent endogenous population, caused by irradiation. 
Recipient mice are then administered a T cell-dependent stimulus, 4-Hydroxy-3-
nitrophenylacetyl chicken gamma-globulin (NP-CGG) adsorbed to alum (Hikida, Casola et 
al. 2009), to drive GC formation. 10 days post stimulus, the percentage of M2- or M2Y-
expressing B cells within the GC population is assessed by flow cytometry, based on the 
CD45 marker and GFP expression, and compared to the percentage of the co-transferred 
mock B cells. The putative competitive advantage provided by the expression of M2 would 
translate into a predominance of M2-expressing B cells in the GC population.  
 
 
Figure 4.1. Schematic representation of the in vivo competition system. The indicated B cell 
populations are co-transferred, at a 1:1 ratio, along with CD4+ T cells, to irradiated mice. (A) M2-
expressing B cells are placed in direct competition with mock B cells (empty). (B) M2Y-expressing 
B cells are placed in direct competition with mock B cells. The CD45 congenic marker system is 
used to allow the tracking and discrimination of the different cellular populations. 48h after transfer, 
mice are administered intraperitoneally a T cell-dependent stimulus, NP-CGG adsorbed to alum. 
GC is analyzed 10 days post stimulus. 
 
To optimize the conditions for adoptive transfer of primary B cells to recipient mice several 
irradiation doses and several numbers of adoptively transferred B cells were tested. B 
cells were recovered by negative selection from the lymph nodes of CD45.1 B6 
background mice, as described in detail in section 7.2.3.3. Flow cytometric analysis of the 
initial cell suspension, in parallel with the purified population, confirmed the enrichment in 
B220+ cells (Figure 4.2). B cell purity was consistently above 98%. CD45.1 B cells were 
then intravenously transferred to sex-matched C57BL/6J recipient mice (CD45.2). One to 
two days post transfer, recipient mice were intraperitoneally injected with a T cell 
dependent stimulus, NP-CGG adsorbed to alum, to drive GC formation. 10 days post 
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transfer the spleen was collected for flow cytometric analysis (Figure 4.3). A naïve mouse, 
that was not adoptively transferred nor injected with the stimulus, was used as a negative 
control. The presence of adoptively transferred cells (CD45.1+CD45.2-) was assessed in 
the GC population, defined as B220+CD95hiGL7hi (Figure 4.3A). 
 
 
Figure 4.2. Flow cytometric analysis of B cell purity. Briefly, B cells were purified from the 
lymph nodes of CD45.1 B6 background mice, using a negative selection kit (MACS, Miltenyi 
Biotec), according to manufacturer’s instructions. A fraction of the initial cell suspension (before) 
and a fraction of the purified population (after) were stained with an anti-B220 antibody and 
analyzed on a LSR Fortessa flow cytometer (BD Biosciences). The percentage of cells in the B cell 
gate is shown. B cell purity was consistently above 98%. 
 
Upon adoptive transfer of 106 B cells to recipient mice, followed by stimulation, very few 
CD45.1 B cells were found in the GC (Figure 4.3B). This could be explained by an 
incorrect homing of these cells to the spleen or by the lack of space for the cells to 
proliferate. To test the latter hypothesis, recipient mice were irradiated (250rad) prior to 
adoptive transfer (Figure 4.3C). This led to a higher percentage of transferred cells within 
the GC population (0.5%). An increase in the irradiation dose, from 250rad to 500rad, 
further improved that result to an average of 6.5% of CD45.1 B cells (Figure 4.3D). 
Together, these results show that irradiation of the recipient mice is required for survival of 
the adoptively transferred population. Transfer of a higher number of adoptively 
transferred B cells (3.5x106 cells) to irradiated mice (500rad) resulted in a major increase, 
with an average of 35% transferred B cells within the GC (Figure 4.3E). Therefore, use of 
a 500rad irradiation dose and transfer of 1-3.5x106 B cells were chosen as the optimal 
conditions for in vivo competition analysis.  
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Figure 4.3. Optimization of the conditions for adoptive transfer of B cells to C57BL/6J mice. 
B cells were purified from the lymph nodes of CD45.1 B6 background mice and adoptively 
transferred to C57BL/6J mice by intravenous injection. One or two days after transfer, recipient 
mice were intraperitoneally injected with a T cell dependent stimulus, 4-Hydroxy-3-
nitrophenylacetyl hapten conjugated to Chicken Gamma Globulin (NP-CGG) adsorbed to alum. 
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Germinal center (GC) analysis by flow cytometry was carried out ten days after the stimulus. A 
naïve mouse, that was not adoptively transferred nor injected with the stimulus, was used as a 
negative control. (A) Gating strategy used for GC analysis defined in a naïve mouse. GC B cells 
were identified as B220+CD95hiGL7hi. The adoptively transferred population was identified, within 
the GC population, as CD45.1+CD45.2-, in contrast with the CD45.1-CD45.2+ endogenous 
population. (B) 106 CD45.1 B cells were adoptively transferred to recipient mice and stimulus was 
injected one day after transfer. (C) 106 CD45.1 B cells were adoptively transferred to irradiated 
(250rad) recipient mice and stimulus was injected two days after transfer. (D) 106 CD45.1 B cells 
were adoptively transferred to irradiated (500rad) recipient mice and stimulus was injected two 
days after transfer. (E) 3.5x106 CD45.1 B cells were adoptively transferred to irradiated (500rad) 
recipient mice and stimulus was injected two days after transfer. (B) to (E) Representative FACS 
plots are shown on the left and compiled data is shown on the right. Values correspond to the 
percentage of transferred cells within GC. 
 
4.2.2 Generation of mouse chimeras 
 
To produce the mock, M2- or M2Y-expressing primary B cells, mouse chimeras were 
generated (Figure 4.4). Fetal liver cellular suspensions were obtained from 15 days-old 
mouse embryos expressing the allelic forms CD45.1, CD45.2 or CD45.1/CD45.2 
heterozygous (section 7.2.7.2). Suspensions were then enriched for hematopoietic stem 
cells (HSCs) by using an antibody against cKit, as described in detail in section 7.2.3.4. 
This enrichment was confirmed with a staining for cKit, followed by flow cytometric 
analysis (Figure 4.5A). As described in detail in section 7.2.3.6, CD45.1, CD45.2 and 
CD45.1/CD45.2 HSC-enriched populations were then transduced with viral particles that 
allowed the expression of GFP alone (empty or mock condition), M2Y-IRES-GFP or M2-
IRES-GFP, respectively. Transduction efficiency was evaluated on the next day as the 
percentage of GFP+ cells (Figure 4.5B). In the empty condition, approximately 50% of the 
cells were transduced. Addition of the M2 or M2Y DNA sequence to the expression 
cassette reduced this efficiency to 36-37%. Sorting of transduced GFP+ cells prior to 
adoptive transfer resulted in cell death and poor reconstitution of the host. Therefore, 
irradiated Rag1-/- CD45.1 hosts were reconstituted with the total cell populations that were 
subjected to transduction. 
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Figure 4.4. Schematic representation of the generation of mouse chimeras. CD45.1 and 
CD45.2 B6 mice were breed as indicated. 15days post breeding, fetal liver HSC-enriched 
populations were obtained from B6 CD45 heterozygous, CD45.2 or CD45.1 embryos and 
transduced with M2-IRES-GFP, M2Y-IRES-GFP or GFP retrovirus, respectively. 2x106 cells of 
each population were then transferred intravenously to independent irradiated (600rad) Rag1-/- 
mice. 6 to 8 weeks following transplantation, blood was collected for flow cytometric analysis, to 
confirm reconstitution. 
  
 
Figure 4.5. Flow cytometric analysis of fetal liver cell enrichment and transduction. CD45.1, 
CD45.2 and CD45.1/2 fetal liver was obtained from 15 days-old mouse embryos (as described in 
section 7.2.7.2). Cell suspensions were enriched for hematopoietic stem cells (HSCs) by positive 
selection of c-kit expressing cells (as described in section 7.2.3.4). Next, cells were transduced with 
viral particles that allow the expression of M2-IRES-eGFP, M2Y-IRES-eGFP or eGFP alone 
CD45.1 x CD45.2
CD45.2 x CD45.2
CD45.1 x CD45.1
Fetal Liver
HSC-enriched
population
Rag1-/- mice
Retroviral particles:
• M2-IRES-GFP
• M2Y-IRES-GFP
• GFP
6-8w
X
15d Reconstitution
check
50.9%
Empty
c-kit
S
S
C
-A
91.6%
A
36.1% 37.0%
M2 M2Y
GFP
F
S
C
-A
B
CHAPTER 4 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
84 
 
(empty), used as a control. (A) Flow cytometric confirmation of HSC enrichment, as determined by 
expression of c-kit. (B) Flow cytometric analysis of transduction efficiency. Following transduction 
cells were cultured O/N. Transduction efficiency was then assessed as the percentage of GFP-
expressing cells.  
 
Chimera mice were analyzed 6 to 8 weeks after adoptive transfer to confirm 
reconstitution. To that end, blood was collected from the facial vein of chimera mice and 
stained for B cells (B220+), myeloid cells (MAC1+GR1+), CD4+ T cells and CD8+ T cells 
(Figure 4.6). In mice reconstituted with M2-transduced HSCs, there was a dramatic 
reduction in the percentage of B cells (15%), which was not observed in mice 
reconstituted with M2Y- (48%) or Empty-transduced HSCs (50%) (Figure 4.6A). The 
decrease in the B cell population observed in the M2 condition allowed an increase in the 
myeloid cell population (Figure 4.6B). No differences were observed in the analyzed T cell 
populations (Figure 4.6C). Together, results suggest that the ability of M2 to assemble 
multiprotein complexes with cell signaling proteins had a negative effect in the 
development and/or proliferation of the M2-transduced B cell population.  
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Figure 4.6. Flow cytometric analysis of chimera mice reconstitution. 6-8 weeks following 
adoptive transfer, blood was collected from the facial vein of chimera mice and stained for (A) B 
cells (B220+), (B) myeloid cells (MAC1+GR1+), and (C) CD4+ T cells and CD8+ T cells. 
Representative FACS plots are shown on top and compiled data obtained from the analysis of 10-
12 mice per group is shown below.  
  
The use of a bi-cistronic vector for viral particle production (section 7.2.3.5) allowed the 
expression of GFP in addition to M2 or M2Y, facilitating the identification of cells that 
successfully integrated and expressed the retroviral vector. Therefore, the percentage of 
B cells and myeloid cells expressing M2 or M2Y was assessed by flow cytometry as the 
percentage of GFP positive events within the indicated populations (Figure 4.7). Mice 
reconstituted with the empty control had an average of 9% of GFP+ B cells (Figure 4.7A) 
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and 4% of GFP+ myeloid cells (Figure 4.7B). Mice reconstituted with M2-transduced HSCs 
had very small percentages of GFP-expressing B cells (0.2%) (Figure 4.7A) and myeloid 
cells (0.3%) (Figure 4.7B). The same was true for mice reconstituted with M2Y-transduced 
HSCs, which had 0.3% of GFP+ B cells (Figure 4.7A) and 1% of GFP+ myeloid cells 
(Figure 4.7B). Comparing these percentages with the initial percentage of GFP+ HSCs that 
were used to reconstitute the Rag1-/- mice (Figure 4.5) suggests that there was shutdown 
of the expression cassette to a certain level.  
 
Due to the intrinsic characteristics of the M2 protein, there was a poor B cell 
reconstitution. Furthermore, in all three conditions, there was shutdown of the expression 
cassette to a certain level. In the case of the M2 and M2Y conditions, this translated to the 
impossibility of recovering M2- or M2Y-expressing primary B cells from the chimera mice. 
Therefore, the in vivo competition experiment could not be performed.  
 
 
Figure 4.7. Flow cytometric analysis of GFP expression in B and myeloid cell populations of 
chimera mice. 6-8 weeks following adoptive transfer, blood was collected from the facial vein of 
chimera mice and stained for several cellular populations. GFP expression was then analyzed in 
(A) B cells and (B) myeloid cells. Representative FACS plots are shown on the left and compiled 
data obtained from the analysis of 10-12 mice per group is shown on the right. 
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4.3 Discussion 
 
To assess whether the in vitro ability of M2 to competitively promote B-TH cell interaction 
in vitro occurred in vivo, and translated into a better access to GC reactions, a competition 
system was designed in collaboration with Dr. Henrique Veiga-Fernandes. Since this 
system depended on the purification of primary B cells from mouse chimeras, where 
reconstitution of the B cell compartment in the M2 condition was unsuccessful, the 
experiment could not be performed. 
 
Irradiated RagKO mice reconstituted with M2-transduced HSC-enriched fetal liver 
population presented a dramatic deficit in the B cell compartment, which was related to 
the ability of the viral protein to assemble multiprotein complexes with B cell signaling 
proteins. The stage of B cell development that was affected by the expression of M2 was 
not determined. 
 
HSC-enriched fetal liver cells transduced for expression of M2-IRES-GFP, M2Y-IRES-
GFP or Empty-GFP were of different allotypes, CD45.1/CD45.2, CD45.2 and CD45.1, 
respectively. Differences in host reconstitution upon adoptive co-transfer of CD45.1 and 
CD45.2 cells have been described (Waterstrat, Liang et al. 2010, Basu, Ray et al. 2013). 
However, these correspond to a differential representation of some B cell subsets, namely 
the CD45.1 allele is associated with an increased percentage of splenic marginal zone B 
cells, while the CD45.2 allele is associated with an increased percentage of mature B cells 
in the lymph nodes and bone marrow. Therefore, these differences in host reconstitution 
do not explain the dramatic reduction in the circulating B cell population observed in the 
reconstitution of mice with M2-IRES-GFP-transduced HSC-enriched population. 
 
During hematopoiesis, HSCs give rise to multipotent progenitors that will be on the basis 
of mature blood cell development. One such progenitor is the common lymphoid 
progenitor (CLP), included in classical models of hematopoiesis (Metcalf 2007), or the 
common myelolymphoid progenitor (CMLP), mentioned in more recent models (Lu, 
Kawamoto et al. 2002). Regardless of the model, these cells are on the basis of pro-B 
cells which give rise to pre-B cells, and, consequently, immature B cells (LeBien and 
Tedder 2008). The absence of a key signal at any stage of development, if not corrected, 
results in apoptosis (Yankee and Clark 2000). The process of B cell development is 
therefore tightly regulated. One of the checkpoints of this process is the expression of the 
pre-B cell receptor (pre-BCR) (Martensson, Almqvist et al. 2010). Signaling downstream 
of this receptor is required for cell proliferation, survival and recombination of the light 
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chain gene. Changes in this signaling pathway result in defects in early B cell 
development, as is the case of patients with mutations in Bruton’s tyrosine kinase (Btk), a 
signaling molecule located downstream of the pre-BCR (Martensson, Almqvist et al. 
2010). Signaling also includes the PI3K-AKT pathway, where activation of AKT promotes 
proliferation, survival and differentiation in B cells (Werner, Hobeika et al. 2010). 
Expression of M2 in B cell lines has been shown to inhibit AKT activation upon BCR 
stimulation (Pires de Miranda, Lopes et al. 2013), an observation that is dependent on the 
unconventional ITAM. Therefore, it is possible that expression of M2 during B cell 
development negatively affected the survival and proliferation of B cell progenitors and, 
consequently, led to a reduced amount of mature B cells.  
 
An alternative strategy would be the use of an inducible gene expression system, such as 
the SparQ™ Cumate Switch (by System Biosciences) (Mullick, Xu et al. 2006), that would 
allow the expression of M2 or M2Y only in the final recipient mice, where competition for 
GC entry takes place. The SparQ™ Cumate Switch (by System Biosciences), currently 
being optimized for in vivo use, employs lentivectors and consists on the utilization of the 
CymR repressor that binds the cumate operator sequences. Addition of Cumate, a non-
toxic molecule, alleviates this repression and allows gene expression. Transduction of the 
HSC-enriched fetal liver population is not 100% efficient. Consequently, not all B cells in 
the chimera mice would carry the expression cassette that includes the coding sequences 
for M2/M2Y-IRES-GFP. Therefore, an induction step could also be required in the chimera 
mice to allow the selection of GFP-expressing B cells. Considering that expression of M2 
may influence B cell development, induction would have to be performed after those 
development stages. In the final recipient mouse, further challenges would be to ensure 
that expression would be induced in the same number of M2- and M2Y-carrying cells, and 
at the same level, so that results would not be biased. An alternative strategy to the 
generation of mouse chimeras would be the direct transduction of primary B cells. This 
approach was initially rejected because most protocols require the prior activation of the B 
cell, which could mask the putative competitive advantage provided by expression of M2. 
Nonetheless, efficient in vitro transduction of primary murine B cells with lentivirus, without 
prior activation, has been described (Warncke, Vogt et al. 2004). 
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5 CHARACTERIZATION OF THE M2Y RECOMBINANT VIRUS 
DELAY IN LATENCY ESTABLISHMENT 
 
5.1 Introduction 
 
Primarily considered to enter the host orally and directly infect B cells, in-depth studies 
have proven that there is more complexity associated with the infection pathway of MuHV-
4 than initially thought. Following intranasal (i.n.) infection of laboratory mice, believed to 
reproduce the physiological route, MuHV-4 targets the olfactory neuroepithelium (Milho, 
Frederico et al. 2012). Free viruses then infect CD11c+ myeloid cells, which provide a 
conduit to lymph nodes (LN) (Gaspar, May et al. 2011). It is proposed that, at this stage, 
MuHV-4 infects B cells, which may differentiate into plasma cells and release virus into 
the afferent lymph (Gillet, Frederico et al. 2015). Next, by entering the blood stream, 
MuHV-4 reaches the spleen, where it exploits normal systemic immune communication 
routes. Particularly, infection reaches GC reactions, where latency is amplified, attaining 
maximal levels at day 14 post infection. Infected B cells may then emerge from this 
process as memory B cells, the long term target population for latent gammaherpesvirus 
infection. 
 
Tracking of MuHV-4 infection in spleen sections, using recombinant viruses that express 
fluorescent proteins, revealed the specific splenic populations that the virus infects as well 
as the order in which they are infected (Frederico, Chao et al. 2014). i.n. infection, 
although thought to be the route that better mimics the physiological one, implies virus 
replication in epithelial cells and LNs, the outcome being a more asynchronous splenic 
infection, where it is difficult to distinctly observe the different stages. Therefore, the 
knowledge on the order of infection of the different splenic populations was only possible 
to obtain due to the use of the intraperitoneal (i.p.) route of infection. Nonetheless, this 
study has proven that i.p. and i.n. infections show the same component steps of splenic 
colonization, thus validating the use of i.p. infection. The first step of spleen colonization, 
as detected at 4dpi, is infection of marginal zone (MZ) macrophages. The use of a virus 
that expresses EGFP from a viral M3 promoter, that is active mainly in lytic infection, 
allowed to conclude that MZ infection is mainly lytic. At 8dpi, MuHV-4 is already detected 
in B cell subsets, with approximately 75% of the infection being restricted to the WP. 
Thorough analysis revealed that macrophages provide access to MZ B cells which, in 
turn, relocate to the white pulp (WP). Follicular dendritic cells (DCs) then make the bridge 
between MZ and follicular (Fo) B cells, which are able to participate in GC reactions.  
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M2 was initially classified as a latency-candidate protein due to the genomic position of its 
coding gene, homologous to the position of genes that code for latency proteins in other 
gammaherpesviruses (Virgin, Latreille et al. 1997, Virgin, Presti et al. 1999). This was 
later on confirmed experimentally (Husain, Usherwood et al. 1999, Virgin, Presti et al. 
1999). Further studies on the establishment of latency in the spleen demonstrated that M2 
gene is expressed in DCs and in several B cell subsets, namely: MZ B cells, Fo B cells 
and GC B cells (Flano, Kim et al. 2002, Marques, Efstathiou et al. 2003). In agreement 
with M2 being a latency-associated protein, expression of M2 is not detected in 
macrophages, a population shown to be lyticaly infected (Frederico, Chao et al. 2014).  
 
The tyrosine residues Y120 and Y129 constitute an unconventional ITAM that is involved 
in the assembly of multiprotein complexes with cell signaling proteins (Pires de Miranda, 
Lopes et al. 2013). i.n. infection with a recombinant virus, designated M2Y, where these 
residues were mutated to phenylalanines, resulted in a delay in latency establishment 
(Pires de Miranda, Alenquer et al. 2008). This was characterized by a deficit in latent 
infection levels and splenic follicle colonization at the latency peak (14dpi). Maximal levels 
of GC infection were only observed at 21dpi. Long term comparison between the levels of 
infection of WT and M2Y viruses showed no differences, indicating that the 
unconventional ITAM of the M2 protein is not important for the maintenance of long term 
latency.  
 
Given what is known on the unconventional ITAM of M2, the M2Y delay in latency 
establishment may be explained by a B cell phenotype. Moreover, it may be due to an 
inefficient colonization of GCs, resultant from the lack of promotion of B-TH cell interaction 
described in Chapter 2. In order to determine the exact step of spleen infection in which 
the M2Y recombinant virus is delayed, infection with a fluorescent mutant virus was 
tracked in vivo, quantitatively by flow cytometry and representatively by 
immunofluorescence of spleen sections. In contrast to what was done by Frederico, Chao 
et al. 2014, the fluorescent viruses used in this study expressed YFP through a human 
cytomegalovirus (HCMV) immediate early (IE) promoter, instead of the viral M3 promoter 
or the elongation factor 1α (EF1α) promoter. In similarity to what was done by Frederico, 
Chao et al. 2014, i.p. infection was used as the route for virus delivery. The existence of 
delay in latency establishment following i.p. virus delivery was confirmed by ex vivo 
reactivation assay and flow cytometric analysis of B cell infection at different times post 
infection.  
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5.2 Results 
 
5.2.1 Characterization of M2Y recombinant virus in the context of 
intraperitoneal infection 
 
Following i.n. inoculation with MuHV-4, the virus replicates in epithelial cells and LN, with 
lytic viruses reaching the spleen at different times post infection. As observed by 
Frederico, Chao et al. 2014 these results in an asynchronous splenic infection, making it 
difficult to distinctly observe the different stages of infection of splenic populations. For this 
reason, in this study, intraperitoneal (i.p.) infection was chosen as the appropriate route 
for virus delivery. Since infection with M2Y recombinant virus has only been characterized 
in the context of i.n. infection, M2Y latent and lytic viral loads were determined at different 
timepoints following i.p. infection (Figure 5.1).  
 
C57BL/6J mice were i.p. injected with 106 PFU of M2Y YFP-expressing recombinant 
MuHV-4 and spleens were collected at 4, 8, 10, 14, and 21dpi. A second group of mice 
was infected with WT YFP-expressing recombinant virus, for comparative purposes. The 
M2Y YFP-expressing MuHV-4 recombinant virus (vM2Y-YFP) was constructed in our lab 
by Dr. Marta Alenquer through a methodology that utilizes the MuHV-4 genome cloned in 
a bacterial artificial chromosome (BAC) (Adler, Messerle et al. 2000). Introduction of the 
M2Y mutation was confirmed by sequencing across the M2 ORF. The genomic integrity of 
the mutant virus was verified by analysis of restriction enzyme digestion profiles of BAC 
DNA, performed by Dr. Marta Alenquer. The WT YFP-expressing MuHV-4 recombinant 
virus (vYFP) was a kind gift from Dr. Samuel Speck (Collins, Boss et al. 2009). Latent 
infection was then quantified, at each timepoint, by infectious center assay (ICA) (Figure 
5.1, closed symbols), as described in detail in section 7.2.8.3. This is an ex vivo 
reactivation assay, in which single cell splenocyte suspensions obtained from infected 
mice are co-cultured with fibroblast cells permissive to infection with MuHV-4. 
Reactivation of latent viruses then causes cytopathic effects (cpe) in the form of cell lysis 
plaques. However, if there are pre-formed infectious virus present at the time of spleen 
collection, these will contribute to the cpe. Therefore, to assess if the viral load determined 
by ICA is due to latent and/or lytic viral infection, pre-formed infectious viruses are 
quantified by plaque assay (PA) (Figure 5.1, open symbols), as described in detail in 
section 7.2.8.4. To that end, single cell splenocyte suspensions are subjected to freeze-
thawing, which disrupts the cells resulting in the impossibility of reactivation from latency. 
Cell suspensions are then co-cultured with permissive cells, later on examined for cpe.  
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Figure 5.1. Characterization of intraperitoneal infection of C57BL/6J mice with WT and M2Y 
recombinant viruses. C57BL/6J mice were intraperitoneally inoculated with 106 PFU of either WT 
or M2Y YFP-expressing MuHV-4. At the indicated days post infection (Day pi), spleens were 
isolated and infection was quantified by ex vivo reactivation assay (closed symbols) in each 
sample. Pre-formed infectious viruses were analyzed by plaque assay (open symbols). Each point 
represents the titer of an individual mouse. Horizontal bars show arithmetic means. The dashed 
horizontal line indicates the limit of detection of the assay.  
 
At 4dpi the latent viral load was slightly (2.6-fold) higher for the WT virus, as determined 
by ICA (Figure 5.1, closed symbols). However, pre-formed infectious virus levels were the 
same, as determined by PA (Figure 5.1, open symbols). Given that the first step of spleen 
colonization consists of lytic infection of macrophage populations (Frederico, Chao et al. 
2014), results suggested that both viruses equally arrived at the spleen and were able to 
infect macrophages. However, at 8dpi, the levels of pre-formed M2Y infectious viruses 
decreased, when compared to the WT virus. The latter presented an increase in latent 
infection, with a peak at 10dpi, that started to decrease at day 14pi. This was 
accompanied by a continuous decrease in lytic infection, that was undetectable from day 
14pi onward. In contrast, the highest levels of infection with M2Y virus were detected at 
days 14 and 21pi, never attaining WT levels. This is concomitant with the delay in latency 
establishment described for i.n. infection with the mutant virus. 
 
MuHV-4 latent infection is associated with the B cell population. To further confirm that the 
M2Y recombinant virus has a delay in latency establishment following i.p. infection, YFP 
expression was analyzed in total B cells (Figure 5.2). Briefly, C57BL/6J mice were i.p. 
infected with 106 PFU of WT or M2Y YFP-expressing viruses. Spleens were then collected 
at 4, 8, 10, 14 and 21dpi and analyzed by flow cytometry. A non-infected mouse was used 
at each timepoint as a negative control and is represented as a dashed line. WT infection 
was visible from day 8pi onward, with a peak at day 10 (Figure 5.2, closed symbols). 
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Subsequently, it decreased from day 14pi onward to nearly undetectable levels at day 
21pi. In contrast, B cell infection with M2Y virus only peaked at 14dpi (Figure 5.2, open 
symbols), never attaining WT levels. This confirmed the latency delay described for this 
virus.  
 
 
Figure 5.2. Characterization of B cell infection following intraperitoneal inoculation with WT 
and M2Y YFP-expressing MuHV-4. C57BL/6J mice were intraperitoneally infected with 106 PFU 
of WT (closed symbols) or M2Y (open symbols) YFP-expressing MuHV-4. At the indicated days 
post infection (dpi), spleens were isolated for flow cytometric analysis of the percentage of YFP+ 
cells in total B cells, defined as CD19+ cells. Representative FACS plots are shown on top and 
compiled data from a single experiment is shown below. Each dot represents a mouse. The 
dashed line represents the limit of detection, as determined by the percentage of YFP+ cells 
obtained with a non-infected (NI) mouse. 
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5.2.2 Tracking M2Y virus infection of splenic populations 
 
MuHV-4 disseminates to secondary lymphoid organs with the purpose of establishing 
latency in memory B cells. Once in the spleen, the virus infects macrophages, a step 
mainly attributed to lytic infection. It then spreads to MZ B cells and follicular B cells, which 
in turn are able to interact with CD4+ T cells and initiate a GC reaction. In order to 
determine the step at which the M2Y virus is delayed, infection was tracked in the 
mentioned cellular populations through flow cytometry (Figure 5.3), namely: Fo B cells 
(CD19+ CD21int CD23+), MZ B cells (CD19+ CD23- CD21+), GC B cells (CD19+ GL7hi 
CD95hi), DCs (B220- CD11bint CD11c+), and macrophages (B220- CD11c- CD11b+). The 
limit of detection of the assay was determined by the YFP+ events obtained with a non-
infected mouse and represented in the graphs as a dashed line.  
 
 
Figure 5.3. Splenic populations analyzed in this study. C57BL/6J mice were intraperitoneally 
inoculated with 106 PFU of WT or M2Y YFP-expressing MuHV-4. At different days post infection, 
spleens were isolated for flow cytometric analysis. (A) After gating on B cells (CD19+), the following 
populations were discriminated: follicular (Fo) B cells (CD19+ CD21int CD23+), marginal zone (MZ) 
B cells (CD19+ CD21hi CD23-), and germinal center (GC) B cells (CD19+ CD95hi GL7hi). (B) After 
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gating on non-B cells (B220-), the following populations were discriminated: dendritic cells (DC) 
(B220- CD11bint CD11c+), and macrophages (B220- CD11bhi CD11c-). 
 
As demonstrated Frederico et al, 2014 infection at 4dpi is mainly lytic. Furthermore, it is 
mainly restricted to macrophage populations. Therefore, high levels of macrophage 
infection were expected at this timepoint. However, only 0.011% and 0.003% of 
macrophages were found to be infected with WT or M2Y viruses, respectively. These 
percentages were disregarded because they corresponded to very few YFP+ events (3 to 
11). Therefore, neither WT nor M2Y virus infection could be detected by flow cytometry at 
4dpi (Figure 5.4). This indicates that either the YFP expression cassette is not expressed 
during lytic infection or that the expression per cell is too low to be distinguished from the 
negative population. At 8dpi, when latency is increasing, the WT virus was already 
detected in several populations, particularly in MZ (3.18% on average), Fo (0.09% on 
average) and GC B cells (3.32% on average). In contrast, M2Y was still below detection 
limits for all populations analyzed except MZ B cells (0.014%) (Figure 5.5). This infection 
was once more disregarded due to the very few positive events (11 on average). 
Percentages of infection of MZ and Fo B cells are most likely underestimated, as the 
markers used to discriminate these populations, CD21 and CD23, have been shown to be 
downregulated as a consequence of MuHV-4 infection (Collins, Boss et al. 2009). 
Nonetheless, infection was detectable with the WT virus and there was a significant 
difference between the latter and M2Y infection of MZ B cells, suggesting a B cell 
phenotype. 
 
To exclude the possibility that at 4dpi the levels of YFP expression per cell were too low to 
be detected by flow cytometry, and in similarity to what was done by Frederico, Chao et 
al. 2014, infection was analyzed by immunofluorescence of frozen spleen sections, with 
an antibody against YFP to amplify the signal. Briefly, C57BL/6J mice were i.p. infected 
with 106 PFU of WT or M2Y YFP-expressing viruses. At the appropriate days post 
infection, spleens were collected, fixed, frozen in OCT and sectioned for 
immunofluorescence (described in detail in section 7.2.9). At 4dpi, spleen sections were 
stained for the two macrophage populations known to be infected by MuHV-4 at that 
timepoint: MZ macrophages (MARCO) and MZ metallophilic macrophages (CD169) 
(Frederico, Chao et al. 2014). No YFP accumulation was detected in any of the 
populations analyzed, independently of the virus tested (Figure 5.6), confirming that YFP-
expressing viruses do not allow the detection of lytic infection. To validate the absence of 
YFP signal observed at 4dpi, as a positive control, immunofluorescence of spleen 
sections was performed at 8dpi, a timepoint when YFP could be detected by flow 
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cytometry. Given that MuHV-4 is known to me mainly found in the WP at this timepoint 
(Frederico, Chao et al. 2014), spleen sections were stained for endothelial cells 
(MAdCAM-1) and follicular B cells (IgD) (Figure 5.7). WT, but not M2Y, infection was 
promptly detected and was mainly restricted to the WP, as denoted by the position of the 
infected cells relative to the endothelial and follicular B cell staining. Together, results 
confirm that lytic infection with YFP-expressing viruses cannot be detected by 
immunofluorescence of frozen spleen sections. As observed by flow cytometry, latent 
infection with M2Y could not be detected. In contrast, WT latent infection was in 
agreement with the observations made by Frederico, Chao et al. 2014.  
 
 
Figure 5.4. Lytic infection following intraperitoneal infection with MuHV-4 is not detectable 
by flow cytometry. C57BL/6J mice were intraperitoneally infected with 106 PFU of WT (closed 
symbols) or M2Y (open symbols) YFP-expressing MuHV-4. At 4 days post infection (dpi), spleens 
were isolated for flow cytometric analysis of the percentage of YFP+ cells in the indicated 
populations. Representative FACS plots are shown on top and compiled data from a single 
experiment is shown below. Each dot represents a mouse. The dashed line represents the limit of 
detection, as determined by the percentage of YFP+ cells obtained with a non-infected (NI) mouse. 
MΦ, macrophages; MZ B, marginal zone B cells; DC, dendritic cells; Fo B, follicular B cells. 
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Figure 5.5. WT, but not M2Y, infection has reached GC B cells at 8dpi. C57BL/6J mice were 
intraperitoneally infected with 106 PFU of WT (closed symbols) or M2Y (open symbols) YFP-
expressing MuHV-4. At 8 days post infection (dpi), spleens were isolated for flow cytometric 
analysis of the percentage of YFP+ cells in the indicated populations. Representative FACS plots 
are shown on top and compiled data from a single experiment is shown below. Each dot represents 
a mouse. The dashed line represents the limit of detection, as determined by the percentage of 
YFP+ cells obtained with a non-infected (NI) mouse. MΦ, macrophages; MZ B, marginal zone B 
cells; DC, dendritic cells; Fo B, follicular B cells. 
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Figure 5.6. Lytic infection following intraperitoneal infection with MuHV-4 is not detectable 
by immunofluorescence of frozen spleen sections. C57BL/6J mice were intraperitoneally 
infected with 106 PFU of WT or M2Y YFP-expressing MuHV-4. At 4 days post infection (dpi), 
spleens were isolated, fixed, frozen in OCT and sectioned. Spleen sections were then stained for 
YFP (green) and either CD169 (MZ metallophilic macrophages) or MARCO (MZ macrophages) 
(red). Nuclei were stained with DAPI (blue). Scale bars = 20µm. Equivalent results were obtained in 
three mice. 
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Figure 5.7. WT, but not M2Y, virus has reached the WP at 8dpi. C57BL/6J mice were 
intraperitoneally infected with 106 PFU of WT or M2Y YFP-expressing MuHV-4. At 8 days post 
infection (dpi) spleens were isolated, fixed, frozen in OCT and sectioned. Spleen sections were 
then stained for YFP (green) and either MAdCAM-1 (endothelial cells) or IgD (Fo B cells) (red). 
Nuclei were stained with DAPI (blue). Scale bars = 40µm. Equivalent results were obtained in three 
mice. 
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As observed previously by ICA and PA (Figure 5.1), 10dpi was the latency peak for the 
WT virus, as depicted by the maximal levels of MZ B cell (13.53% on average), DC 
(3.52% on average), Fo B cell (0.50% on average) and GC B cell infection (20.90% on 
average) (Figure 5.8). At that timepoint, infection with M2Y virus could be detected at very 
low levels in Fo (0.006% on average) and GC B cells (0.18% on average). This reached a 
peak at 14dpi, with an average of 0.02% infected Fo B cells and 0.69% infected GC B 
cells, once more confirming M2Y delay in latency establishment and revealing that, 
although the virus is delayed, it is still able to reach germinal centers (Figure 5.9). In 
contrast, WT levels of infection started to decrease, as observed by the lower percentages 
of MZ B cell (0.13% on average), DC (0.20% on average), Fo B cell (0.009% on average) 
and GC B cell (0.74% on average) infection (Figure 5.9). At 21dpi, the levels of infection 
decreased for both viruses, with WT and M2Y infection being indistinguishable from each 
other (Figure 5.10).  
 
Since macrophage infection, the first step of spleen colonization, could not be quantified 
with neither WT nor M2Y virus, it was not possible to conclude with certainty that there 
were no differences between both viruses at that stage. Consequently, no conclusions 
can be made as to the population in which the M2Y virus is delayed. Nonetheless, the 
major difference between WT and M2Y infection was observed in the B cell compartment, 
as soon as WT infection reached MZ B cells. Therefore, data is not exclusive of a B cell 
phenotype. 
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Figure 5.8. Low levels of M2Y infection are detected at 10dpi. C57BL/6J mice were 
intraperitoneally infected with 106 PFU of WT (closed symbols) or M2Y (open symbols) YFP-
expressing MuHV-4. At 10 days post infection (dpi), spleens were isolated for flow cytometric 
analysis of the percentage of YFP+ cells in the indicated populations. Representative FACS plots 
are shown on top and compiled data from a single experiment is shown below. Each dot represents 
a mouse. The dashed line represents the limit of detection, as determined by the percentage of 
YFP+ cells obtained with a non-infected (NI) mouse. MΦ, macrophages; MZ B, marginal zone B 
cells; DC, dendritic cells; Fo B, follicular B cells. 
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Figure 5.9. M2Y virus reaches a peak of infection at 14dpi. C57BL/6J mice were 
intraperitoneally infected with 106 PFU of WT (closed symbols) or M2Y (open symbols) YFP-
expressing MuHV-4. At 14 days post infection (dpi), spleens were isolated for flow cytometric 
analysis of the percentage of YFP+ cells in the indicated populations. Representative FACS plots 
are shown on top and compiled data from a single experiment is shown below. Each dot represents 
a mouse. The dashed line represents the limit of detection, as determined by the percentage of 
YFP+ cells obtained with a non-infected (NI) mouse. MΦ, macrophages; MZ B, marginal zone B 
cells; DC, dendritic cells; Fo B, follicular B cells. 
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Figure 5.10. Both WT and M2Y infection levels decrease at 21dpi. C57BL/6J mice were 
intraperitoneally infected with 106 PFU of WT (closed symbols) or M2Y (open symbols) YFP-
expressing MuHV-4. At 21 days post infection (dpi), spleens were isolated for flow cytometric 
analysis of the percentage of YFP+ cells in the indicated populations. Representative FACS plots 
are shown on top and compiled data from a single experiment is shown below. Each dot represents 
a mouse. The dashed line represents the limit of detection, as determined by the percentage of 
YFP+ cells obtained with a non-infected (NI) mouse. MΦ, macrophages; MZ B, marginal zone B 
cells; DC, dendritic cells; Fo B, follicular B cells. 
 
5.3 Discussion 
 
Characterization of i.p. infection with M2Y YFP-expressing recombinant virus confirmed 
that, as has been demonstrated for intranasal infection with this mutant (Pires de Miranda, 
Alenquer et al. 2008), there is a delay in latency establishment.  
 
The first stage of spleen colonization is lytic infection of macrophages, detectable four 
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latency-associated protein (Virgin, Latreille et al. 1997, Husain, Usherwood et al. 1999, 
Virgin, Presti et al. 1999) that is not expressed in infected macrophages (Marques, 
Efstathiou et al. 2003), no differences should be expected at this stage. In fact, results 
obtained by PA at this timepoint showed that the total levels of lytic infection with WT and 
M2Y viruses were the same, which is concomitant with a normal macrophage infection 
with M2Y recombinant virus. Surprisingly, at 8dpi the load of pre-formed infectious M2Y 
viruses was lower than the WT. A similar observation has been previously described for a 
M2-deficient virus (Jacoby, Virgin et al. 2002). One possible explanation is that viruses 
reactivate from latency and contribute to the lytic viral load. Therefore, the lower load of 
pre-formed infectious M2Y viruses would reflect the latency deficit that characterizes this 
virus. Due to the difficulty in detecting YFP expression during lytic infection, it was not 
possible to confirm by flow cytometric analysis that macrophage infection was the same 
for both viruses. Concluding, lytic infection with M2Y virus could not be clarified. In the 
future, efforts could be made to detect lytic infection by RT-PCR in sorted macrophage 
populations from mice infected with WT or M2Y viruses. 
 
In their study Frederico, Chao et al. 2014 use recombinant viruses where EGFP is under 
an EF1α promoter or the lytic M3 promoter, and the expression cassette is located 
between ORF57 and ORF58 of the virus genome. The fact that the viruses used in this 
study had YFP expression driven by an HCMV IE promoter, from the ORF27-ORF29b 
intergenic site may account for the difficulty in detecting YFP expression during lytic 
infection. In fact, in their characterization of the YFP-expressing MuHV-4, Collins, Boss et 
al. 2009 could not detect YFP expression neither following i.p. infection nor in long term 
analysis. They propose that the HCMV IE promoter/enhancer is directly targeted for 
silencing by specific host responses, which could explain the absence of YFP expression 
during lytic infection.  
 
The role of M2 in the modulation of B cell signaling pathways downstream of the BCR 
(Madureira, Matos et al. 2005, Rodrigues, Pires de Miranda et al. 2006, Pires de Miranda, 
Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013), as well as its ability to promote 
B-TH cell interaction point out to the possibility of mutation of the Tyr residues leading to a 
B cell phenotype. In agreement, significant differences were observed in infection of all 
the B cell subsets analyzed. However, the impossibility of confirming the equal WT and 
M2Y virus infection of macrophages, the first stage of spleen colonization, does not allow 
to take definite conclusions on the delay in latency establishment presented by the mutant 
virus. Nonetheless, results do not exclude a B cell phenotype, which fits the known 
functions of the unconventional ITAM of M2. 
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6 FINAL CONSIDERATIONS 
 
Gammaherpesviruses have the ability to persist for the lifetime of the host. Following the 
initial productive infection, EBV and KSHV reach an equilibrium with their human host 
where there are no signs of disease. However, this equilibrium may be disturbed giving 
rise to lymphoproliferative disorders, especially in immunocompromised patients 
(Damania 2004). Persistence is attained through the exploitation of normal B cell biology, 
the main target population of these pathogens. Immune evasion, modulation of B cell 
signaling and latency establishment are some of the strategies used during host 
colonization. In particular, accessing the long-lived memory B cell population is a crucial 
step for long-term survival on the host. To achieve that, EBV exploits the GC reaction, 
driving infected B cells through the process of proliferation and differentiation, presumably 
without the need for normal T cell help (Thorley-Lawson 2001, Thorley-Lawson 2005, 
Thorley-Lawson, Duca et al. 2008, Thorley-Lawson, Hawkins et al. 2013). EBV expresses 
the terminal membrane proteins LMP1 and LMP2A that mimic the function of the B cell 
receptor and CD40 receptor, respectively, promoting the activation and differentiation of 
the infected B cell.  KSHV, which was more recently discovered, has not yet been clearly 
linked to this strategy. Nonetheless, it is possible that it similarly exploits the GC. KSHV 
also possesses two terminal membrane proteins, K1 and K15, that interfere with B cell 
signaling (Damania 2004). 
 
MuHV-4, the mouse model of gammaherpesvirus infection, belongs to the same genus of 
KSHV and is also related to EBV. Like the latter, MuHV-4 exploits the GC reaction to have 
access to the memory B cell compartment. Unlike EBV, this mouse pathogen seems to 
depend on normal T cell help (Ehtisham, Sunil-Chandra et al. 1993, Usherwood, Ross et 
al. 1996). The MuHV-4 putative functional homologue of the EBV and KSHV proteins 
involved in B cell signaling is the M2 protein. This is associated with the latency phase 
and its expression is detected in several B cell subsets, namely: marginal zone, follicular 
and GC B cells (Marques, Efstathiou et al. 2003). Furthermore, this protein contains two 
phosphosites (Y120 and Y129), constitutively phosphorylated in B cells, that form an 
unconventional ITAM. Similar to K1, M2 works as a modulator protein, coordinating the 
assembly of multiprotein complexes with several cell signaling proteins. M2 therefore 
assembles a specific signalosome, and it does so independently of BCR stimulation. Such 
ability is lost upon mutation of the phosphosites (M2Y mutant protein). In vivo, the same 
mutation (M2Y recombinant virus) results in a delay in latency establishment 
characterized by a reduced number of infected cells and splenic follicles (Madureira, 
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Matos et al. 2005, Rodrigues, Pires de Miranda et al. 2006, Pires de Miranda, Alenquer et 
al. 2008). This may be explained by the lack of B cell activation promoted by the M2-
associated signalosome. Additionally, this may reflect a delay in accessing the GC 
reaction, for which T cell help is essential.  
 
Given the delay in latency establishment of M2Y recombinant viruses, the role played by 
M2 in modulation of B cell signaling and the importance of T cell help for MuHV-4 
infection, this thesis set out to investigate the possibility of a role for M2 in the modulation 
of B-TH cell interaction. Hypothetically, by manipulating signaling pathways M2 could 
activate the B cell and induce a pro-synaptic state that would attract T cell help. Given that 
T cell-dependent responses and, in particular, GC initiation are dependent on cognate 
interaction (Mills and Cambier 2003, De Silva and Klein 2015), experiments were carried 
out in a MHC class II-restricted OVAp-specific system, where M2- or M2Y-expressing B 
cells presenting OVAp were placed in contact with OVAp-specific CD4+ T cells. To 
address the dependence of M2 function on specific peptide, conjugation experiments 
were carried out in the absence and in the presence of increasing concentrations of 
peptide. 
 
In in vitro studies, M2 localization is cell type-dependent (Liang, Shin et al. 2004). In B 
cells, where M2 is known to be expressed in vivo, the protein has a juxtamembranar 
localization. This is dependent on the interaction of a C-terminal proline-rich SH3 binding 
region of M2 with Src family kinases and is, therefore, not affected in the M2Y mutant. 
Hence, unlike its putative functional homologues LMP1 and LMP2A from EBV and K1 and 
K15 from KSHV that are transmembranar proteins, M2 is a cytosolic protein. Nonetheless, 
the protein can perform its signaling-related functions (Rodrigues, Pires de Miranda et al. 
2006, Pires de Miranda, Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013). 
Interestingly, K1 was shown to be internalized and act from internal cellular compartments 
(Tomlinson and Damania 2008), showing that modulation of cell signaling downstream of 
the BCR by a viral protein is not restricted to a transmembranar localization. In the context 
of the MHC class II-restricted OVAp-specific system, work from Dr. Filipa Lopes in our 
laboratory revealed that M2 localizes to the contact zone upon B-TH cell interaction 
(Fontinha, Lopes et al. 2015). This was the first evidence pointing to a potential role for 
M2 in B-TH cell interaction. Polarization of M2 to the contact zone required the integrity of 
M2 phosphosites, especially of the tyrosine residue Y120, suggesting that it is dependent 
on the correct assembly of the signalosome.  
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The work described in this thesis showed that expression of M2 in B cells per se resulted 
in increased levels of both co-stimulatory and adhesion molecules, which are involved in 
B-TH cell interaction. Upregulation of the co-stimulatory molecule CD80 is usually a 
downstream consequence of antigen binding to the BCR and the resulting B cell 
activation. Therefore, the upregulation of cell surface molecules observed under the 
expression of M2 was probably a consequence of the assembly of a specific signalosome, 
independently of external signals, carried out by the viral protein. Up-regulation of such 
molecules could hypothetically render the B cell more prone to interact with TH cells. In 
agreement, in the context of the MHC class II-restricted OVAp-specific cellular system, 
expression of M2 competitively promoted B-TH cell interaction independently of specific 
antigen presentation. This was most likely due to the increased cell adhesion molecules, 
which are responsible for initial contacts between B and TH cells. Mutation of the 
phosphosites abrogated the ability of M2 to promote B-TH cell interaction, suggesting that 
this process is dependent on the capacity of the viral protein to assemble specific 
signalosomes. Despite the ability of M2 to promote B-TH cell interaction independently of 
specific peptide presentation, its expression was not sufficient to lead to T cell activation. 
Instead, T cell activation upon conjugate formation was a product of cognate interaction. 
 
Cognate interaction between B and TH cells results in the formation of an IS at the contact 
zone (Grakoui, Bromley et al. 1999). The fact that expression of M2 increased the levels 
of co-stimulatory molecules suggests a role for M2 in IS formation. Furthermore, work 
performed by Dr. Filipa Lopes in our laboratory demonstrated that the B cell MTOC 
distance to the contact zone was decreased in the presence of both the WT and the 
mutant viral proteins, when compared to mock B cells (Fontinha, Lopes et al. 2015). 
MTOC polarization is one of the hallmarks of IS formation in T cells. Although the 
functional significance of such polarization is yet to be determined, it has also been 
observed in B cells in the context of IS formation between B and T cells (Duchez, 
Rodrigues et al. 2011). Thus, the incomplete MTOC polarization promoted by M2 
reinforces the possibility of a role for the viral protein in IS. Moreover, NCK is modulated 
by M2 and it is able to promote actin polymerization (Chaki and Rivera 2013), an 
important process during immunological synapse formation. In the future, it would be 
interesting to further dissect the role of M2 in IS. Moreover, the B-TH cell conjugates 
formed in the absence of peptide, which do not lead to T cell activation, could be further 
investigated. In particular, address if they are long-lasting contacts and understand if there 
are any cell surface rearrangements at the contact zone. 
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Previous studies in the B-T cell interaction and IS field have demonstrated that TH cells 
scan several APCs and choose the one that presents a stronger stimulus (Depoil, Zaru et 
al. 2005). The in vitro competition experiment described in section 2.2.3 showed that TH 
cells preferentially conjugated with M2-expressing B cells, to the detriment of M2Y-
expressing B cells, even though they were loaded with the same amount of specific 
peptide. This suggests that the stimulus provided by the first is stronger and is able to 
attract T cell help. In this experiment, competition was assessed in terms of the number of 
conjugates formed. It is known that, in individual encounters, TH cells polarize toward the 
B cell encountered. However, when T cells simultaneously interact with two B cells with 
different activation states they polarize toward the activated B cell. Therefore, to 
complement these observations, another interesting aspect would be to assess T cell 
polarization upon simultaneous interaction with M2- and M2Y-expressing B cells, loaded 
with the same amount of peptide. A major challenge to overcome in this experimental 
setting is the fact that these cell triplets would be rare events. In vivo, the ability to attract 
T cell help would be a major advantage to promote the participation of infected B cells in 
GC reactions, a crucial step in host colonization. B-TH cell interaction is also important 
during the GC reaction, where it contributes to the selection of B cells that have been 
submitted to SHM (Mills and Cambier 2003, De Silva and Klein 2015). Although M2 is not 
necessary for the expansion of latently infected GC B cells (Rodrigues, Pires de Miranda 
et al. 2006, Pires de Miranda, Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013), 
the protein is expressed in these cells, which suggests that it plays a role in the GC 
reaction. Due to the intrinsic characteristics of the M2 protein, that did not allow the 
generation of mouse chimeras with M2-expressing B cells, these observations could not 
be confirmed in vivo.  
 
Infection of laboratory mice with the M2Y recombinant virus results in a delay in latency 
establishment in the spleen, which could possibly be explained by the lack of promotion of 
B-TH cell interaction observed in vitro with M2Y. However, this virus is still able to reach 
GC reactions, suggesting that there are other players involved in this process (Pires de 
Miranda, Alenquer et al. 2008). For example, a putative viral superantigen (Evans, Moser 
et al. 2008) may drive IS formation. Another possibility lies with the choice of B cells for 
latency establishment. This has been demonstrated not to be a stochastic event, in what 
concerns BCR specificity, and to be linked to the formation of GCs (Decalf, Godinho-Silva 
et al. 2014). The delay in latency establishment could also precede the step of GC 
initiation. Tracking of M2Y virus following intraperitoneal infection did not allow the 
determination of the exact step of spleen infection in which M2Y recombinant virus was 
delayed. Nonetheless, the decreased infection of marginal zone B cells, the first B cell 
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population to be infected in the spleen, suggests that the delay starts before GC initiation. 
This does not mean that B-TH cell interaction is not important in vivo, as the delay in 
latency establishment may result from a poor colonization of more than one splenic 
population. Although evidence points out to a general B cell phenotype, it was not 
possible to clearly confirm a normal macrophage infection, the first step of spleen 
colonization. Future studies would benefit from the use of an M2Y recombinant virus that 
can be tracked during lytic infection, similar to the ones used by Frederico et al (Frederico, 
Chao et al. 2014). Furthermore, the measurement of viral load by PCR in the macrophage 
population could be used to address this point. 
 
The two tyrosine residues that constitute the unconventional ITAM of M2 have been 
described to be differentially required (Rodrigues, Pires de Miranda et al. 2006, Pires de 
Miranda, Alenquer et al. 2008, Pires de Miranda, Lopes et al. 2013). Work from 
Rangaswamy et al shows that, although both tyrosines are required in vitro for the 
induction of IL-10 expression, only Y129 is required for reactivation from latency and 
plasma cell differentiation in vivo (Rangaswamy, O'Flaherty et al. 2014). In our laboratory, 
Dr. Marta Alenquer has analyzed individual M2Y mutants, M2Y M2Y120F and M2Y129F, 
with the first or the second tyrosine residues of the unconventional ITAM mutated to 
phenylalanines, respectively. Results have shown that at the latency peak, following 
intranasal inoculation, both individual mutant recombinant viruses have slightly higher 
levels of latency, when compared to the M2Y recombinant virus. Like what was observed 
by Rangaswamy et al, Y129 was more important for latency establishment, as could be 
observed by the relatively lower latency levels. Unlike the above mentioned study, Y120 
was not completely dispensable, as it also showed a delay when compared to a WT virus. 
This suggests that both phosphosites play a role in the establishment of latency in the 
spleen. Y120 and Y129 are known to selectively bind distinct cellular partners and are, 
therefore, associated with different signaling pathways. In this line of thought it would be 
interesting to further dissect the contribution of each tyrosine residue for the delay in 
latency establishment. For that purpose, YFP-expressing individual M2Y mutants have 
been created by me in our laboratory, in order to track infection in the same splenic 
populations that were analyzed in Chapter 5. In agreement with the data obtained by Dr. 
Marta Alenquer, preliminary results have shown that both tyrosines are required, with Y129 
being more important for latency establishment to some extent. At eight days following 
intraperitoneal infection this was true for all B cell populations analyzed. Again, Y120 was 
not dispensable. As mentioned above, work from Dr. Filipa Lopes has shown that the 
polarization of M2 to the contact zone during B-TH cell interaction was especially 
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dependent on Y120. Therefore, in the future, the role of each tyrosine residue in B-TH cell 
interaction could be further explored.  
 
It is not the first time that the modulation of T-APC interaction, and more specifically IS, by 
a viral protein has been described. Inclusively, there are two examples of such modulation 
in the Gammaherpesvirinae sub-family (Coscoy and Ganem 2001). In those cases, the 
viral proteins impair T-APC interaction, instead of promoting it like the MuHV-4 M2 protein 
does. These results do not have to be mutually exclusive. It is possible that different viral 
proteins coordinate different aspects of T-APC interaction, at different stages of the virus 
life cycle. For example, K5, which was shown to impair B-TH cell interaction and IS 
formation, is part of the lytic replicative cycle of KSHV, a step where the virus could 
benefit from this impairment as a mechanism to escape immune surveillance. During the 
latency phase it is possible that another viral protein promotes B-TH cell interaction to 
drive infected B cells through a GC reaction. Similarly, it is reasonable that at earlier 
timepoints of MuHV-4 infection, there is a viral protein that impairs IS formation as a 
mechanism of immune evasion.  
 
Although it is not clear yet, like EBV and MuHV-4, KSHV may take advantage of the GC 
reaction. During this process, EBV is believed to bypass T cell help. Therefore, promotion 
of B-TH cell interaction would not be beneficial for the virus. MuHV-4, on the contrary, is 
dependent on normal T cell help to successfully colonize the host. While EBV is a 
lymphocryptovirus, both KSHV and MuHV-4 are rhadinoviruses (Davison, Eberle et al. 
2009). It is conceivable that these two genera use different strategies to expand B cell 
latency during the early phase of infection. A practical example of the differences between 
the two genera can be observed in X-linked lymphoproliferative disease (XLP) patients. In 
XLP there is a genetic defect in the gene that encodes the slam associated protein (SAP) 
(Sayos, Wu et al. 1998), whose expression is required in CD4+ T cells for the generation 
of GC reactions (Qi, Cannons et al. 2008). These patients appear to be more susceptible 
to EBV infection, which can replace T cell help, than to KSHV. Concluding, other 
gammaherpesviruses, such as KSHV, may also promote B-TH cell interaction as a 
mechanism of host colonization. M2 is a putative functional homologue of LMP1 and 
LMP2A encoded by EBV, and K1 and K15 encoded by KSHV (Madureira, Matos et al. 
2005, Rodrigues, Pires de Miranda et al. 2006, Pires de Miranda, Alenquer et al. 2008). 
Moreover, KSHV K1 protein has been shown to assemble a signaling complex similar to 
the one assembled by MuHV-4 M2 protein, which this work suggests is implied in the 
modulation of B-TH cell interaction. Therefore, this work sets the base for future studies 
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with the mentioned proteins of the human gammaherpesviruses, in what regards T-APC 
interaction. 
 
Summarizing, this work further characterized the role of the latency associated M2 
protein, involved in the assembly of multiprotein complexes with cell signaling proteins 
(Pires de Miranda, Lopes et al. 2013), and linked it to the modulation of B-TH cell 
interactions. Results suggest a model where expression of M2 in B cells increases the 
surface levels of adhesion and co-stimulatory molecules, competitively promoting the 
formation of B-TH cell conjugates, independently of specific peptide (Figure 6.1). Upon cell 
interaction, the adaptor protein increases the B cell MTOC proximity to the contact zone, 
to where it also polarizes. Presentation of a specific peptide in MHC class II molecules is 
then required for T cell activation. Collectively, all the functions that have been attributed 
to M2 in in vitro studies set it as a protein that potentially promotes B cell activation, 
survival and facilitated access to the GC reaction. In agreement, in vivo, its expression is 
required for a normal establishment of latency. 
 
Viruses are clinically important pathogens. Although gammaherpesvirus infection is not 
always associated with disease, it is linked to the development of lymphoproliferative 
disorders (Damania 2004, Cesarman 2011). Currently, there is no unified, highly effective, 
treatment. HIV-1 causes AIDS which affects millions of people globally (Saxena, 
Shrivastava et al. 2012). Although the use of highly active antiretroviral therapy (HAART) 
has substantially improved the survival of patients affected by HIV, it does not cure the 
disease and it is not always effective. Therefore, for both gammaherpesviruses and HIV, 
new therapeutic approaches are needed. Modulation of T-APC interaction seems to be an 
important mechanism that contributes to virus survival. Both HIV and KSHV have been 
described to inhibit T-APC interaction in order to escape immune surveillance and 
promote virus survival (Coscoy and Ganem 2001, Haller, Rauch et al. 2006, Thoulouze, 
Sol-Foulon et al. 2006, Haller, Rauch et al. 2007, Saxena, Shrivastava et al. 2012). 
Furthermore, this work has shown that gammaherpesviruses may possibly promote B-T 
cell interaction to enhance host colonization. This knowledge highlights potential viral 
targets whose abolishment may, on the one hand, allow host immunity to take its course 
of action and, on the other hand, weaken host colonization. Drugs developed against 
these and other important viral targets may potentially be used in combination therapy as 
an effective treatment for infected patients. 
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Figure 6.1. Modulation of B-TH cell interaction by the M2 protein of MuHV-4. B-TH cell 
interaction is required for GC initiation, a pathway that is crucial for gammaherpesviruses to access 
the memory B cell compartment. The latency-associated protein M2 of MuHV-4, represented in 
red, is an adaptor protein that assembles multiprotein complexes with cell signaling proteins and 
modulates B-TH cell interaction. Its effects are also depicted in red. The protein polarizes to the 
contact zone, upregulates the cell surface levels of adhesion (ICAM1 and CD48) and co-
stimulatory (CD80/CD86) molecules, and increases the B cell MTOC polarization to the contact 
zone. As a result, M2 promotes B-TH cell conjugation, a step that peptide-independent. Upon the 
presentation of specific peptide (in orange) in MHC class II molecules, this contact results in 
increased cytosolic calcium concentration and polarization of IFN-γ to the contact zone, both 
hallmarks of T cell activation. 
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7 MATERIALS AND METHODS 
 
7.1 Materials 
 
7.1.1 General Reagents 
 
Analytical or molecular biology grade chemicals used throughout this work were obtained 
from Sigma, Bio-Rad, Calbiochem, Fluka, Merck, VWR, Nzytech, Thermo Scientific and 
Invitrogen.  Molecular biology reagents and enzymes were obtained from Roche, 
Fermentas, New England Biolabs, Promega, and Invitrogen. Tissue culture reagents and 
supplements were obtained from GIBCO® BRL, Invitrogen and Peprotech. Synthetic 
oligonucleotides and peptides were synthesized by Thermo Fisher Scientific. 
 
7.1.2 Antibodies and live dyes 
 
7.1.2.1 Primary antibodies 
 
Anti-M2 polyclonal serum (Madureira, Matos et al. 2005) was produced by immunization 
of New Zealand white rabbits with the fusion protein GST-M2. This antibody was used for 
Western-blot assays.  
 
The remaining antibodies used in this study are commercially available and are listed in 
the table below: 
 
Table 7.1. Primary antibodies. 
Name Clone Use React. Host/Isotype Company 
pTyr-AF647 PY99 IF NA Mouse IgG2b Santa Cruz 
Biotechnology 
IFN-γ AN-18 IF M Rat IgG1, κ BD Pharmingen™ 
TCR DO11.10-PE KJ1.26 FC M Mouse IgG2a, κ MBL – medical and 
biological lab 
CD4-AF405 RM4-5 FC M Rat IgG2a Invitrogen 
CD80-PB 16-10A1 FC M, D Armenian Hamster 
IgG 
BioLegend 
CD86-PE-Cy7 PO3 FC M Rat IgG2b, κ BioLegend 
CD54/ICAM1-APC YN1/1.7.4 FC M Rat IgG2b, κ BioLegend 
CD40-PE-Cy7 3/23 FC M Rat IgG2a, κ BioLegend 
CD48-APC HM48-1 FC M Armenian Hamster Bio Legend 
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IgG 
MHC-II-PB M5/114.15.2 FC M Rat IgG2b, κ BioLegend 
CD19-APC-H7 1D3 FC M Rat IgG2a, κ BD Biosciences 
CD21/35-APC 7G6 FC M Rat IgG2b, κ BD Biosciences 
CD23-PE B3B4 FC M Rat IgG2a, κ BD Biosciences 
CD69-FITC H1.2F3 FC M Armenian Hamster 
IgG 
BioLegend 
CD95-PE Jo2 FC M Armenian Hamster 
IgG2, λ2 
BD Biosciences 
GL7-eF660 GL7 FC M Rat IgM eBioscience 
CD45.2-v450 104 FC M Mouse IgG2a, κ BD Biosciences 
CD45.2-APC 104 FC M Mouse (SJL) IgG2a, κ BD Pharmingen™ 
CD45.1-APC-Cy7 A20 FC M Mouse (A.SW) 
IgG2a, κ 
BioLegend 
B220-APC RA3-6B2 FC M Rat IgG2a, κ BD Biosciences 
CD117 (c-kit)-APC 2B8 Pur M Rat IgG2b, κ eBioscience 
CD11c-APC HL3 FC M Armenian Hamster 
IgG1, λ2 
BD Pharmingen™ 
IgM-PerCP-Cy™5.5 R6-60.2 FC M Rat (LOU) IgG2a, κ BD Pharmingen™ 
IgD-V450 11-26c.2a FC M Rat IgG2a, κ BD Horizon™ 
Ly-6G (Gr-1)-PerCP-
Cy5.5 
RB6-8C5 FC M Rat IgG2b, κ eBioscience 
CD21/CD35 7G6 IF M Rat (SD) IgG2b, κ BD Pharmingen™ 
IgM-biotin Polyclonal IF M Goat Southern Biotec 
IgD 11-26 IF M Rat IgG2a, κ Southern Biotec 
MAdCAM-1 MECA-367 IF M Rat IgG2a AbD Serotec® 
F4/80 CI:A3-1 IF M Rat IgG2b AbD Serotec® 
MARCO ED31 IF M Rat IgG1 AbD Serotec® 
CD169 3D6.112 IF M Rat IgG2a AbD Serotec® 
GFP-AF488 Polyclonal IF M Rabbit IgG Molecular Probes 
EGFP NA WB NA Mouse IgG2a Clontech 
Actin Polyclonal WB V Rabbit Sigma-Aldrich 
React. – Reactivity; IF – Immunofluorescence; FC – Flow Cytometry; Pur – purification; WB – 
Western-blot; NA – non-applicable; M – mouse; D – dog; V – vertebrates. 
 
 
7.1.2.2 Secondary Antibodies 
 
Anti-rabbit (GE Healthcare) and anti-mouse (Jackson Immunoresearch) secondary 
antibodies, conjugated with horse radish peroxidase (HRP) were used in Western blot 
assays. A streptavidin-AF633 (Life Technologies) and an anti-rat AF568 (Molecular 
Probes) secondary antibodies were used in immunofluorescence assays.  
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7.1.2.3 Live Dyes 
 
In conjugation experiments cells were incubated with live dyes from Molecular Probes®, 
Invitrogen: CellTrackerTM Blue CMAC (7-amino-4-chloromethylcoumarin; #C2110), 
CellTrackerTM  Green CMFDA (5-chloromethylfluorescein diacetate; #C7025), 
CellTrackerTM Orange CMTMR ((5-(and-6)-(((4-chloromethyl)benzoyl)amino) 
tetramethylrhodamine; #C2927), and CellTraceTM Far-Red DDAO-SE (#C34553). 
 
7.1.3 Peptides 
 
OVA peptide (aa 323-339), with the protein sequence ISQAVHAAHAEINEAGR, was 
acquired from GenWay Biotech, Inc. (#06-271-83379). 
 
7.1.4 Cell lines 
 
BHK-21 cells – baby hamster kidney cells. Used for growth and titration of viral stocks, for 
ex vivo reactivation assay and for plaque assay. 
 
HEK 293T cells – human embryonic kidney cells. Used for production of viral transduction 
particles. 
 
A20 B cells – BALB/c B cell lymphoma line, derived from a spontaneous reticulum cell 
neoplasm found in an old BALB/cAnN mouse. Used for conjugate and 
immunological synapse assays.  
 
7.1.5 Bacterial strains 
 
Plasmids were grown for the general purpose in Escherichia coli strain DH5α (Invitrogen) 
with the following genotype F– Φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 endA1 hsdR17 
(rκ– mK+) phoA supE44 thi-1 gyrA96 relA1 λ-. 
 
7.1.6 Plasmids 
 
pMSCV-K3-IRES-Zeo – this plasmid contains ORF K3 of MuHV-4 cloned in pMSCV-
IRES-zeo. It was used to produce viral transduction particles for the generation of 
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zeocin-resistant stable A20 B cell lines, expressing K3. This plasmid was 
constructed by P. Madureira (Madureira, Matos et al. 2005). 
 
pMSCV-M2-IRES-Zeo – this plasmid contains ORF M2 of MuHV-4 cloned in pMSCV-
IRES-zeo. It was used to produce viral transduction particles for the generation of 
zeocin-resistant stable A20 B cell lines, expressing M2. ORF M2 was excised from 
pMSCV-M2-IRES-GFP (Rodrigues, Pires de Miranda et al. 2006) by digestion with 
EcoRI and XhoI, and subcloned to pMSCV-K3-IRES-Zeo, using the same 
restriction sites and replacing K3. This plasmid was constructed in our lab by C. 
Silva.  
 
pMSCV-M2Y-IRES-Zeo – this plasmid contains ORF M2Y of MuHV-4 cloned in pMSCV-
IRES-zeo. It was used to produce viral transduction particles for the generation of 
zeocin-resistant stable A20 B cell lines. ORF M2Y was excised from pMSCV-M2Y-
IRES-GFP (Rodrigues, Pires de Miranda et al. 2006) by digestion with EcoRI and 
XhoI, and subcloned to pMSCV-K3-IRES-Zeo, using the same restriction sites and 
replacing K3. This plasmid was constructed in our lab by C. Silva.  
 
pMSCV-EGFP-M2-IRES-Zeo – this plasmid was used to produce viral transduction 
particles for the creation of a zeocin-resistant, eGFP-M2-expressing, stable cell 
line. eGFP was amplified by PCR from pEGFP-N1vector without the STOP signal, 
and flanked by EcoRI and BamHI restriction sites, using the following primers: 5’ – 
AAA GAA TTC CGC CAC CAT GGT GAG (EcoRI) and 3’ – AAA GGA TCC CTT 
GTA CAG CTC GTC (BamHI). Insert was cloned in the pSP72 vector. ORF M2 
was amplified by PCR from the HindIII-E shuttle plasmid using the following 
primers: 5’ – AAA GGA TCC ATG GCC CCA ACA CC (BamHI) and 3’ – AAA CTC 
GAG TTA CTC CTC GCC CCA  (XhoI). Insert was cloned in the pSP72 vector 
that contained the EGFP insert. M2, N-terminally fused to EGFP, was then excised 
by digestion with EcoRI and XhoI restriction enzymes, and subcloned to pMSCV-
K3-IRES-Zeo, replacing K3. This plasmid was constructed in this study. 
 
pMSCV-EGFP-M2Y-IRES-Zeo – this plasmid was used to produce viral transduction 
particles for the creation of a zeocin-resistant, eGFP-M2Y-expressing, stable cell 
line. eGFP was amplified by PCR from pEGFP-N1vector without the STOP signal, 
and flanked by EcoRI and BamHI restriction sites, using the following primers: 5’ – 
AAA GAA TTC CGC CAC CAT GGT GAG (EcoRI) and 3’ – AAA GGA TCC CTT 
GTA CAG CTC GTC (BamHI). Insert was cloned in the pSP72 vector. ORF M2Y 
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was amplified by PCR from the M2Y shuttle plasmid using the following primers: 5’ 
– AAA GGA TCC ATG GCC CCA ACA CC (BamHI) and 3’ – AAA CTC GAG TTA 
CTC CTC GCC CCA  (XhoI). Insert was cloned in the pSP72 vector that contained 
the EGFP insert. M2Y, N-terminally fused to EGFP, was then excised by digestion 
with EcoRI and XhoI restriction enzymes, and subcloned to pMSCV-K3-IRES-Zeo, 
replacing K3. This plasmid was constructed in this study. 
 
pMSCV-EGFP-IRES-Zeo – this plasmid was used to produce viral transduction particles 
for the creation of a zeocin-resistant, eGFP-expressing, stable cell line. eGFP was 
amplified by PCR from pEGFP-N1vector with the STOP signal, and flanked by 
EcoRI and XhoI restriction sites, using the following primers: 5’ – AAA GAA TTC 
CGC CAC CAT GGT GAG (EcoRI) and 3’ – AGC CTC GAG TTA CTT GTA CAG 
CTC (XhoI). Insert was cloned in the pSP72 vector. EGFP was then excised by 
digestion with EcoRI and XhoI restriction enzymes, and subcloned to pMSCV-K3-
IRES-Zeo, replacing K3. This plasmid was constructed in this study. 
 
pEQPAM3 – this was the packaging plasmid used in the production of viral transduction 
particles for the creation of zeocin-resistant A20 B cell lines. It encodes the genes 
gag, pol and env of murine stem cell virus (Persons, Mehaffey et al. 1998).  
 
pMigR1-empty – this was the retroviral expression vector used in the production of viral 
particles for the transduction of fetal liver cells. It contains IRES-GFP. The plasmid 
was a kind gift from Dr. H. Veiga-Fernandes (Instituto de Medicina Molecular, 
Lisbon, Portugal).  
 
pMigR1-M2 – this was the retroviral expression vector used in the production of viral 
particles for the transduction of fetal liver cells. M2 was excised from pMX-M2 
(constructed in our lab by S. Marques) using the restriction enzymes BamHI and 
XhoI. Insert was cloned into pMigR1, using the restriction sites BglII and XhoI. This 
plasmid was constructed in this study. 
 
pMigR1-M2Y – this was the retroviral expression vector used in the production of viral 
particles for the transduction of fetal liver cells. M2Y was excised from pMX-M2Y 
(constructed in our lab by S. Marques) using the restriction enzymes BamHI and 
XhoI. Insert was cloned into pMigR1, using the restriction sites BglII and XhoI. This 
plasmid was constructed in this study. 
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pCL-Eco – this was the packaging plasmid used in the production of viral particles for the 
transduction of fetal liver cells. It encodes the genes gag, pol, and env. pCL-Eco 
was a gift from Inder Verma (Addgene plasmid # 12371). 
 
pCMV-VSV-G – this plasmid encodes the G protein of vesicular stomatitis virus, which 
can serve as a surrogate viral envelope protein, and was used in the production of 
viral particles for the transduction of fetal levar cells. pCMV-VSV-G was a gift from 
Bob Weinberg (Addgene plasmid # 8454). 
 
7.1.7 Mice 
 
C.Cg-Tg(DO11.10)10Dlo/J (DO11.10) mice carry an MHC class II restricted rearranged T 
cell receptor transgene that reacts to OVAp. Mice were a kind gift from Prof. Luís 
Graça (Instituto de Medicina Molecular, Lisbon, Portugal). 
 
B6.SJL-Ptprca Pep3b/BoyJ (CD45.1) is a congenic strain which carries the differential B 
cell antigen originally designated Ly5.1 and CD45.1. The b allele of Ptprc is 
normally present in the BALB and C57BL inbred strains.  
 
B6.129S7-Rag1tm1Mom/J (Rag1-/-) mice are homozygous for the Rag1tm1Mom mutation and 
produce no mature T cells or B cells (lack all mature lymphocytes, i.e. are "non-
leaky").  
 
CD45.1/CD45.2 (CD45.1/2) mice were obtained by breeding CD45.1 C57BL/6 with 
C57BL/6J mice. 
 
C57BL/6J mice were purchased from Charles River Laboratories International Inc. 
CD45.1 C57BL/6 and Rag1-/- mice were purchased from Jackson Laboratory. 
 
Mice were bred and/or housed under specific pathogen-free conditions at Instituto de 
Medicina Molecular animal facility, Lisbon, Portugal.  
 
7.1.8 Viruses 
 
Murid herpesvirus-4 (MuHV-4) used in this study belongs to the strain MHV-68 (murine 
herpesvirus 68) that was originally isolated by Prof. Dr Blaskovic (Blaskovic, Stancekova 
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et al. 1980). Clone G2.4 was isolated from virus grown in BHK-21 cells by Dr Stacey 
Efstathiou (Efstathiou, Ho et al. 1990). 
 
YFP-expressing MuHV-4 recombinant virus (vYFP) used in animal experiments was 
derived from a genomic bacterial artificial chromosome (BAC) and was a kind gift 
from Dr Samuel Speck. This virus expresses the enhanced yellow fluorescent 
protein (YFP), driven by the human cytomegalovirus (HCMV) immediate-early (IE) 
promoter and enhancer, from a neutral locus in the viral genome located between 
open reading frames 27 and 29b (Collins, Boss et al. 2009). The expression 
cassette is flanked by a chromatin insulator from the human major 
histocompatibility complex II locus, an attempt to prolong YFP expression after the 
onset of latency. This virus allows direct detection of infected cells based on YFP 
expression and phenotypic analysis of the infected cell populations.  
 
M2Y YFP-expressing MuHV-4 recombinant virus (vM2Y-YFP) used in animal experiments 
was constructed in our lab by Dr. Marta Alenquer and engineered by mutagenesis 
of the virus genome in E.coli using the YFP MuHV-4 BAC (Collins, Boss et al. 
2009). M2Y contains tyrosine residues at positions 120 and 129 replaced by 
phenylalanines.  
 
 
7.2 Methods 
 
7.2.1 Isolation and analysis of nucleic acids 
 
7.2.1.1 Plasmid DNA isolation 
 
Plasmid DNA was isolated from plasmid-containing E.coli strain DH5α (section 7.1.5) 
grown in Luria Bertani (LB) (1% tryptone, 0.5% yeast extract, 1% NaCl) broth containing 
the appropriate antibiotic(s), using an alkaline lysis method modified accordingly to the 
scale of the preparation and plasmid size. Antibiotics were used at the following 
concentrations: 100μg/mL ampicilin, 17μg/mL chloramphenicol and 30μg/mL kanamycin. 
 
Small scale plasmid preparation  
For small scale plasmid preparations (plasmid minipreps), 2-5mL of LB broth cultures 
containing the appropriate antibiotic(s) were inoculated with single bacterial colonies and 
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incubated overnight (12-18h) at 37ºC, with vigorous shaking. Cultures were pelleted by 
centrifugation at 4000rpm for 10min. Plasmid DNA was obtained using the Wizard Plus 
SV Minipreps DNA Purification System (Promega), by column purification of DNA 
prepared by alkaline lysis, according to manufacturer’s instructions. DNA was eluted in 
50μL of MilliQ water and stored at -20ºC until further use. 
 
Large scale plasmid preparation 
For large scale plasmid preparations (plasmid maxipreps), 5mL of LB broth cultures 
containing the appropriate antibiotic(s) were inoculated with single bacterial colonies and 
incubated overnight (12-18h) at 37ºC, with vigorous shaking. Bacteria were then sub-
cultured 1:500 into 200 mL LB containing the appropriate antibiotic(s) and incubated 
under the same conditions. Bacterial cultures were pelleted by centrifugation at 6000rpm 
for 15min at 4ºC and DNA was purified using the LFU / Plasmid Purification MAXI Kit 
(JETSTAR), according to manufacturer’s instructions. DNA was resuspended in 500μL of 
MilliQ water and stored at -20ºC until further use. 
 
7.2.1.2 Mouse tail or ear DNA extractions 
 
Mouse tail or ear were digested by overnight incubation at 55ºC with 100μL of DirectPCR 
Lysis Reagent (mouse tail) (Viagen Biotec Inc.) supplemented with 0.2-0.4 mg/ml of 
Proteinase K. Proteinase K was then inactivated by heating at 85ºC for 1h. 1μL of lysate 
was used directly in PCR reactions for mice genotyping (section 7.2.1.4). 
 
7.2.1.3 Quantification of nucleic acids 
 
DNA was quantified by UV spectrophotometry using a Nanodrop (ND-1000) 
spectrophotometer.  
 
7.2.1.4 Polymerase chain reaction (PCR) 
 
Polymerase chain reaction was used in this study for different purposes. 
 
Some of the inserts used in cloning procedures (section 7.2.1.9) were amplified by PCR. 
Reaction mixes were prepared in a total volume of 50μL (made up in sterile MilliQ water) 
and consisted of <100ng of template DNA, 300nM of each primer, 200μM of each 
deoxynucleotide triphosphate (dNTP), 1U of high fidelity Pfu DNA polymerase (Promega), 
and PCR buffer (Promega), according to manufacturer’s instructions. Primers used for the 
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amplification of EGFP for cloning into pSP72 or pMSCV vectors (section 7.2.1.9.1) are 
described in table 7.2. Primers used for the amplification of M2 or M2Y for cloning into 
pSP72 vector (section 7.2.1.9.1) are described in table 7.3. DNA was amplified on a 
MyCycler thermal cycler (BioRad), under the following conditions: an initial melting step of 
95ºC for 2min followed by 30 cycles of amplification, composed of denaturation at 95ºC for 
30sec, annealing at 55ºC for 30sec and extension at 72ºC for 2min. A final extension step 
was performed at 72ºC for 10min. 5μL of each PCR product was analyzed by gel 
electrophoresis (section 7.2.1.6) to assess if products had the expected size.  
 
Table 7.2. Primers used for the amplification of EGFP for cloning into pSP72 or pMSCV 
vectors. 
Construct Oligonucleotide Sequence and restriction site Amplicon (bp) 
M2/M2Y 
constructs 
(pSP72) 
Forward primer 
5’ – AAA GAA TTC CGC CAC CAT GGT GAG – 3’    
(EcoRI) 
742 
Reverse primer 
3’ – AAA GGA TCC CTT GTA CAG CTC GTC – 5’     
(BamHI) 
EGFP 
construct 
(pMSCV) 
Forward primer 
5’ – AAA GAA TTC CGC CAC CAT GGT GAG – 3’    
(EcoRI) 
745 
Reverse primer 
3’ – AGC CTC GAG TTA CTT GTA CAG CTC – 5’    
(XhoI) 
 
Table 7.3. Primers for the amplification of M2 or M2Y for cloning into pSP72 vector. 
Oligonucleotide Sequence and restriction site Amplicon (bp) 
Forward primer 
5’ – AAA GGA TCC ATG GCC CCA ACA CC – 3’   
(BamHI) 
597 
Reverse primer 
3’ – AAA CTC GAG TTA CTC CTC GCC CCA – 3’     
(XhoI) 
 
 
PCR was also used for genotyping Rag1-/- mice. Genotyping was performed using the 
primers described in Table 7.4. PCR reaction and conditions were performed according to 
the recommendations of Jackson Laboratory. PCR products were analyzed by gel 
electrophoresis (section 7.2.1.6). 
 
Table 7.4. Primers used for Rag1-/- genotyping. 
Allele Oligonucleotide Sequence Amplicon (bp) 
Rag1tm1Mom 
WT forward primer 5’- GAGGTTCCGCTACGACTCTG-3’ WT: 474 
Mutant: 530 
Heterozygote: 474 + 530 
Mutant forward primer 5’- TGGATGTGGAATGTGTGCGAG-3’ 
Common reverse primer 5’- CCGGACAAGTTTTTCATCGT-3’ 
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7.2.1.5 Restriction digestion 
 
Restriction endonuclease digestion of plasmids or PCR products was used to prepare 
linear or insert purified DNA, and to confirm the presence of inserts cloned in expression 
vectors. Digestions were performed using the appropriate restriction endonucleases and 
correspondent reaction buffers, according to manufacturer’s instructions. DNA amount, 
reaction volume and enzymes used depended on the purpose of the assay. 
  
For digestion of plasmids or PCR products for subsequent ligation and cloning, 1-2μg of 
DNA, 10U of restriction endonuclease per μg of DNA and an appropriate buffer were 
incubated for 2h at 37ºC. Digestion volume ranged from 50-80μL. Diagnosis digestion was 
performed in a 20μL total volume with 1μg of DNA, 10U of restriction endonuclease and 
the appropriate buffer. Multiple digestions of the same DNA were performed with the 
same buffer. Restriction profile and completeness of the digestion were assessed by 
analytical agarose gel electrophoresis (section 7.2.1.6). 
 
7.2.1.6 Analysis and isolation of DNA by gel electrophoresis 
 
Linear DNAs were size fractioned and visualized on agarose gels stained with gel red 
(Biotium) or red safe (iNtRON Biotechnology), according to manufacturer’s instructions. 
Gels were prepared using 0.8-2% agarose in 1x TAE (40mM Tris-acetate, 1mM EDTA, pH 
8.0). Prior to loading on wells, DNA samples were mixed with the appropriate volume of 
DNA loading buffer (10mM EDTA, 5% glycerol, 0.025% bromophenol blue and 0.025% 
xylene cyanol). Samples were electrophoresed at 0.5-5.0 V/cm in 1x TAE buffer. DNA 
was visualized by UV transillumination. Size of DNA bands was estimated by comparison 
with linear DNA standards of known molecular weight (1 Kb plus DNA ladder, Invitrogen) 
that was ran along with samples. Following analysis of DNA by agarose gel 
electrophoresis, DNA fragments of interest were purified by excision of the resolved bands 
from the gel and recovered with the High Pure PCR Product Purification kit (Roche), 
according to manufacturer´s instructions. Typically, DNA was eluted in 50μL of MilliQ 
water and a fraction of the purified samples (usually 1/10 of the total volume of the eluate) 
was re-run on an agarose gel, in order to check the DNA purification.  
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7.2.1.7 DNA sequencing 
 
Integrity of the pMSCV-EGFP-IRES-Zeo, pMSCV-EGFP-M2-IRES-Zeo and pMSCV-
EGFP-M2Y-IRES-Zeo plasmids, namely the EGFP and M2/M2Y sequences introduced, 
was confirmed by sequencing. The primers used are described in table 7.5.  
 
Table 7.5. Primers used for DNA sequencing. 
Sequence to confirm Oligonucleotide Sequence 
EGFP Forward primer 5’ CCC TTG AAC CTC CTC GTT CGA CC 3’ 
M2 
Forward primer 5’ AAA GGT ACC AAC ACC CCC ACA AGG AAA GA 3’ 
Reverse primer 5’ AAA AAG CTT CTC CTC GCC CCA CTC CA 3’ 
 
 
DNA was sequenced at STAB VIDA according to the Sanger method and using an 
automatic DNA sequencer (ABI 3730XL). DNA sequences were analyzed and compared 
to sequences deposited in the NCBI (National Centre for Biotechnology Information) 
database using the BioEdit Sequence Alignment Editor software. 
 
7.2.1.8 DNA ligation 
 
Digested inserts and vectors were ligated using T4 DNA ligase (Roche Applied Science). 
Approximately, 100ng of vector DNA and a similar amount of insert were ligated in 20μL 
reactions containing ligase buffer (Roche Applied Science) and 1U of T4 DNA ligase 
(Roche Applied Science) (made up in sterile MilliQ water). Cohesive-end ligations were 
performed overnight at 14ºC. 
 
7.2.1.9 Cloning procedures 
 
7.2.1.9.1 Cloning of pMSCV plasmids used for viral particle production 
 
This strategy was designed by Dr. Marta Alenquer.  
 
EGFP insert without the STOP signal was obtained by amplification from pEGFP-N1 
vector, with introduction of EcoRI and BamHI restriction sites (section 7.2.1.4). After 
purification using the High Pure PCR Product Purification, insert size was confirmed by 
analysis on agarose gel (section 7.2.1.6). EGFP inserts and pSP72 vector were then 
digested with EcoRI and BamHI restriction enzymes, as described in section 7.2.1.5. 
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Digested inserts and vector were then isolated by gel electrophoresis and purified from 
agarose gel using a High Pure PCR Product Purification kit from Roche (section 7.2.1.6). 
Inserts and vector were ligated as described in section 7.2.1.8. Ligations were 
transformed into competent bacteria as described in section 7.2.2.2. DNA was isolated 
from colonies by plasmid miniprep (section 7.2.1.1). To confirm successful cloning, 
plasmid DNA was digested with EcoRI and BamHI restriction endonucleases. Next, M2 
insert was obtained by amplification from shuttle pHindIII-E, with introduction of BamHI 
and XhoI restriction sites (section 7.2.1.4). M2Y insert was amplified from shuttle M2Y, 
with introduction of BamHI and XhoI restriction sites (section 7.2.1.4). After purification 
using the High Pure PCR Product Purification, insert size was confirmed by analysis on 
agarose gel. M2/M2Y inserts and EGFP-pSP72 vector constructed on the previous step 
were digested with BamHI and XhoI restriction endonucleases. Digested inserts were then 
isolated by gel electrophoresis and purified from agarose gel using a High Pure PCR 
Product Purification kit from Roche. Inserts and vector were ligated as described in 
section 7.2.1.8. Ligations were transformed into competent bacteria. DNA was isolated 
from colonies by plasmid miniprep. To confirm successful cloning, plasmid DNA was 
digested with BamHI and XhoI restriction endonucleases and analyzed on agarose gel. 
 
EGFP-M2 and EGFP-M2Y inserts were obtained by digestion of EGFP-M2-pSP72 and 
EGFP-M2Y-pSP72 plasmids, respectively, with EcoRI and XhoI restriction endonucleases 
(section 7.2.1.5). pMSCV-K3-IRES-Zeo vector was also digested with EcoRI and XhoI 
restriction endonucleases. Digested inserts and vector were then isolated by gel 
electrophoresis and purified from agarose gel using a High Pure PCR Product Purification 
kit from Roche (section 7.2.1.6). Inserts and vector were ligated as described in section 
7.2.1.8. Ligations were transformed into competent bacteria as described in section 
7.2.2.2. DNA was isolated from colonies by plasmid miniprep (section 7.2.1.1). To confirm 
successful cloning, plasmid DNA was digested with EcoRI and XhoI restriction 
endonucleases. DNA integrity was confirmed by sequencing as described in section 
7.2.1.7. Large scale plasmid preparations were prepared as described in section 7.2.1.1 
and their integrity was confirmed by digestion with EcoRI and XhoI restriction 
endonucleases and analysis on agarose gel. 
 
For the construction of the pMSCV-EGFP-IRES-Zeo plasmid, EGFP insert with the STOP 
signal was obtained by amplification from pEGFP-N1 vector, with introduction of EcoRI 
and XhoI restriction sites (section 7.2.1.4). After purification using the High Pure PCR 
Product Purification, insert size was confirmed by analysis on agarose gel (section 
7.2.1.6). EGFP insert and pMSCV-K3-IRES-Zeo vector were then digested with EcoRI 
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and XhoI restriction enzymes (section 7.2.1.5). Digested inserts and vector were then 
isolated by gel electrophoresis and purified from agarose gel using a High Pure PCR 
Product Purification kit from Roche. Inserts and vector were ligated as described in 
section 7.2.1.8. Ligations were transformed into competent bacteria as described in 
section 7.2.2.2. DNA was isolated from colonies by plasmid miniprep (section 7.2.1.1). To 
confirm successful cloning, plasmid DNA was digested with EcoRI and XhoI restriction 
endonucleases and analyzed on agarose gel. DNA integrity was confirmed by sequencing 
as described in section 7.2.1.7. Large scale plasmid preparations were prepared as 
described in section 7.2.1.1 and their integrity was confirmed by digestion with EcoRI and 
XhoI restriction endonucleases and analysis on agarose gel. 
 
7.2.1.9.2 Cloning of pMigR1 plasmids used for viral particle production 
 
M2 and M2Y inserts were obtained by digestion of pMX-M2 and pMX-M2Y plasmids with 
BamHI and XhoI restriction enzymes (section 7.2.1.5). Since BamHI and BglII produce 
compatible sticky ends, pMigR1 empty vector was digested with BglII and XhoI restriction 
enzymes. Digested inserts were then isolated by gel electrophoresis and purified from 
agarose gel using a High Pure PCR Product Purification kit from Roche (section 7.2.1.6). 
Inserts and vector were ligated as described in section 7.2.1.8. Ligations were 
transformed into competent bacteria as described in section 7.2.2.2. DNA was isolated 
from colonies by plasmid miniprep (section 7.2.1.1). To confirm successful cloning, 
plasmid DNA was digested with XhoI and NdeI restriction endonucleases. Large scale 
plasmid preparations were prepared as described in section 7.2.1.1 and their integrity was 
confirmed by digestion with XhoI and NdeI restriction endonucleases and analysis on 
agarose gel. 
 
7.2.2 Bacterial methods 
 
7.2.2.1 Preparation of competent cells 
 
Competent E.coli strain DH5α was prepared by the modified H. Inoue method (Inoue, 
Nojima et al. 1990). Approximately 5μL of E.coli glycerol stock were inoculated into 10mL 
of LB and incubated overnight (12-18h) with vigorous shaking at 37ºC. 10mL of the 
resulting culture were inoculated into 400mL of fresh LB and incubated at 37ºC, 225 rpm. 
When the bacterial culture reached an optical density (OD) at 600nm of 0.6 the cell culture 
was cooled on ice. Cells were pelleted by centrifugation at 4000 rpm (Beckman Coulter 
Avanti J-25, rotor JA-14) for 15 min at 4ºC. Cell pellet was gently resuspended in 100mL 
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of ice cold sterile solution A (0.03M KCH3COO, 0.05M MnCl2, 0.01M CaCl2, 0.1M KCl and 
15% glycerol in sterile MilliQ water). Cells were centrifuged at 4000 rpm for 8 min at 4ºC 
and resulting pellet was resuspended in 20 mL of ice cold solution B (0.01M NaMOPS pH 
7.0, 0.075M CaCl2, 0.01M KCl and 15% glycerol in sterile MilliQ water). 100μL and 300μL 
aliquots were made. Each aliquot was quickly frozen by transferring the vials to dry ice 
immersed in ethanol. Competent cells were stored at -80ºC until further use. 
 
7.2.2.2 Transformation of competent cells 
 
Competent E.coli strain DH5α cells were transformed by the heat shock method. 100μL of 
competent cells were incubated on ice for 30min with 100ng of plasmid DNA or 1-10μL of 
ligation mix. Cells were heat shocked for 45sec at 42ºC and subsequently chilled on ice 
for 2 min. 400-900 μl of SOC medium (2% tryptone, 0.5% yeast extract, 10mM NaCl, 
2.5mM MgCl2, 10mM MgSO4, 20mM glucose) were added to each vial and cells were 
incubated for 1h at 37ºC. Cells were then spread onto LB agar plates containing the 
appropriate antibiotic(s) and incubated at 37ºC, overnight or until colonies were visible. 
Ampicilin was used at 100μg/mL ampicilin, chloramphenicol at 17μg/mL and kanamycin at 
30μg/mL.  
 
7.2.3 Cell culture, transfection and transduction 
 
7.2.3.1 Media and culture conditions 
 
HEK 293T cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS), 2mM glutamine, 100U/mL penicillin 
and streptomycin. BHK-21 cells were cultured in Glasgow’s modified Eagle’s medium 
(GMEM) supplemented as described above with the addition of 10% tryptose phosphate 
broth. A20 B cells were grown in RPMI 1640 supplemented as described above. In the 
case of zeocin-resistant stable cell lines, 4µg/mL of zeocin was added to the culture. 
Conjugates were incubated in RPMI 1640 supplemented with 5% fetal bovine serum, 
2mM glutamine, 100u/mL penicillin and streptomycin and 10mM HEPES. Primary mouse 
CD4+ T cells purified from DO11.10 mice were cultured in RPMI 1640 supplemented as 
described above in addition to 50μM 2-mercaptoethanol, 100μM sodium pyruvate, 10mM 
HEPES and 60U/mL rmIL-2. Primary mouse fetal liver cells were cultured in DMEM 
supplemented with 15% FBS, 2mM glutamine, 100U/mL penicillin and streptomycin, 
20ng/mL of IL-3, 50ng/mL of IL-6 and 100ng/mL of SCF. All cell cultures were grown in a 
humidified tissue culture incubator at 37ºC under 5% CO2. 
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7.2.3.2 Isolation, stimulation and resting of T cells 
 
CD4+ T cells were obtained and purified from spleens of 8-week to 4-months old naïve 
DO11.10 mice (section 7.1.7). Briefly, spleens were collected into 5mL of complete RPMI. 
Single cell suspensions were obtained by mechanical disruption. Cell debris were 
removed by filtering through a 100μm cell strainer and red blood cells were lysed by 
incubation with red blood cell lysis buffer (154mM ammonium chloride, 14mM sodium 
hydrogen carbonate, 1mM EDTA pH7.3) for 5min on ice. Cell suspensions were washed 
with medium, centrifuged at 1200rpm for 5min at 4ºC, resuspended in medium and filtered 
through a 40μm cell strainer. Cells were counted using trypan blue (for cell viability), 
centrifuged at 1200rpm for 10min at 4ºC and resuspended in ice-cold sterile MACS buffer 
(0.5% bovine serum albumine and 2mM EDTA in PBS pH 7.2) at an appropriate cell 
density. CD4+ T cells were then purified by depletion of indirect magnetically labeled non-
CD4+ T cells (negative selection) using mouse CD4+ T cell isolation kit (MACS, Miltenyi 
Biotech), according to manufacturer’s instructions. Purity of the enriched CD4+ T cell 
population was evaluated by flow cytometry (section 7.2.4.1) and was consistently > 90%. 
 
Purified CD4+ T cells were grown in 24-well plates in the presence of Dynabeads® Mouse 
T-activator CD3/CD28 (Invitrogen), according to manufacturer’s instructions. Briefly, 1x106 
cells were resuspended in 1mL of T cell culture media (section 7.2.3.1) and Dynabeads®. 
Beads and cells were cultured at a 1:1 proportion and incubated for three days.  
 
After three days of stimulation, Dynabeads® were removed from culture, according to 
manufacturer’s instructions. Cells were then culture in T cell culture media for a resting 
period that ranged from 5 to 8 days.  
 
7.2.3.3 Isolation of B cells 
 
B cells were obtained and purified from the lymph nodes of CD45.1 B6 background mice 
(section 7.1.7). Briefly, lymph nodes were collected into 5mL of complete RPMI. Single 
cell suspensions were obtained by mechanical disruption. Cell debris were removed by 
filtering through a 100μm cell strainer and red blood cells were lysed by incubation with 
red blood cell lysis buffer (154mM ammonium chloride, 14mM sodium hydrogen 
carbonate, 1mM EDTA pH7.3) for 5min on ice. Cell suspensions were washed with 
medium, centrifuged at 1200rpm for 5min at 4ºC, resuspended in medium and filtered 
through a 40μm cell strainer. Cells were counted using trypan blue (for cell viability), 
centrifuged at 1200rpm for 10min at 4ºC and resuspended in ice-cold sterile MACS buffer 
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(0.5% bovine serum albumine and 2mM EDTA in PBS pH 7.2) at an appropriate cell 
density. B cells were then purified by depletion of indirect magnetically labeled non-B cells 
(negative selection) using mouse B cell isolation kit (MACS, Miltenyi Biotech), according 
to manufacturer’s instructions. Purity of the enriched B cell population was evaluated by 
flow cytometry (section 7.2.4.1) and was consistently > 98%. 
 
7.2.3.4 Isolation of c-kit+ fetal liver cells 
 
CD45.1, CD45.2 and CD45.1/2 fetal liver cells were obtained from 15 days-old mouse 
embryos (section 7.2.7.2). Briefly, mouse fetal liver was dissected to 10mL of DMEM 
supplemented with 15% fetal bovine serum, 2mM glutamine, 100U/mL penicillin and 
streptomycin. Single cell suspensions were obtained by mechanical disruption. Cell debris 
were removed by filtering through a 40μm cell strainer. An aliquot of cells was removed for 
cell count with trypan blue. Cells were centrifuged at 300g for 10min at 4ºC and 
resuspended in MACS buffer (0.5% bovine serum albumine and 2mM EDTA in PBS pH 
7.2) at a density of 5x107 cells/100μL of buffer. Anti-c-kit-APC antibody (table 7.1) was 
next added to the cells at 1:100 dilution and incubated for 25min at 4ºC. Cells were then 
washed and incubated with anti-APC Microbeads (Miltenyi Biotech). Positive selection of 
c-kit expressing cells was carried out according to manufacturer’s instructions.  
 
7.2.3.5 Viral particle production 
 
Viral particles for transduction of A20 B cells were produced by calcium phosphate 
transfection of 293T cells. On the day prior to transfection, 293T cells were seeded in 
10cm cell culture dishes, at the density of 3x106 cells per dish in 10mL of complete DMEM 
(section 7.2.3.1). In a tube labeled A, 20μg of pEQPAM3 packaging vector and 20μg of p-
MSCV-IRES-zeo plasmid (carrying EGFP, EGFP-M2, EGFP-M2Y) (section 7.1.6) were 
added to a 0.2M CaCl2 solution in a total volume of 600μL. 600μL of a 2x concentrated 
HEPES buffered saline (HBS) solution was added to a tube labeled B. Solution A was 
added dropwise to solution B, while bubbling air through solution B with a pipette. This mix 
was incubated for 30min at RT. The DNA precipitate was then added dropwise to the 
cells. Following a 4h incubation period, culture medium was removed, cells were washed 
twice with PBS and a 10% Dimethyl sulfoxide (DMSO) solution was added to the 
monolayer for exactly 2.5min at RT. DMSO solution was then replaced by 10mL of 
complete DMEM and cells were incubated for 48-72h at 37ºC in a humidified CO2 
incubator. Viral supernatants were recovered at 48h and 72h post transfection, aliquoted 
and stored at -80ºC.   
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Viral particles for transduction of fetal liver cells were produced by transfection of 293T 
cells with X-tremeGENE HP DNA transfection reagent by Roche, according to 
manufacturer’s instructions. On the day prior to transfection, 293T cells were seeded in 
10cm cell culture dishes, at the density of 4x106 cells per dish in 8mL of complete DMEM. 
On transfection day, 3µg of pMigR1-empty/M2/M2Y, 2.5µg of pCL-Eco, 0.5µg of pCMV-
VsVg (section 7.1.6) and 3μL of transfection reagent per microgram of DNA were mixed in 
simple DMEM. After 20min of incubation at RT, this mix was added dropwise to the cells. 
On the next day, the culture medium was changed. 48h after transfection, supernatant 
was recovered and cell debris was removed using a 0.45μm filter. Supernatant was then 
centrifuged at 25000rpm for 3h at 4ºC, with a 10min break-off at 500rpm. The pellet was 
then resuspended in complete DMEM (800μL per 10cm dish used initially), aliquoted and 
stored at -80ºC.  
 
7.2.3.6 Transduction 
 
For the generation of A20 stable cells lines expressing EGFP, EGFP-M2 or EGFP-M2Y, 
A20 B cells were infected with the viral particles produced as described in section 7.2.3.5. 
Cells were subjected to two rounds of infection on two consecutive days. For that 
purpose, 2x106 A20 B cells, in exponencial growth phase, were washed and resuspended 
in 1mL of complete RPMI (section 7.2.3.1) supplemented with 8μg/mL of polybrene. On a 
6-well plate, 1mL of the appropriate retrovirus was then added to the cells. Next, cells 
were centrifuged at 700g for 1h at 37ºC to increase transduction efficiency. On the next 
day, another 1mL of the same retroviral supernatant was added to the cells, followed by 
centrifugation as before. 48h after the second infection, the 20% brightest A20 B cells, for 
the GFP color, were sorted as described in section 7.2.4.2. After sorting cells were 
cultured in complete RPMI supplemented with gentamycin to avoid contamination, and 
400μg/mL of zeocin for selective pressure. 
 
For transduction of fetal liver cells (section 7.2.3.4), 1-1.5x106 cells in 100μL of complete 
DMEM, 400μL of complete DMEM, 400μL of the appropriate retrovirus (section 7.2.3.5) 
and 8μg/mL of polybrene were mixed per well of a 24-well plate and centrifuged at 860g 
for 45min at 37ºC. A well containing the same density of fetal liver cells was kept 
untransduced to serve as a negative control in flow cytometric analysis of transduction 
efficiency (section 7.2.4.3). After the centrifugation, cells were cultured in complete DMEM 
supplemented with 20ng/mL of IL-3, 50ng/mL of IL-6 and 100ng/mL of SCF.  
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7.2.4 Flow cytometry 
 
7.2.4.1 Cell staining 
 
Staining for B cell markers  
Staining of B cell markers was used for the analysis of the levels of selected cellular 
surface markers on A20 B cell lines by flow cytometry. This staining was also performed 
every time a new aliquot of A20 B cell lines was placed in culture or every time new EGFP 
cell lines were produced. For those purposes, cells were washed twice with FACS buffer 
(2% FBS in PBS) and 5x105 cells were added, per condition, to the U-shaped wells of a 
96-well plate. The plate was centrifuged at 2000rpm for 1min at 4ºC and cells were 
incubated with the appropriate antibodies (table 7.1) for 15min on ice, in the dark. Cells 
were then washed twice, resuspended in FACS buffer, and kept on ice, protected from 
light, until flow cytometric analysis (section 7.2.4.3). 
 
Checking Rag-/- reconstitution 
To assess Rag-/- reconstitution, approximately 50μL of blood was collected from the facial 
vein of each mouse into an eppendorf containing 15μL of heparin leo (Leo), 7-8 weeks 
after adoptive transfer of transduced fetal liver cells (section 7.2.7.3). Whole blood was 
then incubated with 10μL of staining mix containing the appropriate antibodies (table 7.1) 
for 20min on ice, in the dark. Samples were then transferred to FACS tubes and washed 
with FACS buffer (2% FBS in PBS). Red blood cell lysis was carried out by incubation with 
BD FACS Lysing Solution (BD Biosciences), according to manufacturer’s instructions. 
Next, cells were washed twice, resuspended in FACS buffer, and kept on ice, protected 
from light, until flow cytometric analysis (section 7.2.4.3). 
 
Staining for different splenic cell populations 
Spleens were dissected from mice into 5mL of FACS buffer (2% FBS in PBS) and kept on 
ice until mechanical disruption to obtain single splenocyte suspensions. Cell debris was 
removed by filtering through a 100μm cell strainer. Red blood cells were lysed by 
incubation with red blood cell lysis buffer for 5 min on ice. Cell suspensions were washed 
with FACS buffer and blocked by incubation with anti-CD16/32 (2.4G2) (BD Pharmingen) 
for 15min at 4ºC. Splenocytes were stained by incubation for 25 min, at 4ºC, in the dark, 
with the appropriated antibodies diluted in FACS buffer (table 7.1). Unbound antibodies 
were removed by washing twice with FACS buffer. Cells were resuspended in FACS 
buffer and were kept on ice, protected from light, until flow cytometric analysis (section 
7.2.4.3). 
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Checking cell purity 
CD4+ T, B and c-kit+ cell populations purified using the Miltenyi Biotec technology 
(sections 7.2.3.2, 7.2.3.3, and 7.2.3.4 respectively) had their purity verified by flow 
cytometric analysis. For that purpose, a small aliquot of cells was washed with FACS 
buffer (2% FBS in PBS) and incubated with the appropriate antibodies (table 7.1). Cells 
were then washed twice, resuspended in FACS buffer, and kept on ice, protected from 
light, until flow cytometric analysis (section 7.2.4.3). 
 
7.2.4.2 Purification of cell populations 
 
Single cell suspensions of CD4+ T cells (section 7.2.3.2) or EGFP/EGFP-M2/EGFP-M2Y 
transduced A20 B cells (section 7.2.3.6) were enriched for the wanted populations using a 
FACSAria flow cytometer (BD Biosciences). CD4+ T cells were sorted at 37ºC and kept on 
T cell culture media (section 7.2.3.1) at all times. A20 B cells were sorted at 4ºC and kept 
on ice until further use. 
 
7.2.4.3 Flow cytometric analysis 
 
Total splenocytes, A20 B cell lines, enriched cell populations and mouse blood were 
analyzed on a LSR Fortessa flow cytometer (BD Biosciences), using FACSDiva software 
(BD Biosciences) for acquisition and FlowJo (Tree Star, Inc.) for analysis. 
 
7.2.5 Protein methods 
 
7.2.5.1 SDS-Polyacrylamide Gel Electrophoresis 
 
To confirm expression of M2/M2Y on A20 B cell lines, 2x106 cells were washed with PBS, 
resuspended in 30μL of lysis buffer (10mM Tris-HCl pH 7.5, 150mM NaCl, 1% Triton X-
100, 1mM NaF, 100μM Na3VO4, and cømplete from Roche, according to manufacturer’s 
instructions), and centrifuged at 14000rpm for 30min at 4ºC. Supernatant was recovered 
and added to Laemmli’s sample buffer (50mM Tris-HCl pH 6.8, 10% glycerol, 2% SDS, 
5% β-mercaptoethanol, 0.1% bromophenol blue). Next, protein samples were heated at 
100ºC for 10min and separated through SDS-PAGE, in 1.5mm mini-slab gels of the Bio-
Rad mini-protean II electrophoresis system. Resolving gel was prepared with 12% 
polyacrylamide (Acrylamide:bis-acrylamide 37.5:1, Bio-Rad), 375mM Tris-HCl (pH 8.8), 
0.1% SDS, 0.1% APS, and 0.04% TEMED. The solution was covered with sterile MilliQ 
water and allowed to polymerize at RT. Stacking gel was prepared with 5% 
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polyacrylamide, 125mM Tris-HCl (pH 6.8), 0.1% SDS, 0.1% APS, and 0.1% TEMED. 
Electrophoresis was performed in running buffer (25mM Tris-base, 192mM glycine and 
0.1% SDS), at 120V until maximal resolution of protein bands.  
 
7.2.5.2 Western blot 
 
After separation by SDS-PAGE, proteins were transferred to a nitrocellulose membrane 
(GE Healthcare) using a Trans-Blot Cell (Bio-Rad), assembled according to 
manufacturer’s instructions, in transfer buffer (25mM Tris-base, 200mM glycine and 10% 
methanol) for 1h and 15min at the constant current of 250mA. Protein transfer to the 
nitrocellulose membrane was confirmed by incubation with Ponceau S (Sigma), for 2min. 
The dye was removed by incubation with washing buffer (PBS with 0.05% Tween 20) for 
5min, on a rocking platform. Unoccupied protein binding sites on the membrane were 
blocked by incubation with blocking buffer (5% skimmed milk powder in washing buffer) 
for 1h, on a rocking platform. Incubation with primary antibody (table 7.1), diluted 1:500 to 
1:1000, was carried out in blocking buffer for 1h and 30min, on a rocking platform. 
Membrane was then washed with washing buffer (three times, 5min each) on a rocking 
platform to remove unbound primary antibody. Next, membrane was incubated with HRP-
conjugated secondary antibody (section 7.1.2.2), diluted 1:5000 in blocking buffer, for 
45min, on a rocking platform. Membrane was then washed with washing buffer (three 
times, 5min each) on a rocking platform to remove unbound secondary antibody. Protein 
antibody complexes were detected by chemiluminescence after incubation with the 
Supersignal West Pico Chemiluminescent substrate (Thermo Scientific), according to 
manufacturer’s instructions. All incubation steps were performed at RT. 
 
7.2.5.3 Immunofluorescence 
 
Immunofluorescence for conjugation experiments 
The number of B-TH cell conjugates showing pTyr or IFN-γ polarization to the contact 
zone was assessed by immunofluorescence. After centrifugation and incubation of B and 
TH cells as described in section 7.2.6.3, cells were resuspended using a vortex, added to 
commercial poly-L-lysine coated coverslips and incubated for 20-30min in a humidified 
tissue culture incubator at 37ºC under 5% CO2. Culture media was removed and cells 
were fixed in fixative solution (4% paraformaldehyde, 2% sucrose, PBS) for 20min at RT. 
At this point, in some experiments, 1mL of PBS was added to the coverslips with fixative 
solution and these were stored at 4ºC, covered with parafilm and protected from light. 
Next, excess fixative was removed by washing the coverslips three times with PBS. Cells 
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were then permeabilized by incubation with a solution of 0.2% Triton X-100 diluted in PBS 
for 10min at RT. The indicated primary antibodies (table 7.1) were diluted 1:50 in a 
solution of 0.2% Triton X-100 and 1% BSA in PBS. Incubation was performed in a dark 
humid chamber, for 1h at RT. Coverslips were washed three times in PBS to remove 
unbound primary antibody. When detecting IFN-γ, a secondary antibody (section 7.1.2.2) 
was diluted 1:250 in a solution of 0.2% Triton X-100 and 1% BSA in PBS. Incubation was 
performed in a dark humid chamber, for 1h at RT. When detecting actin, cells were 
incubated for 1h at RT with phalloidin-TRITC diluted 1:250 in a solution of 0.2% Triton X-
100 and 1% BSA in PBS. To remove unbound secondary antibody or phalloidin-TRITC, 
coverslips were washed three times in PBS. Cells were fixed again by incubation with 
fixative solution for 5min. Finally, coverslips were washed three times with PBS to remove 
the fixative solution, rinsed in distilled water and mounted with Fluoromount-G (Southern 
Biotec). After drying for 1h at 37ºC, slides were stored at 4ºC until further use.  
Slides were analyzed by confocal microscopy (LSM 510 META, Zeiss) using a Plan-
Apochromat 63x (1.4 oil) objective, with electronic zoom 1 for counting purposes and 
electronic zoom 3 for representative images. Images were analyzed using the 
AimImageBrowser (Zeiss LSM data server, Zeiss) software.  
 
Immunofluorescence of frozen spleen sections 
Infection of splenic cellular populations by WT or M2Y mutant MuHV-4 was tracked by 
immunofluorescence of frozen spleen sections, prepared as described in section 7.2.9. 
Superfrost Plus slides (Thermo Scientific) containing 9μm thick spleen sections were air 
dried for 1h at RT. Slides were immersed in distilled water for 5min to remove the extra 
OCT compound. Slides were then dried and sections were encircled with a fat pen (Dako), 
to allow the use of different antibodies on the same slide, and dried for 1min. From this 
step forward incubations were made in a dark humid chamber. Hydration of the sections 
was performed by incubation with PBS for 10min at RT. Next, sections were 
permeabilized and blocked by incubation with a perm/block solution (0.3% Triton X-100, 
5% normal goat serum, PBS) for 1h at RT. Primary antibodies (table 7.1) were diluted in a 
second perm/block solution (0.3% triton, 1% BSA, PBS) and added to the sections for 18h 
at 4ºC. Amount of each primary antibody used was optimized and dilution ranged from 
1:100 to 1:200. To remove unbound primary antibody, sections were immersed three 
times in approximately 200mL of PBS for 10min at RT, in the dark. Secondary antibodies 
(section 7.1.2.2) were then diluted in the second perm/block solution and added to the 
sections for 1h at RT. Amount of each secondary antibody used was optimized and 
dilution ranged from 1:250 to 1:300. Next, sections were washed three times with PBS as 
mentioned above to remove unbound secondary antibody and mounted with Prolong Gold 
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with DAPI. After drying for 24h at RT, slides were sealed with nail polish to prevent 
dehydration and subsequent shrinking of the tissue and stored at 4ºC in the dark until 
further use. 
Slides were analyzed by confocal microscopy (LSM 710, Zeiss) using either an EC Plan-
Neofluar 40x (1.3 oil) or a Plan-Apochromat 63x (1.4 oil) objective. Images were analyzed 
using the FIJI software (Schindelin, Arganda-Carreras et al. 2012). 
 
7.2.6 Conjugation assays 
 
7.2.6.1 The cellular system: A20-T CD4+ Tg DO11.10 
 
The cellular system A20-T CD4+ Tg DO11.10 was used for the analysis of conjugate 
formation. A20 B cells were transduced as described in section 7.2.3.6, giving rise to A20 
B cell lines stably expressing M2, M2Y, EGFP, EGFP-M2 or EGFP-M2Y. On the day prior 
to incubation with T cells, A20 B cell lines in exponential growth were pulsed with the 
indicated concentrations of OVAp. Briefly, cells were washed twice with conjugates media 
(section 7.2.3.1), resuspended at a cellular density of 2x106/mL of conjugates media 
supplemented with the indicated concentrations of OVAp and incubated O/N in a 
humidified tissue culture incubator at 37ºC under 5% CO2. TCR transgenic OVAp-specific 
T cells were obtained and prepared as described in section 7.2.3.2. A20 B cells and/or 
mouse CD4+ T cells were washed and loaded, or not, with the indicated live dyes (section 
7.1.2.3), as appropriate.  B and T cells were again washed and then added in the 
indicated ratios to FACS tubes. These were centrifuged for 1min at 1500rpm to promote 
cell encounter, and incubated for a period of time, as is specified. Conjugates were then 
analyzed by flow cytometry or confocal microscopy. 
 
7.2.6.2 Conjugate quantification by flow cytometry 
 
For the quantification of conjugates by flow cytometry, non-fluorescent B cell lines were 
stained with 50nM of CMFDA live dye, diluted in RPMI 1640, for 30min at 37ºC, in the 
dark. In the case of EGFP-expressing B cell lines CMFDA was not used. Cells were then 
washed with conjugates media (section 7.2.3.1) and resuspended at a cellular density of 
2x105/150μL of media. T cells were prepared as described in section 7.2.3.2 and stained 
with 1μM of DDAO live dye, diluted in PBS, for 20min at 37ºC, in the dark. Next, cells 
were washed with conjugates media and resuspended at a cellular density of 
1x105/150μL. 150μL of both B and T cells were then added to a FACS tube, centrifuged at 
1500rpm for 1min and incubated for the indicated times. This was done for each OVAp 
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concentration. Samples were then carefully resuspended on a vortex and analyzed on a 
LSR Fortessa flow cytometer (BD Biosciences) (section 7.2.4.3). 
 
For the in vitro competition assay, M2-expressing B cells were stained with 50nM of 
CMFDA live dye, diluted in RPMI 1640, for 30min at 37ºC, in the dark. M2Y- or EGFP-
M2Y-expressing B cells were stained with 2µM of CMTMR live dye, diluted in RPMI 1640, 
for 15min at 37ºC, in the dark. Next, cells were washed with conjugates media and 
resuspended at a cellular density of 1.5x105/100µL of media. T cells were stained with 
DDAO live dye, as described above and resuspended at a cellular density of 
1.5x105/100µL of media. 100µL (1.5x105 cells) of each cellular population were added to 
the same FACS tube, centrifuged at 1500rpm for 1min and incubated for 30min. This was 
done for each OVAp concentration. Samples were then carefully resuspended on a vortex 
and analyzed on a LSR Fortessa flow cytometer (BD Biosciences) (section 7.2.4.3). 
 
7.2.6.3 Conjugate analysis by confocal microscopy 
 
For the quantification of conjugates by confocal microscopy, non-fluorescent B cell lines 
were stained with 1μM of CMFDA live dye, diluted in RPMI 1640, for 30min at 37ºC, in the 
dark. In the case of EGFP-expressing B cell lines CMFDA was not used. Cells were then 
washed with conjugates media (section 7.2.3.1) and resuspended at a cellular density of 
5x105/100μL of media. T cells were recovered after 5 days of resting and washed with T 
cell culture media (section 7.2.3.1). Cell suspension was then filtered and live resting T 
cells were sorted, based on their FSC-A/SSC-A profile (section 7.2.4.2). T cells were then 
washed and resuspended at a cellular density of 2.5x105/100μL of T cell culture media. 
100µL of each cellular population were added to the same FACS tube, centrifuged at 
1500rpm for 1min and incubated for 30min in a water bath, in the dark. Cells were then 
resuspended using the vortex, added to commercial poly-L-lysine coated coverslips and 
processed for immunofluorescence as described on section 7.2.5.3. 
 
For the quantification of conjugates showing IFN-γ polarization to the B-TH contact zone, T 
cells were stained with 100μM of CMAC live dye, prior to incubation with B cells. B and T 
cells were incubated for 2.5h. The remaining steps were done as described above. 
 
Image quantification was performed in a blinded fashion in randomly selected fields from 
at least three independent experiments. To evaluate the percentage of conjugates 
showing pTyr and/or IFN-γ polarization to the contact zone, only images with a minimum 
of three T cells were analyzed. Number of T cells conjugating was scored visually.  
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7.2.6.4 Analysis of calcium mobilization on T cells by flow cytometry 
 
A20 B cell lines, loaded or not with OVAp, were processed as described in section 7.2.6.1. 
Mouse OVAp-specific CD4+ T cells were obtained as described in section 7.2.3.2. T cells 
were recovered after 6.5-7 days of resting and washed with T cell culture media (section 
7.2.3.1). Cell suspension was then filtered and live resting T cells were sorted, based on 
their FSC-A/SSC-A profile (section 7.2.4.2). Next, T cells were loaded with 5μM of Indo-1 
AM (Invitrogen) (Valitutti, Dessing et al. 1993) for 35-45min in a humidified tissue culture 
incubator at 37ºC under 5% CO2. From this point forward cells were protected from light 
and were used in the next 2h, before Indo-1 degradation. Cells were then incubated with 
A20 B cell lines for 5min at 37ºC. Before starting sample acquisition a baseline was set on 
the 405/525 emission ratio using Indo-1 loaded T cells. Ionomycin (Sigma) activated T 
cells were used as a positive control. Baseline was acquired for approximately 2min and 
samples were lightly vortexed and acquired for an additional 18min on a MoFlow 
cytometer.  
 
7.2.7 Animal experiments 
 
7.2.7.1 Ethics statement 
 
The study accorded with the Portuguese official Veterinary Directorate (Portaria 1005/92), 
European Directive 2010/63/EU, and Federation of European Laboratory Animal Science 
Associations guidelines on laboratory animal welfare. It was approved by the Portuguese 
official veterinary department for welfare licensing (protocol 
AEC_2010_017_PS_Rdt_General) and by the IMM Animal Ethics Committee. Mice were 
sacrificed by CO2 inhalation or cervical dislocation.  
 
7.2.7.2 Mice breeding for fetal liver dissection 
 
72h before mating, females were housed with dirty bedding from male’s cages, to 
stimulate estrus. Breeding trios (CD45.1xCD45.1, CD45.2xCD45.2, CD45.1xCD45.2) 
were then housed together overnight and the day of vaginal plug detection was set as day 
0. Females were checked for pregnancy at day 13 and embryos were collected at day 15 
and processed for fetal liver dissection (section 7.2.3.4). 
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7.2.7.3 Adoptive transfers 
 
When testing the optimal conditions for the in vivo competition system, C57BL/6J mice 
were not irradiated or irradiated with 250rad or 500rad, using an Irradiator Gammacell 
ELAN 3000. 1-3.5x106 CD45.1 B cells, obtained as described in section 7.2.3.3, were 
washed with PBS, filtered (40μm) and adoptively transferred to the sex matched 
C57BL/6J mice via tail vein injection. 
 
Rag-/- mice were irradiated at 600rad using an Irradiator Gammacell ELAN 3000. 2x106 
transduced CD45.1, CD45.2 or CD45.1/2 fetal liver cells were washed with PBS, filtered 
(40μm) and adoptively transferred to sex matched irradiated Rag-/- mice via tail vein 
injection. These cells were obtained as described in section 7.2.3.4 and transduced as 
described in section 7.2.3.6. 
 
Whenever mice were irradiated, antibiotics were added to drinking water 48h prior to 
transfer.  
 
7.2.7.4 Immunization with NP-CGG 
 
When testing the optimal conditions for the in vivo competition system, following adoptive 
transfer of CD45.1 B cells, C57BL/6J mice were intraperitoneally immunized with 100µg of 
NP-CGG (4-Hydroxy-3-nitrophenylacetyl hapten conjugated to Chicken Gamma Globulin) 
adsorbed to 3mg of Alum. Ten days post immunization, spleens were isolated for GC 
analysis by flow cytometry (section 7.2.4). 
 
7.2.7.5 Mice infection 
 
6- to 8-week old female C57BL/6 mice were inoculated intraperitoneally with 106 PFU of 
MuHV-4 viruses: vYFP or vM2Y-YFP (section 7.1.8). Virus inoculations were performed in 
100μL of PBS. At different time points after infection, mice were sacrificed by CO2 
inhalation followed by cervical dislocation, and spleens were dissected and processed for 
subsequent analysis. 
 
 
 
 
CHAPTER 7 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
144 
 
7.2.8 Virus assays 
 
7.2.8.1 Virus infection of cells 
 
BHK-21 cells were seeded in tissue culture flasks and grown to semi-confluence for virus 
stock production. Cell monolayers were adsorbed with virus suspension in 25% of the final 
appropriate culture medium for 1h at 37ºC, then covered with the remaining 75% of 
medium and incubated for the appropriate time. 
 
7.2.8.2 Virus working stocks 
 
Virus working stocks were grown by low multiplicity infection of BHK-21 cells (0.001 
PFU/cell) in 175cm2 culture flasks. When approximately 50% cytopathic effect (cpe) was 
visible (4-5 days), cells and supernatants were transferred to 50mL tubes. Cell-associated 
virus was centrifuged at 1500rpm for 10min at 4ºC. Next, it was resuspended in 2mL of 
fresh complete GMEM medium, subjected to freeze-thawing, and kept at -80ºC in 200μL 
aliquots. Supernatant-associated virus was centrifuged at 15000 rpm for 2h at 4ºC and 
pellet was resuspended in 2mL of fresh medium. 100μL aliquots were made and stored at 
-80ºC. Virus titers were determined in duplicates by suspension assay. 
 
7.2.8.3 Infectious center assay 
 
Spleens were dissected from mice individually into 5mL of complete GMEM (section 
7.2.3.1). Single cell suspensions were obtained by mechanical disruption and cell debris 
was removed by filtering through a 100μm cell strainer. Next, cells were centrifuged at 
1300rpm for 5 min at 4ºC. Red blood cells were lysed by incubation with 1mL of red blood 
cell lysis buffer (154mM ammonium chloride, 14mM sodium hydrogen carbonate, 1mM 
EDTA pH7.3) for 5 min on ice. Cells were then washed with 10mL of complete GMEM, 
pelleted by centrifugation at 1300rpm for 5min at 4ºC and resuspended in 5mL of 
complete GMEM. At this point, a small aliquot of cells was removed for cell count with 
trypan blue. 10-fold serial dilutions were prepared in duplicate. 1mL of this dilution was 
added to 5x105 BHK-21 cells in 6cm dishes, in a final volume of 5mL. The co-culture was 
incubated for 5 days at 37ºC in a humidified incubator with 5% CO2. Cell monolayers 
were then fixed with 4% formaldehyde in PBS for 10min, and stained with 0.05% toluidine 
blue solution for 5min. Viral plaques were counted using an Olympus SZ51 zoom stereo 
microscope and infectious centers were determined from the number of viral plaques in 
duplicate dishes. 
MATERIALS AND METHODS 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
145 
 
7.2.8.4 Plaque assay (suspension assay) 
 
Virus stocks (section 7.2.8.2) and infectious virus present in the spleen of infected mice 
were titrated by plaque assay (or suspension assay). Spleens were dissected from mice 
individually into 5mL of complete GMEM (section 7.2.3.1). Single cell suspensions were 
obtained by mechanical disruption and cell debris were removed by filtering through a 
100μm cell strainer. Next, cells were centrifuged at 1300rpm for 5 min at 4ºC. Red blood 
cells were lysed by incubation with 1mL of red blood cell lysis buffer (154mM ammonium 
chloride, 14mM sodium hydrogen carbonate, 1mM EDTA pH7.3) for 5 min on ice. Cells 
were then washed with 10mL of complete GMEM, pelleted by centrifugation at 1300rpm 
for 5min at 4ºC and resuspended in 5mL of complete GMEM. Cell suspensions were 
subjected to freeze-thawing to disrupt cells and subjected to the vortex. Virus stocks or 
splenic cell suspensions were 10-fold serial diluted in 1mL of complete GMEM. Each 
dilution was incubated with 5x105 BHK-21 cells for 1h at RT, on a rocking platform 
(15rpm). 3mL of media was added to each dilution, mixed by inversion and plated on 6cm 
dishes. The co-culture was incubated for 4 days at 37ºC in a humidified incubator with 5% 
CO2. Cell monolayers were then fixed with 4% formaldehyde in PBS for 10min, and 
stained with 0.05% toluidine blue solution for 5min. Viral plaques were counted using an 
Olympus SZ51 zoom stereo microscope and virus titers were determined from the number 
of viral plaques in duplicate dishes. 
 
7.2.9 Frozen spleen sections 
 
Four or eight days post infection, spleens from intraperitoneally infected mice (section 
7.2.7.5) were dissected individually to 5mL of PBS. Fat tissue was carefully removed and 
the spleens were fixed by incubation in 10mL of fixative solution (1% fresh PFA, 10mM 
sodium metaperiodate, and 75mM L-lysine in PBS) for 24h at 4ºC. Spleens were then 
washed with 10mL of PBS and equilibrated by incubation in 5mL of a 30% sucrose 
solution for 18h at 4ºC. This solution was replaced a fresh solution of 30% sucrose and 
optimal cutting temperature compound (OCT), where spleens were incubated for 3-4h at 
4ºC. Next, spleens were cut in half longitudinally and each half was transferred to 
appropriate tissue molds and embedded in OCT. Samples were then snap-frozen in 
isopentane cooled down to -70/-80ºC in liquid nitrogen. Samples were immediately stored 
at -20ºC and later on transferred to -80ºC for long-term storage. 
 
9μm-thick longitudinal sections were obtained using the cryostat LEICA CM3050. 
Chamber and object temperature ranged from -18ºC to -20ºC. Two to three sections were 
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adhered to Superfrost Plus Slides (Thermo Scientific) and kept at RT for at least 5min. 
Finally, samples embedded in OCT were stored back at -80ºC while sections were stored 
at -20ºC until further use. 
 
7.2.10  Statistical analysis 
 
Statistical significance was evaluated with unpaired one-tailed t-test or non-parametric 
Mann-Whitney U test, as appropriate, using GraphPad Prism software. ns indicates 
p>0.05; * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, **** indicates 
p<0.0001. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 8 
 
REFERENCES 
  
 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
149 
 
8 REFERENCES 
 
Adler, H., M. Messerle, M. Wagner and U. H. Koszinowski (2000). "Cloning and 
mutagenesis of the murine gammaherpesvirus 68 genome as an infectious bacterial 
artificial chromosome." J Virol 74(15): 6964-6974. 
Alarcon, B., D. Mestre and N. Martinez-Martin (2011). "The immunological synapse: a 
cause or consequence of T-cell receptor triggering?" Immunology 133(4): 420-425. 
Allday, M. J., Q. Bazot and R. E. White (2015). "The EBNA3 Family: Two Oncoproteins 
and a Tumour Suppressor that Are Central to the Biology of EBV in B Cells." Curr Top 
Microbiol Immunol 391: 61-117. 
Allen, C. D., T. Okada and J. G. Cyster (2007). "Germinal-center organization and cellular 
dynamics." Immunity 27(2): 190-202. 
Ambroziak, J. A., D. J. Blackbourn, B. G. Herndier, R. G. Glogau, J. H. Gullett, A. R. 
McDonald, E. T. Lennette and J. A. Levy (1995). "Herpes-like sequences in HIV-infected 
and uninfected Kaposi's sarcoma patients." Science 268(5210): 582-583. 
Andjelkovic, M., D. R. Alessi, R. Meier, A. Fernandez, N. J. Lamb, M. Frech, P. Cron, P. 
Cohen, J. M. Lucocq and B. A. Hemmings (1997). "Role of translocation in the activation 
and function of protein kinase B." J Biol Chem 272(50): 31515-31524. 
Babcock, G. J., D. Hochberg and A. D. Thorley-Lawson (2000). "The expression pattern of 
Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the 
infected B cell." Immunity 13(4): 497-506. 
Bagni, R. and D. Whitby (2009). "Kaposi's sarcoma-associated herpesvirus transmission 
and primary infection." Curr Opin HIV AIDS 4(1): 22-26. 
Bannard, O., R. M. Horton, C. D. Allen, J. An, T. Nagasawa and J. G. Cyster (2013). 
"Germinal center centroblasts transition to a centrocyte phenotype according to a timed 
program and depend on the dark zone for effective selection." Immunity 39(5): 912-924. 
Barton, E., P. Mandal and S. H. Speck (2011). "Pathogenesis and host control of 
gammaherpesviruses: lessons from the mouse." Annu Rev Immunol 29: 351-397. 
Basu, S., A. Ray and B. N. Dittel (2013). "Differential representation of B cell subsets in 
mixed bone marrow chimera mice due to expression of allelic variants of CD45 
(CD45.1/CD45.2)." J Immunol Methods 396(1-2): 163-167. 
Batista, F. D. and N. E. Harwood (2009). "The who, how and where of antigen 
presentation to B cells." Nat Rev Immunol 9(1): 15-27. 
Bennett, N. J., J. S. May and P. G. Stevenson (2005). "Gamma-herpesvirus latency 
requires T cell evasion during episome maintenance." PLoS Biol 3(4): e120. 
Bishop, G. A. and B. S. Hostager (2003). "The CD40-CD154 interaction in B cell-T cell 
liaisons." Cytokine Growth Factor Rev 14(3-4): 297-309. 
Blackman, M. A. and E. Flano (2002). "Persistent gamma-herpesvirus infections: what can 
we learn from an experimental mouse model?" J Exp Med 195(7): F29-32. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
150 
 
Blackman, M. A., E. Flano, E. Usherwood and D. L. Woodland (2000). "Murine gamma-
herpesvirus-68: a mouse model for infectious mononucleosis?" Mol Med Today 6(12): 
488-490. 
Blasdell, K., C. McCracken, A. Morris, A. A. Nash, M. Begon, M. Bennett and J. P. Stewart 
(2003). "The wood mouse is a natural host for Murid herpesvirus 4." J Gen Virol 84(Pt 1): 
111-113. 
Blaskovic, D., M. Stancekova, J. Svobodova and J. Mistrikova (1980). "Isolation of five 
strains of herpesviruses from two species of free living small rodents." Acta Virol 24(6): 
468. 
Boname, J. M. and P. G. Stevenson (2001). "MHC class I ubiquitination by a viral 
PHD/LAP finger protein." Immunity 15(4): 627-636. 
Boos, H., R. Berger, C. Kuklik-Roos, T. Iftner and N. Mueller-Lantzsch (1987). 
"Enhancement of Epstein-Barr virus membrane protein (LMP) expression by serum, TPA, 
or n-butyrate in latently infected Raji cells." Virology 159(1): 161-165. 
Boulanger, E., L. Gerard, J. Gabarre, J. M. Molina, C. Rapp, J. F. Abino, J. Cadranel, S. 
Chevret and E. Oksenhendler (2005). "Prognostic factors and outcome of human 
herpesvirus 8-associated primary effusion lymphoma in patients with AIDS." J Clin Oncol 
23(19): 4372-4380. 
Bowden, R. J., J. P. Simas, A. J. Davis and S. Efstathiou (1997). "Murine 
gammaherpesvirus 68 encodes tRNA-like sequences which are expressed during 
latency." J Gen Virol 78 ( Pt 7): 1675-1687. 
Bridgeman, A., P. G. Stevenson, J. P. Simas and S. Efstathiou (2001). "A secreted 
chemokine binding protein encoded by murine gammaherpesvirus-68 is necessary for the 
establishment of a normal latent load." J Exp Med 194(3): 301-312. 
Brinkmann, M. M., M. Glenn, L. Rainbow, A. Kieser, C. Henke-Gendo and T. F. Schulz 
(2003). "Activation of mitogen-activated protein kinase and NF-kappaB pathways by a 
Kaposi's sarcoma-associated herpesvirus K15 membrane protein." J Virol 77(17): 9346-
9358. 
Brinkmann, M. M., M. Pietrek, O. Dittrich-Breiholz, M. Kracht and T. F. Schulz (2007). 
"Modulation of host gene expression by the K15 protein of Kaposi's sarcoma-associated 
herpesvirus." J Virol 81(1): 42-58. 
Brinkmann, M. M. and T. F. Schulz (2006). "Regulation of intracellular signalling by the 
terminal membrane proteins of members of the Gammaherpesvirinae." J Gen Virol 87(Pt 
5): 1047-1074. 
Bustelo, X. R. (2000). "Regulatory and signaling properties of the Vav family." Mol Cell 
Biol 20(5): 1461-1477. 
Calame, K. L. (2001). "Plasma cells: finding new light at the end of B cell development." 
Nat Immunol 2(12): 1103-1108. 
Caldwell, R. G., J. B. Wilson, S. J. Anderson and R. Longnecker (1998). "Epstein-Barr 
virus LMP2A drives B cell development and survival in the absence of normal B cell 
receptor signals." Immunity 9(3): 405-411. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
151 
 
Cannon, J. S., J. Nicholas, J. M. Orenstein, R. B. Mann, P. G. Murray, P. J. Browning, J. 
A. DiGiuseppe, E. Cesarman, G. S. Hayward and R. F. Ambinder (1999). "Heterogeneity 
of viral IL-6 expression in HHV-8-associated diseases." J Infect Dis 180(3): 824-828. 
Carbone, A., A. Gloghini, E. Vaccher, M. Cerri, G. Gaidano, R. Dalla-Favera and U. Tirelli 
(2005). "Kaposi's sarcoma-associated herpesvirus/human herpesvirus type 8-positive 
solid lymphomas: a tissue-based variant of primary effusion lymphoma." J Mol Diagn 7(1): 
17-27. 
Cardin, R. D., J. W. Brooks, S. R. Sarawar and P. C. Doherty (1996). "Progressive loss of 
CD8+ T cell-mediated control of a gamma-herpesvirus in the absence of CD4+ T cells." J 
Exp Med 184(3): 863-871. 
Casola, S., K. L. Otipoby, M. Alimzhanov, S. Humme, N. Uyttersprot, J. L. Kutok, M. C. 
Carroll and K. Rajewsky (2004). "B cell receptor signal strength determines B cell fate." 
Nat Immunol 5(3): 317-327. 
Casper, C., W. G. Nichols, M. L. Huang, L. Corey and A. Wald (2004). "Remission of 
HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment." 
Blood 103(5): 1632-1634. 
Cen, O. and R. Longnecker (2015). "Latent Membrane Protein 2 (LMP2)." Curr Top 
Microbiol Immunol 391: 151-180. 
Cesarman, E. (2011). "Gammaherpesvirus and lymphoproliferative disorders in 
immunocompromised patients." Cancer Lett 305(2): 163-174. 
Cesarman, E. (2014). "Gammaherpesviruses and lymphoproliferative disorders." Annu 
Rev Pathol 9: 349-372. 
Cesarman, E. and D. M. Knowles (1999). "The role of Kaposi's sarcoma-associated 
herpesvirus (KSHV/HHV-8) in lymphoproliferative diseases." Semin Cancer Biol 9(3): 165-
174. 
Chadburn, A., E. M. Hyjek, W. Tam, Y. Liu, T. Rengifo, E. Cesarman and D. M. Knowles 
(2008). "Immunophenotypic analysis of the Kaposi sarcoma herpesvirus (KSHV; HHV-8)-
infected B cells in HIV+ multicentric Castleman disease (MCD)." Histopathology 53(5): 
513-524. 
Chaki, S. P. and G. M. Rivera (2013). "Integration of signaling and cytoskeletal remodeling 
by Nck in directional cell migration." Bioarchitecture 3(3): 57-63. 
Chang, Y., E. Cesarman, M. S. Pessin, F. Lee, J. Culpepper, D. M. Knowles and P. S. 
Moore (1994). "Identification of herpesvirus-like DNA sequences in AIDS-associated 
Kaposi's sarcoma." Science 266(5192): 1865-1869. 
Cho, N. H., P. Feng, S. H. Lee, B. S. Lee, X. Liang, H. Chang and J. U. Jung (2004). 
"Inhibition of T cell receptor signal transduction by tyrosine kinase-interacting protein of 
Herpesvirus saimiri." J Exp Med 200(5): 681-687. 
Choi, J. K., B. S. Lee, S. N. Shim, M. Li and J. U. Jung (2000). "Identification of the novel 
K15 gene at the rightmost end of the Kaposi's sarcoma-associated herpesvirus genome." 
J Virol 74(1): 436-446. 
Choquet, S., V. Leblond, R. Herbrecht, G. Socie, A. M. Stoppa, P. Vandenberghe, A. 
Fischer, F. Morschhauser, G. Salles, W. Feremans, E. Vilmer, M. N. Peraldi, P. Lang, Y. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
152 
 
Lebranchu, E. Oksenhendler, J. L. Garnier, T. Lamy, A. Jaccard, A. Ferrant, F. Offner, O. 
Hermine, A. Moreau, S. Fafi-Kremer, P. Morand, L. Chatenoud, N. Berriot-Varoqueaux, L. 
Bergougnoux and N. Milpied (2006). "Efficacy and safety of rituximab in B-cell post-
transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 
study." Blood 107(8): 3053-3057. 
Christensen, J. P., R. D. Cardin, K. C. Branum and P. C. Doherty (1999). "CD4(+) T cell-
mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-
gamma." Proc Natl Acad Sci U S A 96(9): 5135-5140. 
Coen, N., S. Duraffour, R. Snoeck and G. Andrei (2014). "KSHV targeted therapy: an 
update on inhibitors of viral lytic replication." Viruses 6(11): 4731-4759. 
Collins, C. M., J. M. Boss and S. H. Speck (2009). "Identification of infected B-cell 
populations by using a recombinant murine gammaherpesvirus 68 expressing a 
fluorescent protein." J Virol 83(13): 6484-6493. 
Collins, C. M. and S. H. Speck (2014). "Expansion of murine gammaherpesvirus latently 
infected B cells requires T follicular help." PLoS Pathog 10(5): e1004106. 
Contreras-Salazar, B., B. Ehlin-Henriksson, G. Klein and M. G. Masucci (1990). "Up 
regulation of the Epstein-Barr virus (EBV)-encoded membrane protein LMP in the Burkitt's 
lymphoma line Daudi after exposure to n-butyrate and after EBV superinfection." J Virol 
64(11): 5441-5447. 
Correia, B., S. A. Cerqueira, C. Beauchemin, M. Pires de Miranda, S. Li, R. Ponnusamy, 
L. Rodrigues, T. R. Schneider, M. A. Carrondo, K. M. Kaye, J. P. Simas and C. E. McVey 
(2013). "Crystal structure of the gamma-2 herpesvirus LANA DNA binding domain 
identifies charged surface residues which impact viral latency." PLoS Pathog 9(10): 
e1003673. 
Coscoy, L. (2007). "Immune evasion by Kaposi's sarcoma-associated herpesvirus." Nat 
Rev Immunol 7(5): 391-401. 
Coscoy, L. and D. Ganem (2000). "Kaposi's sarcoma-associated herpesvirus encodes two 
proteins that block cell surface display of MHC class I chains by enhancing their 
endocytosis." Proc Natl Acad Sci U S A 97(14): 8051-8056. 
Coscoy, L. and D. Ganem (2001). "A viral protein that selectively downregulates ICAM-1 
and B7-2 and modulates T cell costimulation." J Clin Invest 107(12): 1599-1606. 
Cousins, E. and J. Nicholas (2014). "Molecular biology of human herpesvirus 8: novel 
functions and virus-host interactions implicated in viral pathogenesis and replication." 
Recent Results Cancer Res 193: 227-268. 
Dal Porto, J. M., S. B. Gauld, K. T. Merrell, D. Mills, A. E. Pugh-Bernard and J. Cambier 
(2004). "B cell antigen receptor signaling 101." Mol Immunol 41(6-7): 599-613. 
Damania, B. (2004). "Oncogenic gamma-herpesviruses: comparison of viral proteins 
involved in tumorigenesis." Nat Rev Microbiol 2(8): 656-668. 
Davison, A. J., R. Eberle, B. Ehlers, G. S. Hayward, D. J. McGeoch, A. C. Minson, P. E. 
Pellett, B. Roizman, M. J. Studdert and E. Thiry (2009). "The order Herpesvirales." Arch 
Virol 154(1): 171-177. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
153 
 
Dawson, C. W., A. B. Rickinson and L. S. Young (1990). "Epstein-Barr virus latent 
membrane protein inhibits human epithelial cell differentiation." Nature 344(6268): 777-
780. 
Dawson, C. W., G. Tramountanis, A. G. Eliopoulos and L. S. Young (2003). "Epstein-Barr 
virus latent membrane protein 1 (LMP1) activates the phosphatidylinositol 3-kinase/Akt 
pathway to promote cell survival and induce actin filament remodeling." J Biol Chem 
278(6): 3694-3704. 
de Lima, B. D., J. S. May, S. Marques, J. P. Simas and P. G. Stevenson (2005). "Murine 
gammaherpesvirus 68 bcl-2 homologue contributes to latency establishment in vivo." J 
Gen Virol 86(Pt 1): 31-40. 
De Silva, N. S. and U. Klein (2015). "Dynamics of B cells in germinal centres." Nat Rev 
Immunol 15(3): 137-148. 
Decalf, J., C. Godinho-Silva, D. Fontinha, S. Marques and J. P. Simas (2014). 
"Establishment of murine gammaherpesvirus latency in B cells is not a stochastic event." 
PLoS Pathog 10(7): e1004269. 
Delgado-Eckert, E. and M. Shapiro (2011). "A model of host response to a multi-stage 
pathogen." J Math Biol 63(2): 201-227. 
Depoil, D., R. Zaru, M. Guiraud, A. Chauveau, J. Harriague, G. Bismuth, C. Utzny, S. 
Muller and S. Valitutti (2005). "Immunological synapses are versatile structures enabling 
selective T cell polarization." Immunity 22(2): 185-194. 
Devergne, O., E. Hatzivassiliou, K. M. Izumi, K. M. Kaye, M. F. Kleijnen, E. Kieff and G. 
Mosialos (1996). "Association of TRAF1, TRAF2, and TRAF3 with an Epstein-Barr virus 
LMP1 domain important for B-lymphocyte transformation: role in NF-kappaB activation." 
Mol Cell Biol 16(12): 7098-7108. 
Dittmer, D. P. and B. Damania (2013). "Kaposi sarcoma associated herpesvirus 
pathogenesis (KSHV)--an update." Curr Opin Virol 3(3): 238-244. 
Doherty, P. C., J. P. Christensen, G. T. Belz, P. G. Stevenson and M. Y. Sangster (2001). 
"Dissecting the host response to a gamma-herpesvirus." Philos Trans R Soc Lond B Biol 
Sci 356(1408): 581-593. 
Duchez, S., M. Rodrigues, F. Bertrand and S. Valitutti (2011). "Reciprocal polarization of T 
and B cells at the immunological synapse." J Immunol 187(9): 4571-4580. 
Dustin, M. L. (2014). "The immunological synapse." Cancer Immunol Res 2(11): 1023-
1033. 
Efstathiou, S., Y. M. Ho and A. C. Minson (1990). "Cloning and molecular characterization 
of the murine herpesvirus 68 genome." J Gen Virol 71 ( Pt 6): 1355-1364. 
Ehtisham, S., N. P. Sunil-Chandra and A. A. Nash (1993). "Pathogenesis of murine 
gammaherpesvirus infection in mice deficient in CD4 and CD8 T cells." J Virol 67(9): 
5247-5252. 
Eliopoulos, A. G. and L. S. Young (1998). "Activation of the cJun N-terminal kinase (JNK) 
pathway by the Epstein-Barr virus-encoded latent membrane protein 1 (LMP1)." 
Oncogene 16(13): 1731-1742. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
154 
 
Epstein, M. A., B. G. Achong and Y. M. Barr (1964). "Virus Particles in Cultured 
Lymphoblasts from Burkitt's Lymphoma." Lancet 1(7335): 702-703. 
Etienne-Manneville, S. and A. Hall (2002). "Rho GTPases in cell biology." Nature 
420(6916): 629-635. 
Evans, A. G., J. M. Moser, L. T. Krug, V. Pozharskaya, A. L. Mora and S. H. Speck 
(2008). "A gammaherpesvirus-secreted activator of Vbeta4+ CD8+ T cells regulates 
chronic infection and immunopathology." J Exp Med 205(3): 669-684. 
Feldman, E. R., M. Kara, C. B. Coleman, K. R. Grau, L. M. Oko, B. J. Krueger, R. Renne, 
L. F. van Dyk and S. A. Tibbetts (2014). "Virus-encoded microRNAs facilitate 
gammaherpesvirus latency and pathogenesis in vivo." MBio 5(3): e00981-00914. 
Feske, S., J. Giltnane, R. Dolmetsch, L. M. Staudt and A. Rao (2001). "Gene regulation 
mediated by calcium signals in T lymphocytes." Nat Immunol 2(4): 316-324. 
Flano, E., S. M. Husain, J. T. Sample, D. L. Woodland and M. A. Blackman (2000). 
"Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic 
cells, and macrophages." J Immunol 165(2): 1074-1081. 
Flano, E., Q. Jia, J. Moore, D. L. Woodland, R. Sun and M. A. Blackman (2005). "Early 
establishment of gamma-herpesvirus latency: implications for immune control." J Immunol 
174(8): 4972-4978. 
Flano, E., I. J. Kim, D. L. Woodland and M. A. Blackman (2002). "Gamma-herpesvirus 
latency is preferentially maintained in splenic germinal center and memory B cells." J Exp 
Med 196(10): 1363-1372. 
Fontinha, D., F. B. Lopes, S. Marques and J. P. Simas (2015). "Murid Gammaherpesvirus 
Latency-Associated Protein M2 Promotes the Formation of Conjugates between 
Transformed B Lymphoma Cells and T Helper Cells." PLoS One 10(11): e0142540. 
Francois, S., S. Vidick, M. Sarlet, D. Desmecht, P. Drion, P. G. Stevenson, A. 
Vanderplasschen and L. Gillet (2013). "Illumination of murine gammaherpesvirus-68 cycle 
reveals a sexual transmission route from females to males in laboratory mice." PLoS 
Pathog 9(4): e1003292. 
Frederico, B., B. Chao, C. Lawler, J. S. May and P. G. Stevenson (2015). "Subcapsular 
sinus macrophages limit acute gammaherpesvirus dissemination." J Gen Virol 96(8): 
2314-2327. 
Frederico, B., B. Chao, J. S. May, G. T. Belz and P. G. Stevenson (2014). "A murid 
gamma-herpesviruses exploits normal splenic immune communication routes for systemic 
spread." Cell Host Microbe 15(4): 457-470. 
Frederico, B., R. Milho, J. S. May, L. Gillet and P. G. Stevenson (2012). "Myeloid infection 
links epithelial and B cell tropisms of Murid Herpesvirus-4." PLoS Pathog 8(9): e1002935. 
Friedl, P., A. T. den Boer and M. Gunzer (2005). "Tuning immune responses: diversity and 
adaptation of the immunological synapse." Nat Rev Immunol 5(7): 532-545. 
Fukuda, M. and Y. Kawaguchi (2014). "Role of the immunoreceptor tyrosine-based 
activation motif of latent membrane protein 2A (LMP2A) in Epstein-Barr virus LMP2A-
induced cell transformation." J Virol 88(9): 5189-5194. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
155 
 
Fukuda, M. and R. Longnecker (2004). "Latent membrane protein 2A inhibits transforming 
growth factor-beta 1-induced apoptosis through the phosphatidylinositol 3-kinase/Akt 
pathway." J Virol 78(4): 1697-1705. 
Fukuda, M. and R. Longnecker (2007). "Epstein-Barr virus latent membrane protein 2A 
mediates transformation through constitutive activation of the Ras/PI3-K/Akt Pathway." J 
Virol 81(17): 9299-9306. 
Ganem, D. (2007). Kaposi's Sarcoma-associated Herpesvirus. Fields' virology. B. N. 
Fields, D. M. Knipe and P. M. Howley. Philadelphia, Wolters Kluwer Health/Lippincott 
Williams & Wilkins. 
Gaspar, M., J. S. May, S. Sukla, B. Frederico, M. B. Gill, C. M. Smith, G. T. Belz and P. G. 
Stevenson (2011). "Murid herpesvirus-4 exploits dendritic cells to infect B cells." PLoS 
Pathog 7(11): e1002346. 
Geere, H. M., Y. Ligertwood, K. M. Templeton, I. Bennet, B. Gangadharan, S. M. Rhind, 
A. A. Nash and B. M. Dutia (2006). "The M4 gene of murine gammaherpesvirus 68 
modulates latent infection." J Gen Virol 87(Pt 4): 803-807. 
Geng, L. and X. Wang (2015). "Epstein-Barr Virus-associated lymphoproliferative 
disorders: experimental and clinical developments." Int J Clin Exp Med 8(9): 14656-14671. 
Giffin, L. and B. Damania (2014). "KSHV: pathways to tumorigenesis and persistent 
infection." Adv Virus Res 88: 111-159. 
Gillet, L., B. Frederico and P. G. Stevenson (2015). "Host entry by gamma-herpesviruses-
lessons from animal viruses?" Curr Opin Virol 15: 34-40. 
Gires, O., U. Zimber-Strobl, R. Gonnella, M. Ueffing, G. Marschall, R. Zeidler, D. Pich and 
W. Hammerschmidt (1997). "Latent membrane protein 1 of Epstein-Barr virus mimics a 
constitutively active receptor molecule." EMBO J 16(20): 6131-6140. 
Glenn, M., L. Rainbow, F. Aurade, A. Davison and T. F. Schulz (1999). "Identification of a 
spliced gene from Kaposi's sarcoma-associated herpesvirus encoding a protein with 
similarities to latent membrane proteins 1 and 2A of Epstein-Barr virus." J Virol 73(8): 
6953-6963. 
Godinho-Silva, C., S. Marques, D. Fontinha, H. Veiga-Fernandes, P. G. Stevenson and J. 
P. Simas (2014). "Defining immune engagement thresholds for in vivo control of virus-
driven lymphoproliferation." PLoS Pathog 10(6): e1004220. 
Grakoui, A., S. K. Bromley, C. Sumen, M. M. Davis, A. S. Shaw, P. M. Allen and M. L. 
Dustin (1999). "The immunological synapse: a molecular machine controlling T cell 
activation." Science 285(5425): 221-227. 
Gray, L. S., J. R. Gnarra, J. A. Sullivan, G. L. Mandell and V. H. Engelhard (1988). 
"Spatial and temporal characteristics of the increase in intracellular Ca2+ induced in 
cytotoxic T lymphocytes by cellular antigen." J Immunol 141(7): 2424-2430. 
Guzman-Rojas, L., J. C. Sims-Mourtada, R. Rangel and H. Martinez-Valdez (2002). "Life 
and death within germinal centres: a double-edged sword." Immunology 107(2): 167-175. 
Hadinoto, V., M. Shapiro, C. C. Sun and D. A. Thorley-Lawson (2009). "The dynamics of 
EBV shedding implicate a central role for epithelial cells in amplifying viral output." PLoS 
Pathog 5(7): e1000496. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
156 
 
Haller, C., S. Rauch and O. T. Fackler (2007). "HIV-1 Nef employs two distinct 
mechanisms to modulate Lck subcellular localization and TCR induced actin remodeling." 
PLoS One 2(11): e1212. 
Haller, C., S. Rauch, N. Michel, S. Hannemann, M. J. Lehmann, O. T. Keppler and O. T. 
Fackler (2006). "The HIV-1 pathogenicity factor Nef interferes with maturation of 
stimulatory T-lymphocyte contacts by modulation of N-Wasp activity." J Biol Chem 
281(28): 19618-19630. 
Hardy, C. L., S. L. Silins, D. L. Woodland and M. A. Blackman (2000). "Murine gamma-
herpesvirus infection causes V(beta)4-specific CDR3-restricted clonal expansions within 
CD8(+) peripheral blood T lymphocytes." Int Immunol 12(8): 1193-1204. 
Harwood, N. E. and F. D. Batista (2008). "New insights into the early molecular events 
underlying B cell activation." Immunity 28(5): 609-619. 
Hawkins, J. B., E. Delgado-Eckert, D. A. Thorley-Lawson and M. Shapiro (2013). "The 
cycle of EBV infection explains persistence, the sizes of the infected cell populations and 
which come under CTL regulation." PLoS Pathog 9(10): e1003685. 
He, B., N. Raab-Traub, P. Casali and A. Cerutti (2003). "EBV-encoded latent membrane 
protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy 
chain class switching." J Immunol 171(10): 5215-5224. 
Heath, E., N. Begue-Pastor, S. Chaganti, D. Croom-Carter, C. Shannon-Lowe, D. Kube, 
R. Feederle, H. J. Delecluse, A. B. Rickinson and A. I. Bell (2012). "Epstein-Barr virus 
infection of naive B cells in vitro frequently selects clones with mutated immunoglobulin 
genotypes: implications for virus biology." PLoS Pathog 8(5): e1002697. 
Herskowitz, J. H., M. A. Jacoby and S. H. Speck (2005). "The murine gammaherpesvirus 
68 M2 gene is required for efficient reactivation from latently infected B cells." J Virol 
79(4): 2261-2273. 
Hikida, M., S. Casola, N. Takahashi, T. Kaji, T. Takemori, K. Rajewsky and T. Kurosaki 
(2009). "PLC-gamma2 is essential for formation and maintenance of memory B cells." J 
Exp Med 206(3): 681-689. 
Hislop, A. D., G. S. Taylor, D. Sauce and A. B. Rickinson (2007). "Cellular responses to 
viral infection in humans: lessons from Epstein-Barr virus." Annu Rev Immunol 25: 587-
617. 
Hladik, W., S. C. Dollard, J. Mermin, A. L. Fowlkes, R. Downing, M. M. Amin, F. Banage, 
E. Nzaro, P. Kataaha, T. J. Dondero, P. E. Pellett and E. M. Lackritz (2006). 
"Transmission of human herpesvirus 8 by blood transfusion." N Engl J Med 355(13): 
1331-1338. 
Huppa, J. B. and M. M. Davis (2003). "T-cell-antigen recognition and the immunological 
synapse." Nat Rev Immunol 3(12): 973-983. 
Husain, S. M., E. J. Usherwood, H. Dyson, C. Coleclough, M. A. Coppola, D. L. 
Woodland, M. A. Blackman, J. P. Stewart and J. T. Sample (1999). "Murine 
gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T 
lymphocytes." Proc Natl Acad Sci U S A 96(13): 7508-7513. 
Huse, M. (2012). "Microtubule-organizing center polarity and the immunological synapse: 
protein kinase C and beyond." Front Immunol 3: 235. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
157 
 
Ide, L. M., E. Javazon and H. T. Spencer (2008). "Transduction of murine hematopoietic 
stem cells and in vivo selection of gene-modified cells." Methods Mol Biol 433: 213-228. 
Ikeda, M., A. Ikeda, L. C. Longan and R. Longnecker (2000). "The Epstein-Barr virus 
latent membrane protein 2A PY motif recruits WW domain-containing ubiquitin-protein 
ligases." Virology 268(1): 178-191. 
Incrocci, R., M. McCormack and M. Swanson-Mungerson (2013). "Epstein-Barr virus 
LMP2A increases IL-10 production in mitogen-stimulated primary B-cells and B-cell 
lymphomas." J Gen Virol 94(Pt 5): 1127-1133. 
Inoue, H., H. Nojima and H. Okayama (1990). "High efficiency transformation of 
Escherichia coli with plasmids." Gene 96(1): 23-28. 
Irving, B. A. and A. Weiss (1991). "The cytoplasmic domain of the T cell receptor zeta 
chain is sufficient to couple to receptor-associated signal transduction pathways." Cell 
64(5): 891-901. 
Ishido, S., C. Wang, B. S. Lee, G. B. Cohen and J. U. Jung (2000). "Downregulation of 
major histocompatibility complex class I molecules by Kaposi's sarcoma-associated 
herpesvirus K3 and K5 proteins." J Virol 74(11): 5300-5309. 
Jacoby, M. A., H. W. t. Virgin and S. H. Speck (2002). "Disruption of the M2 gene of 
murine gammaherpesvirus 68 alters splenic latency following intranasal, but not 
intraperitoneal, inoculation." J Virol 76(4): 1790-1801. 
Kaplan, L. D. (2013). "Human herpesvirus-8: Kaposi sarcoma, multicentric Castleman 
disease, and primary effusion lymphoma." Hematology Am Soc Hematol Educ Program 
2013: 103-108. 
Kaye, K. M., K. M. Izumi and E. Kieff (1993). "Epstein-Barr virus latent membrane protein 
1 is essential for B-lymphocyte growth transformation." Proc Natl Acad Sci U S A 90(19): 
9150-9154. 
Kedes, D. H., M. Lagunoff, R. Renne and D. Ganem (1997). "Identification of the gene 
encoding the major latency-associated nuclear antigen of the Kaposi's sarcoma-
associated herpesvirus." J Clin Invest 100(10): 2606-2610. 
Kempkes, B. and E. S. Robertson (2015). "Epstein-Barr virus latency: current and future 
perspectives." Curr Opin Virol 14: 138-144. 
Kieff, E. and A. B. Rickinson (2007). Epstein-Barr virus and its replication. Fields' virology. 
B. N. Fields, D. M. Knipe and P. M. Howley. Philadelphia, Wolters Kluwer 
Health/Lippincott Williams & Wilkins. 
Kilger, E., A. Kieser, M. Baumann and W. Hammerschmidt (1998). "Epstein-Barr virus-
mediated B-cell proliferation is dependent upon latent membrane protein 1, which 
simulates an activated CD40 receptor." EMBO J 17(6): 1700-1709. 
Kim, I. J., E. Flano, D. L. Woodland, F. E. Lund, T. D. Randall and M. A. Blackman (2003). 
"Maintenance of long term gamma-herpesvirus B cell latency is dependent on CD40-
mediated development of memory B cells." J Immunol 171(2): 886-892. 
Kim, O. J. and J. L. Yates (1993). "Mutants of Epstein-Barr virus with a selective marker 
disrupting the TP gene transform B cells and replicate normally in culture." J Virol 67(12): 
7634-7640. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
158 
 
Klein, U. and R. Dalla-Favera (2008). "Germinal centres: role in B-cell physiology and 
malignancy." Nat Rev Immunol 8(1): 22-33. 
Kong, K. F., T. Yokosuka, A. J. Canonigo-Balancio, N. Isakov, T. Saito and A. Altman 
(2011). "A motif in the V3 domain of the kinase PKC-theta determines its localization in 
the immunological synapse and functions in T cells via association with CD28." Nat 
Immunol 12(11): 1105-1112. 
Krummel, M. F. and M. D. Cahalan (2010). "The immunological synapse: a dynamic 
platform for local signaling." J Clin Immunol 30(3): 364-372. 
Kupfer, A., T. R. Mosmann and H. Kupfer (1991). "Polarized expression of cytokines in 
cell conjugates of helper T cells and splenic B cells." Proc Natl Acad Sci U S A 88(3): 775-
779. 
Kupfer, H., C. R. Monks and A. Kupfer (1994). "Small splenic B cells that bind to antigen-
specific T helper (Th) cells and face the site of cytokine production in the Th cells 
selectively proliferate: immunofluorescence microscopic studies of Th-B antigen-
presenting cell interactions." J Exp Med 179(5): 1507-1515. 
Kurth, J., M. L. Hansmann, K. Rajewsky and R. Kuppers (2003). "Epstein-Barr virus-
infected B cells expanding in germinal centers of infectious mononucleosis patients do not 
participate in the germinal center reaction." Proc Natl Acad Sci U S A 100(8): 4730-4735. 
Kurth, J., T. Spieker, J. Wustrow, G. J. Strickler, L. M. Hansmann, K. Rajewsky and R. 
Kuppers (2000). "EBV-infected B cells in infectious mononucleosis: viral strategies for 
spreading in the B cell compartment and establishing latency." Immunity 13(4): 485-495. 
Lacoste, V., A. Lavergne, B. de Thoisy, J. F. Pouliquen and A. Gessain (2010). "Genetic 
diversity and molecular evolution of human and non-human primate 
Gammaherpesvirinae." Infect Genet Evol 10(1): 1-13. 
Lagunoff, M. and D. Ganem (1997). "The structure and coding organization of the 
genomic termini of Kaposi's sarcoma-associated herpesvirus." Virology 236(1): 147-154. 
Lagunoff, M., R. Majeti, A. Weiss and D. Ganem (1999). "Deregulated signal transduction 
by the K1 gene product of Kaposi's sarcoma-associated herpesvirus." Proc Natl Acad Sci 
U S A 96(10): 5704-5709. 
Le Floc'h, A. and M. Huse (2015). "Molecular mechanisms and functional implications of 
polarized actin remodeling at the T cell immunological synapse." Cell Mol Life Sci 72(3): 
537-556. 
LeBien, T. W. and T. F. Tedder (2008). "B lymphocytes: how they develop and function." 
Blood 112(5): 1570-1580. 
Lee, B. J., U. H. Koszinowski, S. R. Sarawar and H. Adler (2003). "A gammaherpesvirus 
G protein-coupled receptor homologue is required for increased viral replication in 
response to chemokines and efficient reactivation from latency." J Immunol 170(1): 243-
251. 
Lee, B. S., X. Alvarez, S. Ishido, A. A. Lackner and J. U. Jung (2000). "Inhibition of 
intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-
associated herpesvirus K1." J Exp Med 192(1): 11-21. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
159 
 
Lee, B. S., S. H. Lee, P. Feng, H. Chang, N. H. Cho and J. U. Jung (2005). 
"Characterization of the Kaposi's sarcoma-associated herpesvirus K1 signalosome." J 
Virol 79(19): 12173-12184. 
Lee, H., J. Guo, M. Li, J. K. Choi, M. DeMaria, M. Rosenzweig and J. U. Jung (1998). 
"Identification of an immunoreceptor tyrosine-based activation motif of K1 transforming 
protein of Kaposi's sarcoma-associated herpesvirus." Mol Cell Biol 18(9): 5219-5228. 
Lee, H., R. Veazey, K. Williams, M. Li, J. Guo, F. Neipel, B. Fleckenstein, A. Lackner, R. 
C. Desrosiers and J. U. Jung (1998). "Deregulation of cell growth by the K1 gene of 
Kaposi's sarcoma-associated herpesvirus." Nat Med 4(4): 435-440. 
Liang, X., C. M. Collins, J. B. Mendel, N. N. Iwakoshi and S. H. Speck (2009). 
"Gammaherpesvirus-driven plasma cell differentiation regulates virus reactivation from 
latently infected B lymphocytes." PLoS Pathog 5(11): e1000677. 
Liang, X., M. T. Pickering, N. H. Cho, H. Chang, M. R. Volkert, T. F. Kowalik and J. U. 
Jung (2006). "Deregulation of DNA damage signal transduction by herpesvirus latency-
associated M2." J Virol 80(12): 5862-5874. 
Liang, X., Y. C. Shin, R. E. Means and J. U. Jung (2004). "Inhibition of interferon-mediated 
antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein." J Virol 
78(22): 12416-12427. 
Lim, S. T., N. Rubin, J. Said and A. M. Levine (2005). "Primary effusion lymphoma: 
successful treatment with highly active antiretroviral therapy and rituximab." Ann Hematol 
84(8): 551-552. 
Lu, M., H. Kawamoto, Y. Katsube, T. Ikawa and Y. Katsura (2002). "The common 
myelolymphoid progenitor: a key intermediate stage in hemopoiesis generating T and B 
cells." J Immunol 169(7): 3519-3525. 
Mackett, M., J. P. Stewart, V. P. S. de, M. Chee, S. Efstathiou, A. A. Nash and J. R. 
Arrand (1997). "Genetic content and preliminary transcriptional analysis of a 
representative region of murine gammaherpesvirus 68." J Gen Virol 78 ( Pt 6): 1425-1433. 
Macrae, A. I., E. J. Usherwood, S. M. Husain, E. Flano, I. J. Kim, D. L. Woodland, A. A. 
Nash, M. A. Blackman, J. T. Sample and J. P. Stewart (2003). "Murid herpesvirus 4 strain 
68 M2 protein is a B-cell-associated antigen important for latency but not lymphocytosis." 
J Virol 77(17): 9700-9709. 
Madureira, P. A., P. Matos, I. Soeiro, L. K. Dixon, J. P. Simas and E. W. Lam (2005). 
"Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and 
inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells." J Biol 
Chem 280(45): 37310-37318. 
Marques, S., M. Alenquer, P. G. Stevenson and J. P. Simas (2008). "A single CD8+ T cell 
epitope sets the long-term latent load of a murid herpesvirus." PLoS Pathog 4(10): 
e1000177. 
Marques, S., S. Efstathiou, K. G. Smith, M. Haury and J. P. Simas (2003). "Selective gene 
expression of latent murine gammaherpesvirus 68 in B lymphocytes." J Virol 77(13): 
7308-7318. 
Martensson, I. L., N. Almqvist, O. Grimsholm and A. I. Bernardi (2010). "The pre-B cell 
receptor checkpoint." FEBS Lett 584(12): 2572-2579. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
160 
 
Martinez-Guzman, D., T. Rickabaugh, T. T. Wu, H. Brown, S. Cole, M. J. Song, L. Tong 
and R. Sun (2003). "Transcription program of murine gammaherpesvirus 68." J Virol 
77(19): 10488-10503. 
May, J. S., N. J. Bennett and P. G. Stevenson (2010). "An in vitro system for studying 
murid herpesvirus-4 latency and reactivation." PLoS One 5(6): e11080. 
Medvinsky, A., S. Rybtsov and S. Taoudi (2011). "Embryonic origin of the adult 
hematopoietic system: advances and questions." Development 138(6): 1017-1031. 
Mesri, E. A., M. A. Feitelson and K. Munger (2014). "Human viral oncogenesis: a cancer 
hallmarks analysis." Cell Host Microbe 15(3): 266-282. 
Metcalf, D. (2007). "On hematopoietic stem cell fate." Immunity 26(6): 669-673. 
Milho, R., B. Frederico, S. Efstathiou and P. G. Stevenson (2012). "A heparan-dependent 
herpesvirus targets the olfactory neuroepithelium for host entry." PLoS Pathog 8(11): 
e1002986. 
Milho, R., C. M. Smith, S. Marques, M. Alenquer, J. S. May, L. Gillet, M. Gaspar, S. 
Efstathiou, J. P. Simas and P. G. Stevenson (2009). "In vivo imaging of murid 
herpesvirus-4 infection." J Gen Virol 90(Pt 1): 21-32. 
Mills, D. M. and J. C. Cambier (2003). "B lymphocyte activation during cognate 
interactions with CD4+ T lymphocytes: molecular dynamics and immunologic 
consequences." Semin Immunol 15(6): 325-329. 
Minamitani, T., T. Yasui, Y. Ma, H. Zhou, D. Okuzaki, C. Y. Tsai, S. Sakakibara, B. E. 
Gewurz, E. Kieff and H. Kikutani (2015). "Evasion of affinity-based selection in germinal 
centers by Epstein-Barr virus LMP2A." Proc Natl Acad Sci U S A 112(37): 11612-11617. 
Minhas, V. and C. Wood (2014). "Epidemiology and transmission of Kaposi's sarcoma-
associated herpesvirus." Viruses 6(11): 4178-4194. 
Monks, C. R., B. A. Freiberg, H. Kupfer, N. Sciaky and A. Kupfer (1998). "Three-
dimensional segregation of supramolecular activation clusters in T cells." Nature 
395(6697): 82-86. 
Morrison, S. J., H. D. Hemmati, A. M. Wandycz and I. L. Weissman (1995). "The 
purification and characterization of fetal liver hematopoietic stem cells." Proc Natl Acad 
Sci U S A 92(22): 10302-10306. 
Moser, J. M., M. L. Farrell, L. T. Krug, J. W. Upton and S. H. Speck (2006). "A 
gammaherpesvirus 68 gene 50 null mutant establishes long-term latency in the lung but 
fails to vaccinate against a wild-type virus challenge." J Virol 80(3): 1592-1598. 
Mullick, A., Y. Xu, R. Warren, M. Koutroumanis, C. Guilbault, S. Broussau, F. Malenfant, 
L. Bourget, L. Lamoureux, R. Lo, A. W. Caron, A. Pilotte and B. Massie (2006). "The 
cumate gene-switch: a system for regulated expression in mammalian cells." BMC 
Biotechnol 6: 43. 
Nador, R. G., E. Cesarman, A. Chadburn, D. B. Dawson, M. Q. Ansari, J. Sald and D. M. 
Knowles (1996). "Primary effusion lymphoma: a distinct clinicopathologic entity associated 
with the Kaposi's sarcoma-associated herpes virus." Blood 88(2): 645-656. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
161 
 
Nash, A. A., B. M. Dutia, J. P. Stewart and A. J. Davison (2001). "Natural history of murine 
gamma-herpesvirus infection." Philos Trans R Soc Lond B Biol Sci 356(1408): 569-579. 
Niederman, J. C., G. Miller, H. A. Pearson, J. S. Pagano and J. M. Dowaliby (1976). 
"Infectious mononucleosis. Epstein-Barr-virus shedding in saliva and the oropharynx." N 
Engl J Med 294(25): 1355-1359. 
Niiro, H. and E. A. Clark (2002). "Regulation of B-cell fate by antigen-receptor signals." 
Nat Rev Immunol 2(12): 945-956. 
Ning, S., A. M. Hahn, L. E. Huye and J. S. Pagano (2003). "Interferon regulatory factor 7 
regulates expression of Epstein-Barr virus latent membrane protein 1: a regulatory circuit." 
J Virol 77(17): 9359-9368. 
Nutt, S. L. and D. M. Tarlinton (2011). "Germinal center B and follicular helper T cells: 
siblings, cousins or just good friends?" Nat Immunol 12(6): 472-477. 
Ogawa, M., Y. Matsuzaki, S. Nishikawa, S. Hayashi, T. Kunisada, T. Sudo, T. Kina, H. 
Nakauchi and S. Nishikawa (1991). "Expression and function of c-kit in hemopoietic 
progenitor cells." J Exp Med 174(1): 63-71. 
Ogilvie, M. M. (2007). Herpesviruses. Medical microbiology : a guide to microbial 
infections : pathogenesis, immunity, laboratory diagnosis and control. D. Greenwood. 
Edinburgh, Churchill Livingstone: xvi, 778 p. 
Ogura, M., K. Tobinai, K. Hatake, K. Ishizawa, N. Uike, T. Uchida, T. Suzuki, T. Aoki, T. 
Watanabe, D. Maruyama, M. Yokoyama, T. Takubo, H. Kagehara and T. Matsushima 
(2014). "Phase I / II study of brentuximab vedotin in Japanese patients with relapsed or 
refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell 
lymphoma." Cancer Sci 105(7): 840-846. 
Ok, C. Y., L. Li and K. H. Young (2015). "EBV-driven B-cell lymphoproliferative disorders: 
from biology, classification and differential diagnosis to clinical management." Exp Mol 
Med 47: e132. 
Okada, T., M. J. Miller, I. Parker, M. F. Krummel, M. Neighbors, S. B. Hartley, A. O'Garra, 
M. D. Cahalan and J. G. Cyster (2005). "Antigen-engaged B cells undergo chemotaxis 
toward the T zone and form motile conjugates with helper T cells." PLoS Biol 3(6): e150. 
Okkenhaug, K. and B. Vanhaesebroeck (2003). "PI3K in lymphocyte development, 
differentiation and activation." Nat Rev Immunol 3(4): 317-330. 
Park, J., N. H. Cho, J. K. Choi, P. Feng, J. Choe and J. U. Jung (2003). "Distinct roles of 
cellular Lck and p80 proteins in herpesvirus saimiri Tip function on lipid rafts." J Virol 
77(16): 9041-9051. 
Parry, C. M., J. P. Simas, V. P. Smith, C. A. Stewart, A. C. Minson, S. Efstathiou and A. 
Alcami (2000). "A broad spectrum secreted chemokine binding protein encoded by a 
herpesvirus." J Exp Med 191(3): 573-578. 
Persons, D. A., M. G. Mehaffey, M. Kaleko, A. W. Nienhuis and E. F. Vanin (1998). "An 
improved method for generating retroviral producer clones for vectors lacking a selectable 
marker gene." Blood Cells Mol Dis 24(2): 167-182. 
Pfeffer, S., A. Sewer, M. Lagos-Quintana, R. Sheridan, C. Sander, F. A. Grasser, L. F. 
van Dyk, C. K. Ho, S. Shuman, M. Chien, J. J. Russo, J. Ju, G. Randall, B. D. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
162 
 
Lindenbach, C. M. Rice, V. Simon, D. D. Ho, M. Zavolan and T. Tuschl (2005). 
"Identification of microRNAs of the herpesvirus family." Nat Methods 2(4): 269-276. 
Pierce, S. K. (2002). "Lipid rafts and B-cell activation." Nat Rev Immunol 2(2): 96-105. 
Pires de Miranda, M., M. Alenquer, S. Marques, L. Rodrigues, F. Lopes, X. R. Bustelo and 
J. P. Simas (2008). "The Gammaherpesvirus m2 protein manipulates the Fyn/Vav 
pathway through a multidocking mechanism of assembly." PLoS One 3(2): e1654. 
Pires de Miranda, M., F. B. Lopes, C. E. McVey, X. R. Bustelo and J. P. Simas (2013). 
"Role of Src homology domain binding in signaling complexes assembled by the murid 
gamma-herpesvirus M2 protein." J Biol Chem 288(6): 3858-3870. 
Polcicova, K., Z. Hrabovska, J. Mistrikova, J. Tomaskova, J. Pastorek, S. Pastorekova 
and J. Kopacek (2008). "Up-regulation of Murid herpesvirus 4 ORF50 by hypoxia: possible 
implication for virus reactivation from latency." Virus Res 132(1-2): 257-262. 
Polizzotto, M. N., T. S. Uldrick, D. Hu and R. Yarchoan (2012). "Clinical Manifestations of 
Kaposi Sarcoma Herpesvirus Lytic Activation: Multicentric Castleman Disease (KSHV-
MCD) and the KSHV Inflammatory Cytokine Syndrome." Front Microbiol 3: 73. 
Prakash, O., O. R. Swamy, X. Peng, Z. Y. Tang, L. Li, J. E. Larson, J. C. Cohen, J. Gill, G. 
Farr, S. Wang and F. Samaniego (2005). "Activation of Src kinase Lyn by the Kaposi 
sarcoma-associated herpesvirus K1 protein: implications for lymphomagenesis." Blood 
105(10): 3987-3994. 
Prakash, O., Z. Y. Tang, X. Peng, R. Coleman, J. Gill, G. Farr and F. Samaniego (2002). 
"Tumorigenesis and aberrant signaling in transgenic mice expressing the human 
herpesvirus-8 K1 gene." J Natl Cancer Inst 94(12): 926-935. 
Purushothaman, P., T. Uppal and S. C. Verma (2015). "Molecular biology of KSHV lytic 
reactivation." Viruses 7(1): 116-153. 
Qi, H., J. L. Cannons, F. Klauschen, P. L. Schwartzberg and R. N. Germain (2008). "SAP-
controlled T-B cell interactions underlie germinal centre formation." Nature 455(7214): 
764-769. 
Qiu, J., K. Cosmopoulos, M. Pegtel, E. Hopmans, P. Murray, J. Middeldorp, M. Shapiro 
and D. A. Thorley-Lawson (2011). "A novel persistence associated EBV miRNA 
expression profile is disrupted in neoplasia." PLoS Pathog 7(8): e1002193. 
Rangaswamy, U. S., B. M. O'Flaherty and S. H. Speck (2014). "Tyrosine 129 of the 
murine gammaherpesvirus M2 protein is critical for M2 function in vivo." PLoS One 9(8): 
e105197. 
Rangaswamy, U. S. and S. H. Speck (2014). "Murine gammaherpesvirus M2 protein 
induction of IRF4 via the NFAT pathway leads to IL-10 expression in B cells." PLoS 
Pathog 10(1): e1003858. 
Rebel, V. I., C. L. Miller, C. J. Eaves and P. M. Lansdorp (1996). "The repopulation 
potential of fetal liver hematopoietic stem cells in mice exceeds that of their liver adult 
bone marrow counterparts." Blood 87(8): 3500-3507. 
Rechsteiner, M. P., C. Berger, L. Zauner, J. A. Sigrist, M. Weber, R. Longnecker, M. 
Bernasconi and D. Nadal (2008). "Latent membrane protein 2B regulates susceptibility to 
induction of lytic Epstein-Barr virus infection." J Virol 82(4): 1739-1747. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
163 
 
Renne, R., W. Zhong, B. Herndier, M. McGrath, N. Abbey, D. Kedes and D. Ganem 
(1996). "Lytic growth of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) 
in culture." Nat Med 2(3): 342-346. 
Reth, M. (1989). "Antigen receptor tail clue." Nature 338(6214): 383-384. 
Rickinson, A. B. and E. Kieff (2007). Epstein-Barr Virus. Fields' virology. B. N. Fields, D. 
M. Knipe and P. M. Howley. Philadelphia, Wolters Kluwer Health/Lippincott Williams & 
Wilkins. 
Rochford, R., M. L. Lutzke, R. S. Alfinito, A. Clavo and R. D. Cardin (2001). "Kinetics of 
murine gammaherpesvirus 68 gene expression following infection of murine cells in 
culture and in mice." J Virol 75(11): 4955-4963. 
Rodrigues, L., J. Filipe, M. P. Seldon, L. Fonseca, J. Anrather, M. P. Soares and J. P. 
Simas (2009). "Termination of NF-kappaB activity through a gammaherpesvirus protein 
that assembles an EC5S ubiquitin-ligase." EMBO J 28(9): 1283-1295. 
Rodrigues, L., M. Pires de Miranda, M. J. Caloca, X. R. Bustelo and J. P. Simas (2006). 
"Activation of Vav by the gammaherpesvirus M2 protein contributes to the establishment 
of viral latency in B lymphocytes." J Virol 80(12): 6123-6135. 
Rodrigues, L., N. Popov, K. M. Kaye and J. P. Simas (2013). "Stabilization of Myc through 
heterotypic poly-ubiquitination by mLANA is critical for gamma-herpesvirus 
lymphoproliferation." PLoS Pathog 9(8): e1003554. 
Roizman, B. and P. E. Pellett (2007). The Family Herpesviridae: A Brief Introduction. 
Fields' virology. B. N. Fields, D. M. Knipe and P. M. Howley. Philadelphia, Wolters Kluwer 
Health/Lippincott Williams & Wilkins. 
Rooney, C. M., C. A. Smith, C. Y. Ng, S. K. Loftin, J. W. Sixbey, Y. Gan, D. K. Srivastava, 
L. C. Bowman, R. A. Krance, M. K. Brenner and H. E. Heslop (1998). "Infusion of cytotoxic 
T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in 
allogeneic transplant recipients." Blood 92(5): 1549-1555. 
Roughan, J. E. and D. A. Thorley-Lawson (2009). "The intersection of Epstein-Barr virus 
with the germinal center." J Virol 83(8): 3968-3976. 
Rovedo, M. and R. Longnecker (2007). "Epstein-barr virus latent membrane protein 2B 
(LMP2B) modulates LMP2A activity." J Virol 81(1): 84-94. 
Rovedo, M. and R. Longnecker (2008). "Epstein-Barr virus latent membrane protein 2A 
preferentially signals through the Src family kinase Lyn." J Virol 82(17): 8520-8528. 
Sadler, R., L. Wu, B. Forghani, R. Renne, W. Zhong, B. Herndier and D. Ganem (1999). 
"A complex translational program generates multiple novel proteins from the latently 
expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus." J Virol 
73(7): 5722-5730. 
Sangster, M. Y., D. J. Topham, S. D'Costa, R. D. Cardin, T. N. Marion, L. K. Myers and P. 
C. Doherty (2000). "Analysis of the virus-specific and nonspecific B cell response to a 
persistent B-lymphotropic gammaherpesvirus." J Immunol 164(4): 1820-1828. 
Saxena, S. K., G. Shrivastava, S. Tiwari, M. A. Swamy and M. P. Nair (2012). "Modulation 
of HIV pathogenesis and T-cell signaling by HIV-1 Nef." Future Virol 7(6): 609-620. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
164 
 
Sayos, J., C. Wu, M. Morra, N. Wang, X. Zhang, D. Allen, S. van Schaik, L. Notarangelo, 
R. Geha, M. G. Roncarolo, H. Oettgen, J. E. De Vries, G. Aversa and C. Terhorst (1998). 
"The X-linked lymphoproliferative-disease gene product SAP regulates signals induced 
through the co-receptor SLAM." Nature 395(6701): 462-469. 
Schindelin, J., I. Arganda-Carreras, E. Frise, V. Kaynig, M. Longair, T. Pietzsch, S. 
Preibisch, C. Rueden, S. Saalfeld, B. Schmid, J. Y. Tinevez, D. J. White, V. Hartenstein, 
K. Eliceiri, P. Tomancak and A. Cardona (2012). "Fiji: an open-source platform for 
biological-image analysis." Nat Methods 9(7): 676-682. 
Scholle, F., K. M. Bendt and N. Raab-Traub (2000). "Epstein-Barr virus LMP2A transforms 
epithelial cells, inhibits cell differentiation, and activates Akt." J Virol 74(22): 10681-10689. 
Schulz, T. F. and E. Cesarman (2015). "Kaposi Sarcoma-associated Herpesvirus: 
mechanisms of oncogenesis." Curr Opin Virol 14: 116-128. 
Schwickert, T. A., G. D. Victora, D. R. Fooksman, A. O. Kamphorst, M. R. Mugnier, A. D. 
Gitlin, M. L. Dustin and M. C. Nussenzweig (2011). "A dynamic T cell-limited checkpoint 
regulates affinity-dependent B cell entry into the germinal center." J Exp Med 208(6): 
1243-1252. 
Seto, E., A. Moosmann, S. Gromminger, N. Walz, A. Grundhoff and W. Hammerschmidt 
(2010). "Micro RNAs of Epstein-Barr virus promote cell cycle progression and prevent 
apoptosis of primary human B cells." PLoS Pathog 6(8): e1001063. 
Shannon-Lowe, C. and M. Rowe (2014). "Epstein Barr virus entry; kissing and 
conjugation." Curr Opin Virol 4: 78-84. 
Sharp, T. V., H. W. Wang, A. Koumi, D. Hollyman, Y. Endo, H. Ye, M. Q. Du and C. 
Boshoff (2002). "K15 protein of Kaposi's sarcoma-associated herpesvirus is latently 
expressed and binds to HAX-1, a protein with antiapoptotic function." J Virol 76(2): 802-
816. 
Siegel, A. M., J. H. Herskowitz and S. H. Speck (2008). "The MHV68 M2 protein drives IL-
10 dependent B cell proliferation and differentiation." PLoS Pathog 4(4): e1000039. 
Simas, J. P. and S. Efstathiou (1998). "Murine gammaherpesvirus 68: a model for the 
study of gammaherpesvirus pathogenesis." Trends Microbiol 6(7): 276-282. 
Simas, J. P., S. Marques, A. Bridgeman, S. Efstathiou and H. Adler (2004). "The M2 gene 
product of murine gammaherpesvirus 68 is required for efficient colonization of splenic 
follicles but is not necessary for expansion of latently infected germinal centre B cells." J 
Gen Virol 85(Pt 10): 2789-2797. 
Simas, J. P., D. Swann, R. Bowden and S. Efstathiou (1999). "Analysis of murine 
gammaherpesvirus-68 transcription during lytic and latent infection." J Gen Virol 80 ( Pt 
1): 75-82. 
Sousa-Squiavinato, A. C., R. N. Silvestre and D. Elgui De Oliveira (2015). "Biology and 
oncogenicity of the Kaposi sarcoma herpesvirus K1 protein." Rev Med Virol 25(5): 273-
285. 
Souza, T. A., B. D. Stollar, J. L. Sullivan, K. Luzuriaga and D. A. Thorley-Lawson (2005). 
"Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of 
classical antigen-selected memory B cells." Proc Natl Acad Sci U S A 102(50): 18093-
18098. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
165 
 
Souza, T. A., B. D. Stollar, J. L. Sullivan, K. Luzuriaga and D. A. Thorley-Lawson (2007). 
"Influence of EBV on the peripheral blood memory B cell compartment." J Immunol 
179(5): 3153-3160. 
Speck, S. H. and D. Ganem (2010). "Viral latency and its regulation: lessons from the 
gamma-herpesviruses." Cell Host Microbe 8(1): 100-115. 
Stevenson, P. G. and P. C. Doherty (1998). "Kinetic analysis of the specific host response 
to a murine gammaherpesvirus." J Virol 72(2): 943-949. 
Stevenson, P. G. and P. C. Doherty (1999). "Non-antigen-specific B-cell activation 
following murine gammaherpesvirus infection is CD4 independent in vitro but CD4 
dependent in vivo." J Virol 73(2): 1075-1079. 
Stevenson, P. G. and S. Efstathiou (2005). "Immune mechanisms in murine 
gammaherpesvirus-68 infection." Viral Immunol 18(3): 445-456. 
Stevenson, P. G., S. Efstathiou, P. C. Doherty and P. J. Lehner (2000). "Inhibition of MHC 
class I-restricted antigen presentation by gamma 2-herpesviruses." Proc Natl Acad Sci U 
S A 97(15): 8455-8460. 
Sunil-Chandra, N. P., S. Efstathiou, J. Arno and A. A. Nash (1992). "Virological and 
pathological features of mice infected with murine gamma-herpesvirus 68." J Gen Virol 73 
( Pt 9): 2347-2356. 
Sunil-Chandra, N. P., S. Efstathiou and A. A. Nash (1993). "Interactions of murine 
gammaherpesvirus 68 with B and T cell lines." Virology 193(2): 825-833. 
Svobodova, J., D. Blaskovic and J. Mistrikova (1982). "Growth characteristics of 
herpesviruses isolated from free living small rodents." Acta Virol 26(4): 256-263. 
Swaminathan, S. (2008). "Noncoding RNAs produced by oncogenic human 
herpesviruses." J Cell Physiol 216(2): 321-326. 
Taylor, J. J., K. A. Pape and M. K. Jenkins (2012). "A germinal center-independent 
pathway generates unswitched memory B cells early in the primary response." J Exp Med 
209(3): 597-606. 
Thompson, M. P. and R. Kurzrock (2004). "Epstein-Barr virus and cancer." Clin Cancer 
Res 10(3): 803-821. 
Thorley-Lawson, D. A. (2001). "Epstein-Barr virus: exploiting the immune system." Nat 
Rev Immunol 1(1): 75-82. 
Thorley-Lawson, D. A. (2005). "EBV the prototypical human tumor virus--just how bad is 
it?" J Allergy Clin Immunol 116(2): 251-261; quiz 262. 
Thorley-Lawson, D. A., K. A. Duca and M. Shapiro (2008). "Epstein-Barr virus: a paradigm 
for persistent infection - for real and in virtual reality." Trends Immunol 29(4): 195-201. 
Thorley-Lawson, D. A. and A. Gross (2004). "Persistence of the Epstein-Barr virus and the 
origins of associated lymphomas." N Engl J Med 350(13): 1328-1337. 
Thorley-Lawson, D. A., J. B. Hawkins, S. I. Tracy and M. Shapiro (2013). "The 
pathogenesis of Epstein-Barr virus persistent infection." Curr Opin Virol 3(3): 227-232. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
166 
 
Thoulouze, M. I., N. Sol-Foulon, F. Blanchet, A. Dautry-Varsat, O. Schwartz and A. 
Alcover (2006). "Human immunodeficiency virus type-1 infection impairs the formation of 
the immunological synapse." Immunity 24(5): 547-561. 
Tomlinson, C. C. and B. Damania (2008). "Critical role for endocytosis in the regulation of 
signaling by the Kaposi's sarcoma-associated herpesvirus K1 protein." J Virol 82(13): 
6514-6523. 
Tracy, S. I., K. Kakalacheva, J. D. Lunemann, K. Luzuriaga, J. Middeldorp and D. A. 
Thorley-Lawson (2012). "Persistence of Epstein-Barr virus in self-reactive memory B 
cells." J Virol 86(22): 12330-12340. 
Trautmann, A. and S. Valitutti (2003). "The diversity of immunological synapses." Curr 
Opin Immunol 15(3): 249-254. 
Tripp, R. A., A. M. Hamilton-Easton, R. D. Cardin, P. Nguyen, F. G. Behm, D. L. 
Woodland, P. C. Doherty and M. A. Blackman (1997). "Pathogenesis of an infectious 
mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral 
superantigen?" J Exp Med 185(9): 1641-1650. 
Tsai, Y. H., M. F. Wu, Y. H. Wu, S. J. Chang, S. F. Lin, T. V. Sharp and H. W. Wang 
(2009). "The M type K15 protein of Kaposi's sarcoma-associated herpesvirus regulates 
microRNA expression via its SH2-binding motif to induce cell migration and invasion." J 
Virol 83(2): 622-632. 
Turner, M. and D. D. Billadeau (2002). "VAV proteins as signal integrators for multi-
subunit immune-recognition receptors." Nat Rev Immunol 2(7): 476-486. 
Uchida, J., T. Yasui, Y. Takaoka-Shichijo, M. Muraoka, W. Kulwichit, N. Raab-Traub and 
H. Kikutani (1999). "Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte 
responses." Science 286(5438): 300-303. 
Uppal, T., S. Banerjee, Z. Sun, S. C. Verma and E. S. Robertson (2014). "KSHV LANA--
the master regulator of KSHV latency." Viruses 6(12): 4961-4998. 
Usherwood, E. J., A. J. Ross, D. J. Allen and A. A. Nash (1996). "Murine 
gammaherpesvirus-induced splenomegaly: a critical role for CD4 T cells." J Gen Virol 77 ( 
Pt 4): 627-630. 
Usherwood, E. J., J. P. Stewart and A. A. Nash (1996). "Characterization of tumor cell 
lines derived from murine gammaherpesvirus-68-infected mice." J Virol 70(9): 6516-6518. 
Valitutti, S. and M. Dessing (2000). "Measurement of calcium mobilization responses in 
killer cell/target conjugates by FACS analysis." Methods Mol Biol 121: 305-311. 
Valitutti, S., M. Dessing and A. Lanzavecchia (1993). "Role of cAMP in regulating 
cytotoxic T lymphocyte adhesion and motility." Eur J Immunol 23(4): 790-795. 
Van Dross, R., S. Yao, S. Asad, G. Westlake, D. J. Mays, L. Barquero, S. Duell, J. A. 
Pietenpol and P. J. Browning (2005). "Constitutively active K-cyclin/cdk6 kinase in Kaposi 
sarcoma-associated herpesvirus-infected cells." J Natl Cancer Inst 97(9): 656-666. 
Varma, R., G. Campi, T. Yokosuka, T. Saito and M. L. Dustin (2006). "T cell receptor-
proximal signals are sustained in peripheral microclusters and terminated in the central 
supramolecular activation cluster." Immunity 25(1): 117-127. 
REFERENCES 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
167 
 
Vereide, D. T., E. Seto, Y. F. Chiu, M. Hayes, T. Tagawa, A. Grundhoff, W. 
Hammerschmidt and B. Sugden (2014). "Epstein-Barr virus maintains lymphomas via its 
miRNAs." Oncogene 33(10): 1258-1264. 
Victora, G. D. and L. Mesin (2014). "Clonal and cellular dynamics in germinal centers." 
Curr Opin Immunol 28: 90-96. 
Virgin, H. W. t., P. Latreille, P. Wamsley, K. Hallsworth, K. E. Weck, A. J. Dal Canto and 
S. H. Speck (1997). "Complete sequence and genomic analysis of murine 
gammaherpesvirus 68." J Virol 71(8): 5894-5904. 
Virgin, H. W. t., R. M. Presti, X. Y. Li, C. Liu and S. H. Speck (1999). "Three distinct 
regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently 
infected mice." J Virol 73(3): 2321-2332. 
Wakeling, M. N., D. J. Roy, A. A. Nash and J. P. Stewart (2001). "Characterization of the 
murine gammaherpesvirus 68 ORF74 product: a novel oncogenic G protein-coupled 
receptor." J Gen Virol 82(Pt 5): 1187-1197. 
Wang, D., D. Liebowitz and E. Kieff (1985). "An EBV membrane protein expressed in 
immortalized lymphocytes transforms established rodent cells." Cell 43(3 Pt 2): 831-840. 
Wang, G. H., T. L. Garvey and J. I. Cohen (1999). "The murine gammaherpesvirus-68 
M11 protein inhibits Fas- and TNF-induced apoptosis." J Gen Virol 80 ( Pt 10): 2737-
2740. 
Warncke, M., B. Vogt, J. Ulrich, M. D. von Laer, W. Beyer, H. Klump, B. Micheel and A. 
Sheriff (2004). "Efficient in vitro transduction of naive murine B cells with lentiviral 
vectors." Biochem Biophys Res Commun 318(3): 673-679. 
Waterstrat, A., Y. Liang, C. F. Swiderski, B. J. Shelton and G. Van Zant (2010). "Congenic 
interval of CD45/Ly-5 congenic mice contains multiple genes that may influence 
hematopoietic stem cell engraftment." Blood 115(2): 408-417. 
Weck, K. E., M. L. Barkon, L. I. Yoo, S. H. Speck and H. I. Virgin (1996). "Mature B cells 
are required for acute splenic infection, but not for establishment of latency, by murine 
gammaherpesvirus 68." J Virol 70(10): 6775-6780. 
Werner, M., E. Hobeika and H. Jumaa (2010). "Role of PI3K in the generation and survival 
of B cells." Immunol Rev 237(1): 55-71. 
Willer, D. O. and S. H. Speck (2003). "Long-term latent murine Gammaherpesvirus 68 
infection is preferentially found within the surface immunoglobulin D-negative subset of 
splenic B cells in vivo." J Virol 77(15): 8310-8321. 
Yankee, T. M. and E. A. Clark (2000). "Signaling through the B cell antigen receptor in 
developing B cells." Rev Immunogenet 2(2): 185-203. 
Yasui, T., M. Luftig, V. Soni and E. Kieff (2004). "Latent infection membrane protein 
transmembrane FWLY is critical for intermolecular interaction, raft localization, and 
signaling." Proc Natl Acad Sci U S A 101(1): 278-283. 
Yates, J. L., N. Warren and B. Sugden (1985). "Stable replication of plasmids derived from 
Epstein-Barr virus in various mammalian cells." Nature 313(6005): 812-815. 
CHAPTER 8 
 ______________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________  
 
168 
 
Ye, F. C., F. C. Zhou, J. P. Xie, T. Kang, W. Greene, K. Kuhne, X. F. Lei, Q. H. Li and S. 
J. Gao (2008). "Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral 
lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel 
mechanism of virus control of latency." J Virol 82(9): 4235-4249. 
Yokosuka, T., W. Kobayashi, K. Sakata-Sogawa, M. Takamatsu, A. Hashimoto-Tane, M. 
L. Dustin, M. Tokunaga and T. Saito (2008). "Spatiotemporal regulation of T cell 
costimulation by TCR-CD28 microclusters and protein kinase C theta translocation." 
Immunity 29(4): 589-601. 
Young, L. S. and P. G. Murray (2003). "Epstein-Barr virus and oncogenesis: from latent 
genes to tumours." Oncogene 22(33): 5108-5121. 
Yuseff, M. I., P. Pierobon, A. Reversat and A. M. Lennon-Dumenil (2013). "How B cells 
capture, process and present antigens: a crucial role for cell polarity." Nat Rev Immunol 
13(7): 475-486. 
Zhang, Y., M. Meyer-Hermann, L. A. George, M. T. Figge, M. Khan, M. Goodall, S. P. 
Young, A. Reynolds, F. Falciani, A. Waisman, C. A. Notley, M. R. Ehrenstein, M. Kosco-
Vilbois and K. M. Toellner (2013). "Germinal center B cells govern their own fate via 
antibody feedback." J Exp Med 210(3): 457-464. 
Zhu, J. Y., M. Strehle, A. Frohn, E. Kremmer, K. P. Hofig, G. Meister and H. Adler (2010). 
"Identification and analysis of expression of novel microRNAs of murine 
gammaherpesvirus 68." J Virol 84(19): 10266-10275. 
Zou, P., J. Kawada, L. Pesnicak and J. I. Cohen (2007). "Bortezomib induces apoptosis of 
Epstein-Barr virus (EBV)-transformed B cells and prolongs survival of mice inoculated with 
EBV-transformed B cells." J Virol 81(18): 10029-10036. 
 
  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 1 
  
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 2 
  
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX 3 
  
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
